<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion - Shalchi, Z - 2020 | Cochrane Library</title> <meta content="Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion - Shalchi, Z - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009510.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion - Shalchi, Z - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009510.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009510.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion" name="citation_title"/> <meta content="Zaid Shalchi" name="citation_author"/> <meta content="z.shalchi@nhs.net" name="citation_author_email"/> <meta content="Omar Mahroo" name="citation_author"/> <meta content="Moorfields Eye Hospital NHS Foundation Trust" name="citation_author_institution"/> <meta content="Catey Bunce" name="citation_author"/> <meta content="Danny Mitry" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD009510.pub3" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/07/07" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009510.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009510.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009510.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Angiogenesis Inhibitors [*administration &amp; dosage, adverse effects]; Antibodies, Monoclonal, Humanized [*administration &amp; dosage, adverse effects]; Bevacizumab [administration &amp; dosage]; Intravitreal Injections; Laser Coagulation; Laser Therapy; Macular Edema [*drug therapy, etiology, surgery]; Randomized Controlled Trials as Topic; Ranibizumab [administration &amp; dosage]; Receptors, Vascular Endothelial Growth Factor [administration &amp; dosage]; Recombinant Fusion Proteins [administration &amp; dosage]; Retinal Vein Occlusion [*complications]; Salvage Therapy [methods]; Steroids [administration &amp; dosage]; Vascular Endothelial Growth Factor A [*antagonists &amp; inhibitors]; Visual Acuity [drug effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009510.pub3&amp;doi=10.1002/14651858.CD009510.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009510.pub3&amp;doi=10.1002/14651858.CD009510.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009510.pub3&amp;doi=10.1002/14651858.CD009510.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009510.pub3&amp;doi=10.1002/14651858.CD009510.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009510.pub3&amp;doi=10.1002/14651858.CD009510.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009510.pub3&amp;doi=10.1002/14651858.CD009510.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009510.pub3&amp;doi=10.1002/14651858.CD009510.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009510.pub3&amp;doi=10.1002/14651858.CD009510.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009510.pub3&amp;doi=10.1002/14651858.CD009510.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009510.pub3&amp;doi=10.1002/14651858.CD009510.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009510.pub3&amp;doi=10.1002/14651858.CD009510.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009510.pub3&amp;doi=10.1002/14651858.CD009510.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009510.pub3&amp;doi=10.1002/14651858.CD009510.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009510.pub3&amp;doi=10.1002/14651858.CD009510.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009510.pub3&amp;doi=10.1002/14651858.CD009510.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009510.pub3&amp;doi=10.1002/14651858.CD009510.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009510.pub3&amp;doi=10.1002/14651858.CD009510.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009510.pub3&amp;doi=10.1002/14651858.CD009510.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009510.pub3&amp;doi=10.1002/14651858.CD009510.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009510.pub3&amp;doi=10.1002/14651858.CD009510.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009510.pub3&amp;doi=10.1002/14651858.CD009510.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009510.pub3&amp;doi=10.1002/14651858.CD009510.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009510.pub3&amp;doi=10.1002/14651858.CD009510.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="loVWuZlx";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009510\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009510\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009510\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009510\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","fa","ko","fr","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009510.pub3",title:"Anti\\u2010vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion",firstPublishedDate:"Jul 7, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=loVWuZlx&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009510.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009510.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009510.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009510.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009510.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009510.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009510.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009510.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009510.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009510.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2979 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009510.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/full#CD009510-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/full#CD009510-sec-0089"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/full#CD009510-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/full#CD009510-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/full#CD009510-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/full#CD009510-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/full#CD009510-sec-0045"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/full#CD009510-sec-0076"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/appendices#CD009510-sec-0094"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/supinfo/CD009510StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/supinfo/CD009510StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/information#CD009510-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Zaid Shalchi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/information#CD009510-cr-0005">Omar Mahroo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/information#CD009510-cr-0006">Catey Bunce</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009510.pub3/information#CD009510-cr-0007">Danny Mitry</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/information/en#CD009510-sec-0105">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 07 July 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009510.pub3">https://doi.org/10.1002/14651858.CD009510.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009510-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009510-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009510-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009510-abs-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009510-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD009510-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009510-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009510-abs-0001" lang="en"> <section id="CD009510-sec-0001"> <h3 class="title" id="CD009510-sec-0001">Background</h3> <p>Branch retinal vein occlusion (BRVO) is one of the most commonly occurring retinal vascular abnormalities. The most common cause of visual loss in people with BRVO is macular oedema (MO). Grid or focal laser photocoagulation has been shown to reduce the risk of visual loss. Limitations to this treatment exist, however, and newer modalities may have equal or improved efficacy. Antiangiogenic therapy with anti‐vascular endothelial growth factor (anti‐VEGF) has recently been used successfully to treat MO resulting from a variety of causes. </p> </section> <section id="CD009510-sec-0002"> <h3 class="title" id="CD009510-sec-0002">Objectives</h3> <p>To investigate the efficacy and gather evidence from randomised controlled trials (RCTs) on the potential harms of anti‐vascular endothelial growth factor (VEGF) agents for the treatment of macular oedema (MO) secondary to branch retinal vein occlusion (BRVO). </p> </section> <section id="CD009510-sec-0003"> <h3 class="title" id="CD009510-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2019, Issue 6); MEDLINE Ovid; Embase Ovid; the ISRCTN registry; ClinicalTrials.gov; and the WHO ICTRP. The date of the last search was 12 June 2019. </p> </section> <section id="CD009510-sec-0004"> <h3 class="title" id="CD009510-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) investigating BRVO. Eligible trials had to have at least six months' follow‐up where anti‐VEGF treatment was compared with another treatment, no treatment, or placebo. We excluded trials where combination treatments (anti‐VEGF plus other treatments) were used; and trials that investigated the dose and duration of treatment without a comparison group (other treatment/no treatment/sham). </p> </section> <section id="CD009510-sec-0005"> <h3 class="title" id="CD009510-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted the data using standard methodological procedures expected by Cochrane. The primary outcome was the proportion of participants with an improvement from baseline in best‐corrected visual acuity of greater than or equal to 15 letters (3 lines) on the Early Treatment in Diabetic Retinopathy Study (ETDRS) Chart at six months and 12 months of follow‐up. The secondary outcomes were the proportion of participants who lost greater than or equal to 15 ETDRS letters (3 lines) and the mean visual acuity (VA) change at six and 12 months, as well as the change in central retinal thickness (CRT) on optical coherence tomography from baseline at six and 12 months. We also collected data on adverse events and quality of life (QoL). </p> </section> <section id="CD009510-sec-0006"> <h3 class="title" id="CD009510-sec-0006">Main results</h3> <p>We found eight RCTs of 1631 participants that met the inclusion criteria after independent and duplicate review of the search results. These studies took place in Europe, North America, Eastern Mediterranean region and East Asia. Included participants were adults aged 18 or over with VA of 20/40 or worse. Studies varied by duration of disease but permitted previously treated eyes as long as there was sufficient treatment‐free interval. All anti‐VEGF agents (bevacizumab, ranibizumab and aflibercept) and steroids (triamcinolone and dexamethasone) were included. Overall, we judged the studies to be at moderate or unclear risk of bias. Four of the eight studies did not mask participants or outcome assessors, or both. </p> <p>One trial compared anti‐VEGF to sham. At six months, eyes receiving anti‐VEGF were significantly more likely to have a gain of 15 or more ETDRS letters (risk ratio (RR) 1.72, 95% confidence interval (CI) 1.19 to 2.49; 283 participants; moderate‐certainty evidence). Mean VA was better in the anti‐VEGF group at six months compared with control (mean difference (MD) 7.50 letters, 95% CI 5.29 to 9.71; 282 participants; moderate‐certainty evidence). Anti‐VEGF also proved more effective at reducing CRT at six months (MD −57.50 microns, 95% CI −108.63 to −6.37; 281 participants; lower CRT is better; moderate‐certainty evidence). There was only very low‐certainty evidence on adverse effects. There were no reports of endophthalmitis. Mean change in QoL (measured using the National Eye Institute Visual Functioning Questionnaire VFQ‐25) was better in people treated with anti‐VEGF compared with people treated with sham (MD 7.6 higher score, 95% CI 4.3 to 10.9; 281 participants; moderate‐certainty evidence). </p> <p>Three RCTs compared anti‐VEGF with macular laser (total participants = 473). The proportion of eyes gaining 15 or more letters was greater in the anti‐VEGF group at six months (RR 2.09, 95% CI 1.44 to 3.05; 2 studies, 201 participants; moderate‐certainty evidence). Mean VA in the anti‐VEGF groups was better than the laser groups at six months (MD 9.63 letters, 95% CI 7.23 to 12.03; 3 studies, 473 participants; moderate‐certainty evidence). There was a greater reduction in CRT in the anti‐VEGF group compared with the laser group at six months (MD −147.47 microns, 95% CI −200.19 to −94.75; 2 studies, 201 participants; moderate‐certainty evidence). There was only very low‐certainty evidence on adverse events. There were no reports of endophthalmitis. QoL outcomes were not reported. </p> <p>Four studies compared anti‐VEGF with intravitreal steroid (875 participants). The proportion of eyes gaining 15 or more ETDRS letters was greater in the anti‐VEGF group at six months (RR 1.67, 95% CI 1.33 to 2.10; 2 studies, 330 participants; high‐certainty evidence) and 12 months (RR 1.76, 95% CI 1.36 to 2.28; 1 study, 307 participants; high‐certainty evidence). Mean VA was better in the anti‐VEGF group at six months (MD 8.22 letters, 95% CI 5.69 to 10.76; 2 studies, 330 participants; high‐certainty evidence) and 12 months (MD 9.15 letters, 95% CI 6.32 to 11.97; 2 studies, 343 participants; high‐certainty evidence). Mean CRT also showed a greater reduction in the anti‐VEGF arm at 12 months compared with intravitreal steroid (MD −26.92 microns, 95% CI −65.88 to 12.04; 2 studies, 343 participants; moderate‐certainty evidence). People receiving anti‐VEGF showed a greater improvement in QoL at 12 months compared to those receiving steroid (MD 3.10, 95% CI 0.22 to 5.98; 1 study, 307 participants; moderate‐certainty evidence). Moderate‐certainty evidence suggested increased risk of cataract and raised IOP with steroids. There was only very low‐certainty evidence on APTC events. No cases of endophthalmitis were observed. </p> </section> <section id="CD009510-sec-0007"> <h3 class="title" id="CD009510-sec-0007">Authors' conclusions</h3> <p>The available RCT evidence suggests that treatment of MO secondary to BRVO with anti‐VEGF improves visual and anatomical outcomes at six and 12 months. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009510-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009510-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009510-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009510-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009510-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD009510-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009510-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009510-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009510-abs-0002" lang="en"> <h3>Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion </h3> <p><b>What is the aim of this review?</b><br/>The aim of this Cochrane Review was to find out if anti‐vascular endothelial growth factor (anti‐VEGF) works for the treatment of macular oedema (MO) secondary to branch retinal vein occlusion (BRVO). Cochrane researchers collected and analysed all relevant studies to answer this question and found eight studies. </p> <p><b>Key messages</b> The review shows that people with MO due to BRVO benefit from treatment with anti‐VEGF with an increased chance of improved vision at six and 12 months when compared with no treatment, laser or steroid injection. </p> <p><b>What was studied in the review?</b><br/>There are small blood vessels at the back of the eye (retina) known as arteries (when blood comes into the eye) and veins (when blood leaves the eye). BRVO occurs when a vein that drains part of the retina becomes blocked. This can lead to swelling (oedema) at the back of eye which may result in loss of vision, particularly if it occurs at the centre of the retina (macula). </p> <p>One treatment option for MO due to BRVO is anti‐VEGF injections. VEGF is a molecule found in the back of the eye associated with the inflammation. Anti‐VEGF blocks the action of VEGF, which can help to reduce the amount of damage. Treating MO due to BRVO is important as it can prevent sight loss occurring. </p> <p>The most commonly used anti‐VEGF drugs are:</p> <p>∙ ranibizumab (Lucentis)<br/>∙ aflibercept (Eylea)<br/>∙ bevacizumab (Avastin) </p> <p><b>What are the main results of the review?</b> Cochrane researchers found eight relevant studies. These studies took place in Europe, North America, Eastern Mediterranean region and East Asia. </p> <p>One study compared anti‐VEGF to no treatment (sham injection); three studies compared anti‐VEGF to another type of treatment (laser); and four studies compared anti‐VEGF to steroids. The findings were as follows. </p> <p>∙ People treated with anti‐VEGF were more likely to have improved vision and less swelling at the back of the eye at six months after treatment compared to people who were not treated with anti‐VEGF or who were treated with laser or steroids (moderate‐certainty evidence). </p> <p>∙ In general, there was only very low‐certainty evidence on adverse events (harms) comparing anti‐VEGF treatment to these other treatments. There were no cases of eye infection (endophthalmitis). There was evidence that people treated with steroids (injected into the eye) were more likely to develop cataract or raised pressure in the eye compared with anti‐VEGF. </p> <p>∙ Treatment with anti‐VEGF was associated with a greater improvement in quality of life (moderate certainty). </p> <p><b>How up to date is this review?</b> Cochrane researchers searched for studies that had been published up to June 2019. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009510-sec-0089" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009510-sec-0089"></div> <h3 class="title" id="CD009510-sec-0090">Implications for practice</h3> <section id="CD009510-sec-0090"> <p>Based on the findings of this systematic review of multiple randomised controlled trials of cystoid macular oedema in branch retinal vein occlusion, anti‐VEGF agents provide the most effective treatment in terms of functional (visual acuity) and anatomical (central macular thickness) outcomes when compared with sham, macular laser or intravitreal steroids. They also proved a safer treatment than intravitreal steroids, which led to an increase in intraocular pressure and cataract formation. </p> <p>The follow‐up of the RCTs included was variable. Studies comparing anti‐VEGF with sham or laser were short, with up to six months' follow‐up before rescue treatment was permitted. Trials comparing anti‐VEGF with intravitreal steroid were six to 12 months in duration. This makes long‐term comparison of treatment effect difficult. </p> <p>The economic implications of anti‐VEGF treatment are significant. The drugs licensed for intraocular use (ranibizumab and aflibercept) are expensive. Bevacizumab is much cheaper although not licensed for intraocular use. All drugs require frequent injection, typically monthly for the first three doses. This requires an expanded healthcare delivery system composed of treating doctors, nurses as well as administrative staff. Longer‐acting treatments such as laser or steroid injection do not require a large expansion in the capacity of the healthcare system. The cost of delivering anti‐VEGF treatment is passed on the taxpayer in many developed nations, such as in Europe. Nevertheless, poorer people in poor countries face a struggle to afford frequent anti‐VEGF treatment. </p> </section> <h3 class="title" id="CD009510-sec-0091">Implications for research</h3> <section id="CD009510-sec-0091"> <p>Future research should focus on comparing the various anti‐VEGF agents (bevacizumab, ranibizumab, aflibercept) against each other to determine which, if any, is most effective in the treatment of BRVO. Better description of patient subgroups (e.g. ischaemic versus non‐ischaemic; type of vein occlusion ‒ BRVO/HRVO) and transparent reporting of subgroup outcomes will be important. Re‐treatment decision criteria should be standardised and easy to apply, and more consideration should be given to the time from onset of BRVO and individuals who have previously received other treatments. Trial investigators should report the proportion of patients gaining or losing 15 or more ETDRS letters as well as mean changes in VA. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009510-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009510-sec-0008"></div> <div class="table" id="CD009510-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Anti‐VEGF compared to sham for macular oedema secondary to branch retinal vein occlusion</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Anti‐VEGF v sham for macular oedema secondary to branch retinal vein occlusion</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> macular oedema secondary to branch retinal vein occlusion<br/><b>Setting:</b> eye hospital<br/><b>Intervention:</b> anti‐VEGF<br/><b>Comparison:</b> sham injection </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with sham</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with anti‐VEGF</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Gain of 15 letters or more of visual acuity at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>269 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>462 per 1000<br/>(320 to 669) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.72<br/>(1.19 to 2.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>283<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Data not available because participants in sham group received anti‐VEGF after 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean change in visual acuity letters at 6 months measured with a logMAR chart (higher letter score is better visual acuity) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VA change with sham was 5 letters</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of letters read with anti‐VEGF was 7.50 letters more (5.29 more to 9.71 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>282<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Data not available because participants in sham group received anti‐VEGF after 6 months</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Mean central retinal thickness (CRT) change at 6 months in microns (lower value is better) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean CRT change with sham was −207 microns</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean CRT with anti‐VEGF was 57.5 microns less<br/>(108.63 less to 6.37 less) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Adverse outcomes at any time point</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cataract</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11 per 1000 (1 to 106)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.98 (0.09 to 10.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>283 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕<br/>VERY LOW<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>12 month results. Patients in the sham arm were able to receive rescue anti‐VEGF after 6 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raised IOP*</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>6 per 1000</p> <p>(0 to 101)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 5.41 (0.30 to 96.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>283 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕<br/>VERY LOW<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>APTC events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>22 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>32 per 1000 (6 to 142)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.47 (0.30 to 7.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>283 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕<br/>VERY LOW<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endophthalmitis</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>No endophthalmitis was reported in either anti‐VEGF (n = 190) or sham (n = 91) arms</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Mean change in quality of life (QoL) at 12 months on the National Eye Institute Visual Functioning Questionnaire‐25 (VFQ‐25) (scored 0 to 100) (higher score is better quality of life) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean QoL change with sham was 0</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean QoL score with anti‐VEGF was 7.60 higher (4.30 to 10.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>281 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕<br/>MODERATE<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data collected at 6 months because participants in sham group received anti‐VEGF after 6 months </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). Where no events observed in control group, we have used an estimate of 1 per 1000 for illustrative purposes.<br/><br/><b>ATPC:</b> Antiplatelet Trialists’ Collaboration; <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup>Downgraded 1 level for risk of bias </p> <p><sup>2</sup>Downgraded 2 levels for imprecision and 1 level for risk of bias </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009510-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Anti‐VEGF compared to laser for branch retinal vein occlusion (BRVO)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Anti‐VEGF compared to laser for branch retinal vein occlusion (BRVO)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with BRVO<br/><b>Setting:</b> eye hospital<br/><b>Intervention:</b> anti‐VEGF<br/><b>Comparison:</b> laser </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with laser</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with anti‐VEGF</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Gain of 15 letters or more of visual acuity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>260 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>543 per 1000<br/>(374 to 793) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.09<br/>(1.44 to 3.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Data not available because participants in sham group received anti‐VEGF after 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean change in visual acuity letters measured with a logMAR chart (higher letter score is better visual acuity) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean visual acuity change with laser ranged from 2 to 7 letters</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of letters read with anti‐VEGF was 9.63 letters more<br/>(7.23 more to 12.03 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>473<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Data not available because participants in sham group received anti‐VEGF after 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Mean central retinal thickness (CRT) change at 6 months in microns (lower value is better) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean CRT change with laser was −128 microns</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean CRT change with anti‐VEGF was 147.47 microns less<br/>(200.19 less to 94.75 less) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Adverse outcomes at any time point</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cataract*</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3 per 1000 (0 to 75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.97 (0.12 to 71.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>456 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕<br/>VERY LOW<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raised IOP*</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No raised IOP was reported in either anti‐VEGF (n = 182) or laser (n = 93) groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕<br/>VERY LOW<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>APTC events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>4 per 1000 (1 to 37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.99 (0.15 to 6.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>476 (3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕<br/>VERY LOW<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endophthalmitis</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No endophthalmitis was reported in either anti‐VEGF (n = 284) or laser (n = 192) arms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕<br/>VERY LOW<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Mean change in quality of life at 12 months on the National Eye Institute Visual Functioning Questionnaire‐25 (VFQ‐25) (scored 0 to 100) (higher score is better quality of life) </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). Where no events observed in control group, we have used an estimate of 1 per 1000 for illustrative purposes.<br/><br/><b>ATPC:</b> Antiplatelet Trialists’ Collaboration; <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup>Downgraded 1 level for risk of bias </p> <p><sup>2</sup>Downgraded 1 level for risk of bias and 2 levels for imprecision </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009510-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Anti‐VEGF compared to steroid for branch retinal vein occlusion (BRVO)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Anti‐VEGF compared to steroid for BRVO</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with BRVO<br/><b>Setting:</b> eye hospital<br/><b>Intervention:</b> anti‐VEGF<br/><b>Comparison:</b> steroid </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with steroid</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with anti‐VEGF</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Gain of 15 letters or more of visual acuity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>379 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>633 per 1000<br/>(466 to 802) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.67<br/>(1.33 to 2.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>330<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>338 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>595 per 1000</p> <p>(460 to 771)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.76<br/>(1.36 to 2.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>307<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/>HIGH<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean change in visual acuity letters measured with a logMAR chart (higher letter score is better visual acuity) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean visual acuity change with steroid ranged from 9 to 11 letters</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of letters read with anti‐VEGF was 8.22 more<br/>(5.69 more to 10.76 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>330<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean visual acuity change with steroid ranged from 6 to 8 letters</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean number of letters read with anti‐VEGF was on average 9.15 letters more (6.32 more to 11.97 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>343</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/>HIGH<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Mean central retinal thickness (CRT) change at 12 months in microns (lower value is better) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean CRT change with steroid ranged from −249 to −306 microns</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean CRT change with anti‐VEGF was 26.92 microns less<br/>(65.88 less to 12.04 less) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>343<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕<br/>MODERATE<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Adverse outcomes at any time point</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cataract</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>125 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>22 per 1000 (7 to 75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.12 (0.04 to 0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>551 (3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕<br/>MODERATE<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raised IOP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>240 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>57 per 1000 (34 to 94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.25 (0.16 to 0.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>673 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕<br/>MODERATE<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>APTC events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3 per 1000 (0 to 74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 3.02 (0.12 to 73.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>587 (3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕<br/>VERY LOW<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endophthalmitis</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No endophthalmitis was reported in either anti‐VEGF (n = 187) or steroid (n = 179) arms. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Mean change in quality of life at 12 months on the National Eye Institute Visual Functioning Questionnaire‐25 (VFQ‐25) (scored 0 to 100) (higher score is better quality of life) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life score with steroid was 3.5</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life score with anti‐VEGF was 3.10 higher<br/>(0.22 higher to 5.98 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>307<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕<br/>MODERATE<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ATPC:</b> Antiplatelet Trialists’ Collaboration; <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> One study was judged to be at high risk of attrition bias because participants in the steroid group dropped out of the study due to adverse effects and poor response. We did not downgrade for risk of bias as the direction of the risk of bias is likely to be favouring the steroid group and so the estimate of effect reported here may well be an under‐estimate. </p> <p><sup>2</sup>Downgraded 1 level for risk of bias (studies were at high risk of attrition bias) </p> <p><sup>3</sup>Downgraded 2 levels for imprecision and 1 level for risk of bias </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009510-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009510-sec-0009"></div> <section id="CD009510-sec-0010"> <h3 class="title" id="CD009510-sec-0010">Description of the condition</h3> <p>Branch retinal vein occlusion (BRVO) is the second most commonly occurring retinal vascular abnormality after diabetic retinopathy (<a href="./references#CD009510-bbs2-0086" title="MitchellP , SmithW , ChangA . Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Archives of Ophthalmology1996;114(10):1243-7.">Mitchell 1996</a>). A BRVO is an occlusion of either a major branch retinal vein draining one quadrant of the retina, a macular branch vein draining the macula, or a peripheral branch vein draining a portion of the retinal periphery. The pathogenesis of BRVO is thought to involve both retinal vein compression and damage to the vessel wall, possibly leading to thrombus formation. BRVOs are thought to occur at sites where retinal arterioles cross retinal veins. Histopathological studies support the hypothesis that because of a common adventitial sheath, thickening of the arteriolar wall compresses the lumen of the vein which alters blood flow causing thrombosis and venous occlusion (<a href="./references#CD009510-bbs2-0059" title="FrangiehGT , GreenWR , Barraquer-SomersE , FinkelsteinD . Histopathologic study of nine branch retinal vein occlusions. Archives of Ophthalmology1982;100(7):1132-40.">Frangieh 1982</a>). Once the occlusion occurs, increased vascular pressure behind the occlusion may lead to leakage of fluid and small molecules across the vascular wall and into the surrounding retinal tissue, resulting in local oedema. This oedema is characterised by the collection of fluid in intercellular spaces within the outer plexiform layer of the retina and results from the breakdown of the capillary endothelium blood‐retinal barrier and leakage of fluid from the vasculature. Vascular endothelial damage to the affected vein may induce low‐grade, chronic inflammation of the retinal microvasculature and upregulation of inflammatory mediators. These mediators include prostaglandins, leukotrienes, intercellular adhesion molecule‐1, integrins, tumour necrosis factor‐a, and vascular endothelial growth factor (VEGF) (<a href="./references#CD009510-bbs2-0056" title="EhlersJP , FekratS . Retinal vein occlusion: beyond the acute event. Survey of Ophthalmology2011;56(4):281-99.">Ehlers 2011</a>; <a href="./references#CD009510-bbs2-0060" title="FunkM , KriechbaumK , PragerF , BeneschT , GeorgopoulosM , ZlabingerGJ , et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Investigative Ophthalmology and Visual Science2009;50(3):1025-32.">Funk 2009</a>; <a href="./references#CD009510-bbs2-0096" title="RehakJ , RehakM . Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Current Eye Research2008;33(2):111-31.">Rehak 2008</a>). </p> <p>The 15‐year incidence of BRVO in an elderly (aged 65 to 74 years) Caucasian (understood to be white) population is 1.8% (<a href="./references#CD009510-bbs2-0078" title="KleinR , MossSE , MeuerSM , KleinBE . The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Archives of Ophthalmology2008;126(4):513-8.">Klein 2008</a>); and most studies report a range of between 0.6% and 2% (<a href="./references#CD009510-bbs2-0077" title="KleinR , KleinBE , MossSE , MeuerSM . The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Transactions of the American Ophthalmological Society2000;98:133-41.">Klein 2000</a>; <a href="./references#CD009510-bbs2-0086" title="MitchellP , SmithW , ChangA . Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Archives of Ophthalmology1996;114(10):1243-7.">Mitchell 1996</a>; <a href="./references#CD009510-bbs2-0107" title="WongTY , LarsenEK , KleinR , MitchellP , CouperDJ , KleinBE , et al. Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities &amp; Cardiovascular Health studies. Ophthalmology2005;112(4):540-7.">Wong 2005</a>; <a href="./references#CD009510-bbs2-0108" title="XuL , LiuWW , WangYX , YangH , JonasJB . Retinal vein occlusions and mortality: the Beijing Eye Study. American Journal of Ophthalmology2007;144(6):972-3.">Xu 2007</a>; <a href="./references#CD009510-bbs2-0109" title="YasudaM , KiyoharaY , ArakawaS , HataY , YonemotoK , DoiY , et al. Prevalence and systemic risk factors for retinal vein occlusion in a general Japanese population: the Hisayama study. Investigative Ophthalmology and Visual Science2010;51(6):3205-9.">Yasuda 2010</a>). A recent pooled analysis of 68,751 individuals indicates an age and gender standardised prevalence for BRVO of 4.42 per 1000 (confidence interval (CI) 3.65 to 5.19; <a href="./references#CD009510-bbs2-0099" title="RogersSL , McIntoshRL , LimL , MitchellP , CheungN , KowalskiJW , et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology2010;117(6):1094-101.">Rogers 2010a</a>); however, significant heterogeneity between studies precluded a formal meta‐analysis. Second eye involvement by BRVO may occur in between 3.5% to 9% of cases over time (<a href="./references#CD009510-bbs2-0062" title="Glacet-BernardA , CoscasG , ChabanelA , ZourdaniA , LelongF , SamamaMM . Prognostic factors for retinal vein occlusion: prospective study of 175 cases. Ophthalmology1996;103(4):551-60.">Glacet‐Bernard 1996</a>; <a href="./references#CD009510-bbs2-0100" title="RogersS , McIntoshRL , CheungN , LimL , WangJJ , MitchellP , et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology2010;117(2):313-9.">Rogers 2010b</a>); and affected individuals have a loss in vision‐related quality of life even with normal vision in the fellow eye (<a href="./references#CD009510-bbs2-0042" title="AwdehRM , ElsingSH , DeramoVA , StinnettS , LeePP , FekratS . Vision-related quality of life in persons with unilateral branch retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. British Journal of Ophthalmology2010;94(3):319-23.">Awdeh 2010</a>). </p> <p>BRVO may be classified on a spectrum of ischaemic or non‐ischaemic designated by the disc areas (DA) of hypoperfusion on fluorescein angiography. The extent of ischaemia has a relationship with the likelihood of neovascular complications with reports suggesting a rate of retinal neovascularisation in 36% to 62% of eyes with more than 5 DA of non‐perfusion over two years of follow‐up (<a href="./references#CD009510-bbs2-0105" title="ShillingJS , KohnerEM . New vessel formation in retinal branch vein occlusion. British Journal of Ophthalmology1976;60(12):810-5.">Shilling 1976</a>). </p> <p>Known risk factors for BRVO include hypertension, atherosclerosis, hyperlipidaemia, diabetes mellitus, thrombophilia and other inflammatory and myeloproliferative disorders (<a href="./references#CD009510-bbs2-0053" title="DodsonPM , GaltonDJ , HamiltonAM , BlachRK . Retinal vein occlusion and the prevalence of lipoprotein abnormalities. British Journal of Ophthalmology1982;66(3):161-4.">Dodson 1982</a>; <a href="./references#CD009510-bbs2-0054" title="DodsonPM , KritzingerEE , CloughCG . Diabetes mellitus and retinal vein occlusion in patients of Asian, West Indian and white European origin. Eye1992;6(1):66-8.">Dodson 1992</a>; <a href="./references#CD009510-bbs2-0055" title="Anonymous. Risk factors for branch retinal vein occlusion. The Eye Disease Case-Control Study Group. American Journal of Ophthalmology1993;116(3):286-96.">EDCCS Group 1993</a>). A systematic review of the natural history of BRVO suggests that although the baseline visual acuity (VA) is generally poor (less than 20/40), with time the VA improves, and between one third and three quarters of eyes show at least a two‐line improvement in VA without intervention. However, clinically significant improvement beyond 20/40 is uncommon (<a href="./references#CD009510-bbs2-0100" title="RogersS , McIntoshRL , CheungN , LimL , WangJJ , MitchellP , et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology2010;117(2):313-9.">Rogers 2010b</a>). </p> <p>The most common cause of visual loss in BRVO patients is macular oedema (MO), which occurs in 5% to 15% of patients within the first year (<a href="./references#CD009510-bbs2-0100" title="RogersS , McIntoshRL , CheungN , LimL , WangJJ , MitchellP , et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology2010;117(2):313-9.">Rogers 2010b</a>). Other causes of visual loss include macular ischaemia, glaucoma and neovascularisation (<a href="./references#CD009510-bbs2-0100" title="RogersS , McIntoshRL , CheungN , LimL , WangJJ , MitchellP , et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology2010;117(2):313-9.">Rogers 2010b</a>). Macular oedema and neovascularisation of the retina or disc are the two major complications that require therapy (<a href="./references#CD009510-bbs2-0044" title="The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. American Journal of Ophthalmology1984;98(3):271-82.">BVOS Group 1984</a>; <a href="./references#CD009510-bbs2-0105" title="ShillingJS , KohnerEM . New vessel formation in retinal branch vein occlusion. British Journal of Ophthalmology1976;60(12):810-5.">Shilling 1976</a>). Many treatment strategies, both medical and surgical, have been reported for BRVO. Surgical treatments thought to be of benefit include vitrectomy with internal limiting membrane peeling and vitrectomy with arteriovenous sheathotomy (<a href="./references#CD009510-bbs2-0056" title="EhlersJP , FekratS . Retinal vein occlusion: beyond the acute event. Survey of Ophthalmology2011;56(4):281-99.">Ehlers 2011</a>). Medical therapies of clinical benefit include grid laser photocoagulation (GLP), sector panretinal photocoagulation, intravitreal steroids (triamcinolone, dexamethasone) and intravitreal vascular endothelial growth factor inhibitors. </p> <p>The BVOS clinical trial evaluated whether grid macular laser photocoagulation improved the VA in patients with a VA of 20/40 or worse resulting from MO secondary to BRVO. This multicentre randomised controlled trial (RCT) assigned 139 participants to either grid macular laser photocoagulation or no laser treatment. The groups were well matched at baseline in terms of risk factors, duration of symptoms, and VA. With a mean follow‐up of 3.1 years (68% of participants), the grid laser group had statistically significant improvements in VA with 65% (28/43) treated versus 37% (13/35) controls gaining two or more lines of vision over consecutive visits (P = 0.014). Since its publication in 1984, this has been the 'gold standard' treatment; there were, however, several limitations, notably the exclusion of participants who had a BRVO within three months and the exclusion of those with foveal haemorrhage (<a href="./references#CD009510-bbs2-0044" title="The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. American Journal of Ophthalmology1984;98(3):271-82.">BVOS Group 1984</a>). This study has led to the current recommendation in the UK (Royal College of Ophthalmologists) that GLP is an effective treatment to reduce MO and to improve VA in BRVO with MO and VA of 20/40 or less. Treatment should be postponed for three months after onset to allow for any spontaneous resolution and reduction in haemorrhage. Fluorescein angiography is recommended before treatment to quantify the level of macular ischaemia, which may limit the value of laser photocoagulation. In addition, grid laser treatment is thought unlikely to provide significant benefit in eyes with BRVO of more than one year’s duration and VA of 20/200 or worse. </p> <p>The SCORE study (<a href="./references#CD009510-bbs2-0104" title="ScottIU , IpMS , VanVeldhuisenPC , OdenNL , BlodiBA , FisherM , et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Archives of Ophthalmology2009;127(9):1115-28.">Scott 2009</a>) examined intravitreal triamcinolone (IVTA) versus standard of care (GLP) to elucidate the differences in GLP versus IVTA for MO secondary to BRVO in 411 eyes. Approximately 45% of individuals had a BRVO with MO of three to six months' duration and 9% of included participants had more than 10 disc areas of non‐perfusion. The mean (standard deviation (SD)) number baseline Early Treatment in Diabetic Retinopathy Study (ETDRS) letters was 57 (12.6). Eyes were randomised to either grid‐pattern laser (n = 137), 1 mg IVTA (n= 136), or 4 mg IVTA (n = 138). In the SCORE study, eyes were retreated with their assigned dose of IVTA or grid‐pattern laser every four months during the study period unless there was a predefined significant improvement or a significant adverse event. The results of the SCORE study demonstrated that there was no difference in VA between eyes treated with IVTA or GLP at 12 months. Twenty‐nine per cent, 26%, and 27% gained three or more lines of visual acuity at one year in the laser, 1 mg, and 4 mg groups, respectively. All three groups showed similar reductions in MO as measured by optical coherence tomography (OCT). The IVTA groups had an increased rate of side effects, particularly raised intraocular pressure (IOP) requiring medication (7%: 1 mg; 41%; 4 mg; versus 2% laser) and cataract formation (25%: 1 mg; 35%: 4 mg; versus 13% laser). There were no cases of endophthalmitis in the laser and 1 mg group, but there was one case in the 4 mg group. Other reported adverse events were vitreous floaters and conjunctival haemorrhage: 31% of the 1 mg triamcinolone group and 26% of 4 mg triamcinolone group had vitreous floaters and 30% of the 1 mg triamcinolone group and 33% of the 4 mg triamcinolone group had conjunctival haemorrhage. </p> <p>Recently, the utility of extended‐release corticosteroid delivery systems has been evaluated in the GENEVA study (<a href="./references#CD009510-bbs2-0069" title="HallerJA , BandelloF , Belfort R Jr, BlumenkranzMS , GilliesM , HeierJ , et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology2010;117(6):1134-46.">Haller 2010</a>). An international study at 167 sites in 24 countries was designed to examine the effect of a sustained‐release intravitreal dexamethasone delivery system at the 0.35 mg and 0.7 mg (Ozurdex, Allergan) dose for MO in eyes with BRVO or central retinal vein occlusion (CRVO) over a 6‐month period. At baseline, the mean VA was approximately 54 letters (20/80) in all groups, and the mean central retinal thickness was approximately 550 microns. Ten per cent of participants (131/1267) had a history of photocoagulation, and 17% had a duration of retinal vein occlusion (RVO) and MO of less than three months. All comparison groups were well matched. Primary outcome was reported for all RVO eyes grouped together. In a subgroup analysis of 291 eyes with BRVO receiving the 0.7 mg implant, at 60 days following treatment 30% gained 15 letters or more compared to 13% in the sham group. At 90 days, 24% gained 15 letters or more compared to 15% in the sham group. The difference was significant at both time points, but not at the 180‐day time point. The overall incidence of ocular adverse events was significantly higher in the Ozudex implant 0.7 mg group (62.9%) and Ozudex implant 0.35 mg group (61.9%) than in the sham group (42.8%). Cataract progression was similar in both the treatment and the sham groups in the 6‐month study. The only adverse events that occurred significantly more frequently in either the Ozudex implant treatment group than in the sham group were eye pain, ocular hypertension, and anterior chamber cells. Ocular hypertension (≥ 25 mmHg) occurred in 4% of treated eyes (0.35 mg and 0.7 mg implants) compared to 0.7% of sham eyes (<a href="./references#CD009510-bbs2-0069" title="HallerJA , BandelloF , Belfort R Jr, BlumenkranzMS , GilliesM , HeierJ , et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology2010;117(6):1134-46.">Haller 2010</a>). Ozurdex received Food and Drug Administration (FDA) approval for treatment of MO secondary to BRVO in 2009. </p> </section> <section id="CD009510-sec-0011"> <h3 class="title" id="CD009510-sec-0011">Description of the intervention</h3> <p>Vascular endothelial growth factor (VEGF) plays a role in the development of MO and in the neovascular complications of BRVO. Elevated intraocular levels of VEGF have been demonstrated in patients with RVOs (<a href="./references#CD009510-bbs2-0010" title="CampochiaroPA , HafizG , ShahSM , NguyenQD , YingH , DoDV , et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Molecular Therapy2008;16(4):791-9. ">Campochiaro 2008</a>); and sustained release of VEGF in primate eyes causes vascular leakage and MO (<a href="./references#CD009510-bbs2-0089" title="OzakiH , HayashiH , VinoresSA , MoromizatoY , CampochiaroPA , OshimaK . Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Experimental Eye Research1997;64(4):505-17.">Ozaki 1997</a>). There are several anti‐VEGF agents available. The first licensed drug was bevacizumab (Avastin®), a recombinant humanised monoclonal whole immunoglobulin antibody that binds to VEGF and blocks the binding of VEGF to endothelial cell receptors (<a href="./references#CD009510-bbs2-0057" title="FerraraN , DamicoL , ShamsN , LowmanH , KimR . Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina2006;26(8):859-70.">Ferrara 2006</a>). Bevacizumab was licensed for the treatment of bowel cancer. Pegaptanib sodium (Macugen®) is a pegylated modified oligonucleotide, which binds to extracellular VEGF‐165 and antagonises its biological effects (<a href="./references#CD009510-bbs2-0066" title="GragoudasES , AdamisAP , Cunningham ET Jr, FeinsodM , GuyerDR . Pegaptanib for neovascular age-related macular degeneration. New England Journal of Medicine2004;351(27):2805-16.">Gragoudas 2004</a>). Ranibizumab (Lucentis®) is a recombinant humanised monoclonal immunoglobulin antibody fragment that binds to the receptors of biologically active VEGF‐A (<a href="./references#CD009510-bbs2-0093" title="PrestaLG , ChenH , O'ConnorSJ , ChisholmV , MengYG , KrummenL , et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Research1997;57(20):4593-9.">Presta 1997</a>); it has been licensed for the treatment of age‐related macular degeneration (AMD) and RVOs in the USA and Europe. Aflibercept (VEGF Trap‐eye) (Eylea®) is a further VEGF‐binding recombinant fusion protein, and has been hypothesised to have the greatest efficacy of its class due to its binding to VEGF isoforms A and B, as well as placental growth factor (PGF). Monoclonal antibodies against VEGF administered intravitreally have been approved for the treatment of AMD (<a href="./references#CD009510-bbs2-0101" title="RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine2006;355(14):1419-31.">Rosenfeld 2006</a>), and widespread evidence has suggested a benefit and favourable side effect profile of their use in MO secondary to RVOs (<a href="./references#CD009510-bbs2-0047" title="CampochiaroPA , HeierJS , FeinerL , GrayS , SarojN , RundleAC , et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology2010;117(6):1102-12.">Campochiaro 2010b</a>; <a href="./references#CD009510-bbs2-0092" title="PragerF , MichelsS , KriechbaumK , GeorgopoulosM , FunkM , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. British Journal of Ophthalmology2009;93(4):452-6.">Prager 2009</a>, <a href="./references#CD009510-bbs2-0061" title="Garnock-JonesKP . Ranibizumab: in macular oedema following retinal vein occlusion. Drugs2011;71(4):455-63.">Garnock‐Jones 2011</a>). </p> </section> <section id="CD009510-sec-0012"> <h3 class="title" id="CD009510-sec-0012">How the intervention might work</h3> <p>Elevated intraocular levels of VEGF have been demonstrated in patients with RVOs (<a href="./references#CD009510-bbs2-0088" title="NomaH , MinamotoA , FunatsuH , TsukamotoH , NakanoK , YamashitaH , et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology2006;244(3):309-15.">Noma 2006</a>). Sustained release of VEGF in primate eyes causes vascular leakage and MO (<a href="./references#CD009510-bbs2-0089" title="OzakiH , HayashiH , VinoresSA , MoromizatoY , CampochiaroPA , OshimaK . Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Experimental Eye Research1997;64(4):505-17.">Ozaki 1997</a>); and several studies have demonstrated that anti‐VEGF antibodies inhibit VEGF mediated neovascularisation and permeability in both in vitro and in vivo studies (<a href="./references#CD009510-bbs2-0040" title="AielloLP , PierceEA , FoleyED , TakagiH , ChenH , RiddleL , et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proceedings of the National Academy of Sciences of the United States of America1995;92(23):10457-61.">Aiello 1995a</a>; <a href="./references#CD009510-bbs2-0041" title="AielloLP , NorthrupJM , KeytBA , TakagiH , IwamotoMA . Hypoxic regulation of vascular endothelial growth factor in retinal cells. Archives of Ophthalmology1995;113(12):1538-44.">Aiello 1995b</a>; <a href="./references#CD009510-bbs2-0043" title="BoydSR , ZacharyI , ChakravarthyU , AllenGJ , WisdomGB , CreeIA , et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Archives of Ophthalmology2002;120(12):1644-50.">Boyd 2002</a>). Thus there is a strong basis for the hypothesis that anti‐VEGF agents may be beneficial in the treatment of vascular leakage and MO (<a href="./references#CD009510-bbs2-0010" title="CampochiaroPA , HafizG , ShahSM , NguyenQD , YingH , DoDV , et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Molecular Therapy2008;16(4):791-9. ">Campochiaro 2008</a>). </p> </section> <section id="CD009510-sec-0013"> <h3 class="title" id="CD009510-sec-0013">Why it is important to do this review</h3> <p>BRVO is the most common RVO and a significant cause of visual morbidity. Current treatment regimens licensed in the UK include macular photocoagulation and more recently intravitreal dexamethasone (Ozurdex®) implants. Intravitreal anti‐VEGF therapy has a good side effect profile (serious adverse ocular events less than 0.1% (out of 1301 participants)) (<a href="./references#CD009510-bbs2-0080" title="KourlasH , AbramsP . Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clinical Therapeutics2007;29(9):1850-61.">Kourlas 2007</a>) (see systematic review <a href="./references#CD009510-bbs2-0087" title="MitchellP . A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. Current Medical Research and Opinion2011;27(7):1465-75.">Mitchell 2011</a>) and has not been found to be associated commonly with side effects such as a sustained rise in IOP commonly seen with steroid preparations. Several early reports suggested an important clinical efficacy for the use of anti‐VEGF in MO secondary to BRVO (<a href="./references#CD009510-bbs2-0047" title="CampochiaroPA , HeierJS , FeinerL , GrayS , SarojN , RundleAC , et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology2010;117(6):1102-12.">Campochiaro 2010b</a>; <a href="./references#CD009510-bbs2-0011" title="CampochiaroPA , HafizG , ChannaR , ShahSM , NguyenQD , YingH , et al. Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes. Ophthalmology2010;117(12):2387-94. ">Campochiaro 2010a</a>; <a href="./references#CD009510-bbs2-0082" title="KriechbaumK , MichelsS , PragerF , GeorgopoulosM , FunkM , GeitzenauerW , et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. British Journal of Ophthalmology2008;92(4):518-22.">Kriechbaum 2008</a>; <a href="./references#CD009510-bbs2-0026" title="MoradianS , FaghihiH , SadeghiB , PiriN , AhmadiehH , SoheilianM , et al. Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1). Graefe's Archive for Clinical and Experimental Ophthalmology2011;249(2):193-200. ">Moradian 2011</a>; <a href="./references#CD009510-bbs2-0092" title="PragerF , MichelsS , KriechbaumK , GeorgopoulosM , FunkM , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. British Journal of Ophthalmology2009;93(4):452-6.">Prager 2009</a>; <a href="./references#CD009510-bbs2-0095" title="RabenaMD , PieramiciDJ , CastellarinAA , NasirMA , AveryRL . Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina2007;27(4):419-25.">Rabena 2007</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009510-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009510-sec-0014"></div> <p>To investigate the efficacy and gather evidence from randomised controlled trials (RCTs) on the potential harms of anti‐vascular endothelial growth factor (VEGF) agents for the treatment of macular oedema (MO) secondary to branch retinal vein occlusion (BRVO). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009510-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009510-sec-0015"></div> <section id="CD009510-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009510-sec-0017"> <h4 class="title">Types of studies</h4> <p>In this review, we sought to include all randomised controlled trials of at least six months' duration: we judged a minimum of six months was required to determine treatment efficacy and adverse effects. We included published and unpublished studies in all languages to ensure the widest possible collection of evidence. We included studies as long as they reported at least one primary or secondary outcome that this review is considering. </p> </section> <section id="CD009510-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included trials with participants of all ages and both genders who have had a diagnosis of unilateral or bilateral macular oedema secondary to branch retinal vein occlusion or hemi‐retinal vein occlusion. All countries and ethnic groups were eligible for inclusion. We included treatment‐naive and previously‐treated eyes. </p> </section> <section id="CD009510-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included trials where anti‐VEGF treatment was compared with another treatment, no treatment, or placebo. We excluded trials where combination treatments (anti‐VEGF plus other treatments) were used and excluded trials that investigated the dose and duration of treatment without a comparison group (other treatment/no treatment/sham). We judged that choosing clear, distinct comparisons would help produce clear results of treatment outcome. </p> </section> <section id="CD009510-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD009510-sec-0021"> <h5 class="title">Primary outcomes</h5> <p>The primary outcome for this review was the proportion of participants with an improvement from baseline in best‐corrected visual acuity (BCVA) of greater than or equal to 15 letters (three lines) on the Early Treatment in Diabetic Retinopathy Study (ETDRS) chart at six months and at 12 months of follow‐up. </p> </section> <section id="CD009510-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p>We examined the following secondary outcomes as they represent important clinical and therapeutic indices of safety and efficacy. </p> <p> <ol id="CD009510-list-0001"> <li> <p>Mean visual acuity (VA) change at six and 12 months.</p> </li> <li> <p>The proportion of participants with a loss of 15 or more letters (ETDRS) compared with baseline at six and 12 months. </p> </li> <li> <p>Change in central retinal thickness (CRT) on optical coherence tomography (OCT) from baseline at 12 months. </p> </li> </ol> </p> <section id="CD009510-sec-0023"> <h6 class="title">Adverse outcomes</h6> <p>We sought to report any ocular or systemic adverse outcomes reported in the trials.</p> </section> <section id="CD009510-sec-0024"> <h6 class="title">Quality of life data</h6> <p>We reported any quality of life data reported in the studies.</p> </section> </section> </section> </section> <section id="CD009510-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD009510-sec-0026"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Eyes and Vision Information Specialist conducted systematic searches in the following electronic databases for RCTs and controlled clinical trials. There were no restrictions to language or year of publication. The date of the search was 12 June 2019. </p> <p> <ul id="CD009510-list-0002"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 6) (which contains the Cochrane Eyes and Vision Trials Register) in the Cochrane Library (searched 12 June 2019) (<a href="./appendices#CD009510-sec-0095">Appendix 1</a>). </p> </li> <li> <p>MEDLINE Ovid (1946 to 12 June 2019) (<a href="./appendices#CD009510-sec-0096">Appendix 2</a>). </p> </li> <li> <p>Embase Ovid (1980 to 12 June 2019) (<a href="./appendices#CD009510-sec-0097">Appendix 3</a>). </p> </li> <li> <p>Latin American and Caribbean Literature on Health Sciences (LILACS) (1982 to 12 June 2019) (<a href="./appendices#CD009510-sec-0098">Appendix 4</a>). </p> </li> <li> <p>ISRCTN registry (<a href="http://www.isrctn.com/editAdvancedSearch" target="_blank">www.isrctn.com/editAdvancedSearch</a>; searched 12 June 2019) (<a href="./appendices#CD009510-sec-0099">Appendix 5</a>). </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register (<a href="http://www.clinicaltrials.gov" target="_blank">www.ClinicalTrials.gov</a>; searched 12 June 2019) (<a href="./appendices#CD009510-sec-0100">Appendix 6</a>). </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a>; searched 12 June 2019) (<a href="./appendices#CD009510-sec-0101">Appendix 7</a>). </p> </li> </ul> </p> </section> <section id="CD009510-sec-0027"> <h4 class="title">Searching other resources</h4> <p>We manually searched the references of identified studies to try to find other relevant studies. We also contacted the corresponding authors of included studies to find further information. </p> </section> </section> <section id="CD009510-sec-0028"> <h3 class="title" id="CD009510-sec-0028">Data collection and analysis</h3> <section id="CD009510-sec-0029"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently reviewed all the titles and abstracts identified from the electronic and manual searches against the inclusion criteria. We classified each report into one of four categories: include; possibly include; exclude; and unclear. We obtained the full‐text articles of all 'possibly include' articles and both review authors independently assessed and classified these articles. We resolved disagreement by discussion between the review authors. </p> </section> <section id="CD009510-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>We extracted the following participant and trial characteristics and reported them in appropriate table format. </p> <p> <ul id="CD009510-list-0003"> <li> <p>Participant characteristics (gender, age, diagnostic criteria, baseline VA, central retinal thickness) </p> </li> <li> <p>Intervention (drug, dose, timing interval, time from diagnosis, frequency and length of treatment) </p> </li> <li> <p>Methodology (group size, randomisation, masking, unit of analysis)</p> </li> <li> <p>Primary and secondary outcomes</p> </li> <li> <p>Additional data (quality of life)</p> </li> <li> <p>Treatment compliance and dropout rate/loss to follow‐up</p> </li> </ul> </p> <p>Two review authors extracted the data independently using forms developed by the Cochrane Eyes and Vision Group. The review authors compared the two sets of extracted data and resolved any identified discrepancies through discussion. One review author entered data into Review Manager 5 (RevMan 5) and a second review author checked that the data entered were correct (<a href="./references#CD009510-bbs2-0098" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). Where more than one report was present for a single study, we used all reports to extract data into a single data collection form. </p> <p>When data were missing from a publication or ClinicalTrials.gov, we contacted investigators by email with a request to provide data for this review. We used intention‐to‐treat analysis to deal with missing data. </p> </section> <section id="CD009510-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors assessed the methodological quality of the selected trials according to Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009510-bbs2-0071" title="HigginsJPT , SavovićJ , PageMJ , ElbersRG , SterneJAC . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>). We considered the following main criteria according to the GRADE approach. </p> <p> <ul id="CD009510-list-0004"> <li> <p>Selection bias: sequence generation, allocation concealment</p> </li> <li> <p>Detection bias: blinding (masking) of outcome assessment</p> </li> <li> <p>Performance bias: masking of participants, researchers and outcome assessors</p> </li> <li> <p>Attrition bias: loss to follow‐up, rates of compliance</p> </li> <li> <p>Reporting bias: selective outcome reporting</p> </li> </ul> </p> <p>We reported each parameter as high risk of bias, low risk of bias or unclear.</p> </section> <section id="CD009510-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>We defined these according to the data types established in Chapter 9 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009510-bbs2-0052" title="DeeksJJ , HigginsJP , AltmanDG , editor(s) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Deeks 2017</a>); they include the following. </p> <section id="CD009510-sec-0033"> <h5 class="title">Dichotomous data</h5> <p>Variables in this group included the primary outcome, the proportion of participants with a loss of 15 or more letters (ETDRS) compared with baseline, the proportion of participants experiencing a complication or adverse event during follow‐up and the proportion of participants given additional treatments during follow‐up. We reported dichotomous variables as risk ratios (RRs) with 95% confidence intervals (CIs). </p> </section> <section id="CD009510-sec-0034"> <h5 class="title">Continuous data</h5> <p>These variables included mean change in visual acuity (VA) and mean change in central retinal thickness (CRT). We reported continuous variables as a mean difference (MD) ± standard deviation (SD) (normal distribution) or median and inter‐quartile range (not normally distributed). </p> </section> <section id="CD009510-sec-0035"> <h5 class="title">Ordinal data</h5> <p>The types of adverse events, complications and interventions performed were ordinal data. </p> </section> <section id="CD009510-sec-0036"> <h5 class="title">Counts and rates data</h5> <p>We measured the number of adverse events, number of complications and interventions performed as counts or rates data. </p> </section> </section> <section id="CD009510-sec-0037"> <h4 class="title">Unit of analysis issues</h4> <p>All studies considered one eye per person. When dealing with multi‐arm studies, we only extracted data from the arms dealing with the basis of this review. </p> </section> <section id="CD009510-sec-0038"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the authors of the <a href="./references#CD009510-bbs2-0008" title="CampochiaroPA , ClarkWL , BoyerDS , HeierJS , BrownDM , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology2015;122(3):538-44. ClarkWL , BoyerDS , HeierJS , BrownDM , HallerJA , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology2016;123(2):330-6. ">VIBRANT</a> study to request SD data for mean letters gained and mean change in central retinal thickness at six months. This was provided. We contacted the authors of unpublished and unreported studies <a href="./references#CD009510-bbs2-0035" title="NCT01189526. Comparison of intravitreal ranibizumab and macular laser photocoagulation for ME following branch retinal vein occlusion (BRVO). clinicaltrials.gov/ct2/show/NCT01189526 (first received 26 August 2010). ">NCT01189526</a> and <a href="./references#CD009510-bbs2-0036" title="NCT01795209. Ranibizumab for macular edema secondary to branch retinal vein occlusion in patients with fair vision (RVOFV). clinicaltrials.gov/ct2/show/NCT01795209 (first received 20 February 2013). ">NCT01795209</a> to obtain results but did not receive responses to our email requests. </p> </section> <section id="CD009510-sec-0039"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered heterogeneity between studies by looking at the basic characteristics of participants (e.g. age, gender or ethnicity) as well as their inclusion and exclusion criteria. We used the I² statistic to assess heterogeneity. This is a measure of the percentage variance attributable to study heterogeneity. </p> </section> <section id="CD009510-sec-0040"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed reporting bias by comparing the published results against the study protocol. We assessed publication bias by searching both published articles and trial registries. </p> </section> <section id="CD009510-sec-0041"> <h4 class="title">Data synthesis</h4> <p>We used RevMan 5 to combine results across studies. We used GRADE software to produce 'Summary of findings' tables, along with certainty assessments, which we used to summarise risk of bias in presented results. </p> </section> <section id="CD009510-sec-0042"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed subgroup analysis by comparing the efficacy of the anti‐VEGF agents (bevacizumab, ranibizumab and aflibercept) across studies. </p> <p>We assessed heterogeneity between studies with the I² statistic as outlined in <a href="#CD009510-sec-0039">Assessment of heterogeneity</a> above. </p> </section> <section id="CD009510-sec-0043"> <h4 class="title">Sensitivity analysis</h4> <p>No sensitivity analysis was performed for this review.</p> </section> <section id="CD009510-sec-0044"> <h4 class="title">'Summary of findings' table</h4> <p>We prepared 'Summary of findings' tables for the following three comparisons using GRADEpro software (<a href="./references#CD009510-bbs2-0065" title="GRADEpro GDT. Version accessed prior to 11 July 2019. Hamilton (ON): McMaster University (developed by Evidence Prime).Available at gradepro.org.">GRADEpro GDT</a>): anti‐VEGF versus sham, anti‐VEGF versus laser and anti‐VEGF versus steroids. We included the following outcomes in the 'Summary of findings' table. </p> <p> <ol id="CD009510-list-0005"> <li> <p>Gain of 15 letters or more of visual acuity at six months</p> </li> <li> <p>Gain of 15 letters or more of visual acuity at 12 months</p> </li> <li> <p>Mean visual acuity change at six months</p> </li> <li> <p>Mean visual acuity change at 12 months</p> </li> <li> <p>Mean central retinal thickness change at 12 months</p> </li> <li> <p>Adverse outcomes at any time point</p> </li> <li> <p>Quality of life change at 12 months</p> </li> </ol> </p> <p>We graded the certainty of the evidence using GRADE (<a href="./references#CD009510-bbs2-0064" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editors The GRADE Working Group. GRADE Handbook for grading quality of evidence and strength of recommendations. gdt.gradepro.org/app/handbook/handbook.html (initially accessed 2013).">GRADE 2013</a>). GRADE has four categories: high‐, moderate‐, low‐ and very low‐certainty evidence. We considered randomised controlled trials to be high‐certainty evidence and downgraded for serious limitations in study design (risk of bias), inconsistency, imprecision, indirectness and evidence of publication bias. Two authors did the GRADE assessment independently using a checklist designed to aid consistency and reproducibility of the GRADE assessments (<a href="./references#CD009510-bbs2-0084" title="MeaderN , KingK , LlewellynA , NormanG , BrownJ , RodgersM , et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews2014;3:82. [DOI: 10.1186/2046-4053-3-82]">Meander 2014</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009510-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009510-sec-0045"></div> <section id="CD009510-sec-0046"> <h3 class="title">Description of studies</h3> <section id="CD009510-sec-0047"> <h4 class="title">Results of the search</h4> <p>The electronic searches run in 2012 yielded a total of 448 references. The Cochrane Information Specialist (CIS) scanned the search results, removed duplicates and 325 references which were not relevant to the scope of the review. We screened 163 reports to identify potentially relevant studies. We identified 29 case series and summarised the results of these studies (see <a href="#CD009510-tbl-0004">Table 1</a>). We excluded a further 121 records after reading the abstract. We obtained full‐text copies of eight records for further investigation. We included two studies in the review. One RCT (two reports) compared anti‐VEGF with sham injection; and one quasi‐RCT compared macular grid laser with anti‐VEGF. We excluded five studies and identified five ongoing studies (<a href="https://archie.cochrane.org/sections/documents/view?version=z1211261603450976286212009980708&amp;format=REVMAN#STD-EUCTR2010_x002d_023900_x002d_29_x002d_GB" target="_blank">EUCTR2010-023900-29-GB</a>; <a href="./references#CD009510-bbs2-0035" title="NCT01189526. Comparison of intravitreal ranibizumab and macular laser photocoagulation for ME following branch retinal vein occlusion (BRVO). clinicaltrials.gov/ct2/show/NCT01189526 (first received 26 August 2010). ">NCT01189526</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1211261603450976286212009980708&amp;format=REVMAN#STD-NCT01396057" target="_blank">NCT01396057</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1211261603450976286212009980708&amp;format=REVMAN#STD-NCT01521559" target="_blank">NCT01521559</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1211261603450976286212009980708&amp;format=REVMAN#STD-NCT01635803" target="_blank">NCT01635803</a>). We marked these studies for assessment and possible inclusion in the review when data became available. </p> <div class="table" id="CD009510-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Interventional case studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of eyes included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective recruitment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug and dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean IVI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean f‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0038" title="AbeggM , TappeinerC , Wolf-SchnurrbuschU , BarthelmesD , WolfS , FleischhauerJ . Treatment of branch retinal vein occlusion induced macular edema with bevacizumab. BMC Ophthalmology2008;8:18. [DOI: 10.1186/1471-2415-8-18]">Abegg 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 m (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BCVA (logMAR) improved from 0.7 to 0.5 and mean CMT improved from 454 µm to 305 µm </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0039" title="AhmadiAA , ChuoJY , BanashkevichA , MaPE , MaberleyDA . The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion. Canadian Journal of Ophthalmology2009;44(2):154-9.">Ahmadi 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 eyes</p> <p>(All non‐ischaemic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in mean Snellen BCVA from 20/280 to 20/170 at final follow‐up. Mean CMT reduction from 451 µm to 400 µm at 6 mths. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0045" title="ByeonSH , KwonYA , OhHS , KimM , KwonOW . Short-term results of intravitreal bevacizumab for macular edema with retinal vein obstruction and diabetic macular edema. Journal of Ocular Pharmacology and Therapeutics2007;23(4):387-94.">Byeon 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 eyes (14 with MO and BRVO)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50% of patients had previous laser treatment. The mean log‐MAR of the BRVO group was 0.71, and this improved 1 month after the second injection to 0.34. The mean CMT was 468.6 µm which decreased to 186.4 µm at final follow‐up. No significant ocular or systemic SE. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0046" title="ByunYJ , RohMI , LeeSC , KohHJ . Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology2010;248(7):963-71.">Byun 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191 eyes</p> <p>Comparative study: IVB (n = 73) versus IVTA (n = 118)</p> <p>(non‐ischaemic = 90%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.1 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BCVA (logMAR) improved from 0.91 to 0.45 in the IVB group and mean CMT decreased from 477 µm to 218 µm. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0048" title="CekicO , CakirM , YaziciAT , AlagozN , BozkurtE , Faruk YilmazO . A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion. Current Eye Research2010;35(10):925-9.">Cekic 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 eyes</p> <p>Comparative study: IVTA (n = 17), IVB (n = 14), combined  (n = 21)</p> <p>(All non‐ischaemic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BCVA (logMAR) improved from 0.92 to 0.45 in the IVB group. No significant ocular or systemic SE. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0049" title="ChenCH , ChenYH , WuPC , ChenYJ , LeeJJ , LiuYC , et al. Treatment of branch retinal vein occlusion induced macular edema in treatment-naive cases with a single intravitreal triamcinolone or bevacizumab injection. Chang Gung Medical Journal2010;33(4):424-35.">Chen 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83 eyes</p> <p>Comparative study: IVTA (n = 25), IVB (n = 24), no treatment (n = 34)</p> <p>(56% ischaemic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 2.5 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.4 wks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BCVA (logMAR) improved from 0.95 to 0.79 at 12 weeks</p> <p>Mean CMT decreased from 457 µm to 323 µm 24 weeks after treatment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0050" title="ChengKC , WuWC , ChenKJ . Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion. Eye2009;23(11):2023-33.">Cheng 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 eyes</p> <p>Comparative study: IVTA (n = 16), IVB (n = 13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.5% of IVB group received previous laser treatment. Improvement in mean BCVA (logMAR) from 0.99 to 0.35 at final follow‐up. Reduction in mean CMT from 538 µm to 222 µm microns. No significant ocular or systemic side effects. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0051" title="ChungEJ , HongYT , LeeSC , KwonOW , KohHJ . Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology2008;246(9):1241-7.">Chung 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.9 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56% gained 5 or more ETDRS letters; 44% had less than 5 ETDRS letter gain or worse final BCVA. No significant ocular or systemic side effects. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0058" title="FigueroaMS , ContrerasI , NovalS , ArruabarrenaC . Results of bevacizumab as the primary treatment for retinal vein occlusions. British Journal of Ophthalmology2010;94(8):1052-6.">Figueroa 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in mean BCVA (logMAR) from 0.8 to 0.44 at final follow‐up. Reduction in mean CMT from 486 µm to 268 µm. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0067" title="GregoriNZ , RattanGH , RosenfeldPJ , PuliafitoCA , FeuerW , Flynn HW Jr, et al. Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion. Retina2009;29(7):913-25.">Gregori 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 eyes</p> <p>(23% ischaemic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 17 eyes (26%) returned for follow‐up. The median Snellen BCVA improved from 20/100 at baseline to 20/50 at 12 months. The mean CMT decreased by 205 µm compared with baseline. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0068" title="GunduzK , BakriSJ . Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. Eye2008;22(9):1168-71.">Gunduz 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 eyes</p> <p>(40% ischaemic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in mean BCVA (logMAR) from 0.91 to 0.48 at final follow‐up. Reduction in mean CMT from 506 µm to 267.5 µm. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0070" title="HaraS , SakurabaT , KataokaH , YanagihashiS , SaitouK , NodaY . Effect of repeated intravitreal bevacizumab injections for secondary macular edema of branch retinal vein occlusion. Nihon Ganka Gakkai Zasshi2010;114(12):1013-8.">Hara 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 3 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean reduction in CMT from 610 µm to 368 µm after 1 injection</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0072" title="HoehAE , AchT , SchaalKB , ScheuerleAF , DithmarS . Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology2009;247(12):1635-41.">Hoeh 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 eyes (34 with BRVO)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 2.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BCVA (logMAR) improved from 0.50 to 0.32. Mean CMT decreased from 602 µm to 386 µm.  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0073" title="HouJ , TaoY , JiangYR , LiXX , GaoL . Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study. Chinese Medical Journal2009;122(22):2695-9.">Hou 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 eyes</p> <p>Comparative study: IVTA (n = 34), IVB (n = 34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.9 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BCVA improved by 0.14 logMAR units. Mean CMT decreased from 506 µm to 228 µm.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0075" title="JaissleGB , LeitritzM , GeliskenF , ZiemssenF , Bartz-SchmidtKU , SzurmanP . One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology2009;247(1):27-33.">Jaissle 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> <p>(All non‐ischaemic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 in first 6 months and 0.8 in second 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The median VA gained 3.0 lines from baseline at 48 weeks and there was a decrease of 39% of the median CMT. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0076" title="JaissleGB , SzurmanP , FeltgenN , SpitzerB , PielenA , RehakM , et al. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology2011;249(2):183-92.">Jaissle 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.8 wks</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The median BCVA (logMAR) was 0.6 at baseline improving to 0.4. Reduction in CMT, from a baseline of 454 µm to 248 µm. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0079" title="KondoM , KondoN , ItoY , KachiS , KikuchiM , YasumaTR , et al. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion:results after 12 months and multiple regression analysis. Retina2009;29(9):1242-8.">Kondo 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean BCVA (logMAR) improved from 0.53 to 0.26. Mean CMT decreased from 523 µm to 305 µm. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0081" title="KreutzerTC , AlgeCS , WolfAH , KookD , BurgerJ , StraussR , et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. British Journal of Ophthalmology2008;92(3):351-5.">Kreutzer 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean BCVA (logMAR) improved from 0.79 to 0.51 at 6 months. Mean CMT decreased from 474 µm to 316 µm. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0082" title="KriechbaumK , MichelsS , PragerF , GeorgopoulosM , FunkM , GeitzenauerW , et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. British Journal of Ophthalmology2008;92(4):518-22.">Kriechbaum 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 eyes (21 with BRVO)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.0 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline mean BCVA was 50 ETDRS letters, by month 6, BCVA improved  to 65 letters. CMT decreased from 558 µm to 382 µm.  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0085" title="MehanySA . Early Avastin management in acute retinal vein occlusion. Saudi Journal of Ophthalmology2010;24(3):87-94.">Mehany 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 eyes with BRVO</p> <p>(All non‐ischaemic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline BCVA was 20/240 (logMAR 1.08) improving to 20/60 (logMAR 0.48) at the end of follow‐up (approx 12 months). The mean CMT decreased to 250 ± 48 µm. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0090" title="PaiSA , ShettyR , VijayanPB , VenkatasubramaniamG , YadavNK , ShettyBK , et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. American Journal of Ophthalmology2007;143(4):601-6.">Pai 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 wks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BCVA (logMAR) was 1.22 improving to 0.61. The mean CMT was 672.8 µm at baseline. There was a 44.6% decrease in CMT from baseline. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0091" title="PeceA , IsolaV , PiermarocchiS , CaloriG . Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up. British Journal of Ophthalmology2011;95(1):56-68.">Pece 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean improvement in BCVA (logMAR) from 0.80 0.41. Mean reduction of 275 µm in CMT from baseline. Contrast sensitivity, time and reading fluency improved significantly in the treated eyes. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0092" title="PragerF , MichelsS , KriechbaumK , GeorgopoulosM , FunkM , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. British Journal of Ophthalmology2009;93(4):452-6.">Prager 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 eyes (BRVO only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In the BRVO group (n =  18), visual acuity increased from 55 letters (20/80) at baseline to 73 letters (20/32) at month 12. CMT decreased significantly by 241 μm after 12 months of follow‐up. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0095" title="RabenaMD , PieramiciDJ , CastellarinAA , NasirMA , AveryRL . Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina2007;27(4):419-25.">Rabena 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BCVA improved from 20/200 to 20/100 at final follow‐up. Mean CMT decreased from 487 µm to 332 µm at final follow‐up. No adverse side effects were observed following injections. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0097" title="RenschF , JonasJB , SpandauUH . Early intravitreal bevacizumab for non-ischaemic branch retinal vein occlusion. Ophthalmologica2009;223(2):124-7.">Rensch 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.2 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BCVA (logMAR) improved from 0.81 to 0.55 at 6 months. Mean CMT decreased from 492 µm to 316 µm. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0102" title="RouvasA , PetrouP , NtourakiA , DouvaliM , LadasI , VergadosI . Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study. Retina2010;30(6):893-902.">Rouvas 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BCVA (logMAR) improved from 0.74 to 0.49. Mean CMT decreased from 349 µm at baseline to 229 µm. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0103" title="SchaalKB , HohAE , ScheuerleA , SchuttF , DithmarS . Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe2007;104(4):285-9.">Schaal 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 eyes (BRVO only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 2.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 wks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.5% of those with BRVO had a significant improved visual acuity (by at least 3 lines). Mean CMT decreased from 678 µm to 236 µm. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0106" title="StahlA , AgostiniH , HansenLL , FeltgenN . Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefe's Archive for Clinical and Experimental Ophthalmology2007;245(10):1429-36.">Stahl 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 wks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BCVA (logMAR) improved from 0.5 to 0.31 at 9 weeks. Mean CMT reduced from 408 µm to 309 µm. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0074" title="HungKH , LeeSM , LeeSY , LeeFL , YangCS . Intravitreal bevacizumab (avastin) in the treatment of macular edema associated with perfused retinal vein occlusion. Journal of Ocular Pharmacology and Therapeutics2010;26(1):85-90.">Hung 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 eyes (12 with BRVO only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 2.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 6.5 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50% (6/12) had received previous treatment. Mean BCVA (logMAR) improved from 0.94 to 0.54 at final follow‐up. Mean CMT reduced from 392 µm to 234 µm. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>m: months; wks: weeks; BCVA: best‐corrected visual acuity; CMT: central macular thickness; IVTA: intravitreal triamcinolone; IVB: intravitreal bevacizumab; IVI: intravitreal injections; f‐up: follow‐up; VA: visual acuity </p> </div> </div> <p>Update searches run in June 2019 yielded a further 1735 records (<a href="#CD009510-fig-0001">Figure 1</a>). After 538 duplicates were removed, the Cochrane Information Specialist (CIS) screened the remaining 1197 records and removed 710 references that were not relevant to the scope of the review. We screened the remaining 487 references and obtained 35 full‐text reports for further assessment. We identified 13 reports of eight new studies; for further details see <a href="./references#CD009510-sec-0111" title="">Characteristics of included studies</a>. We excluded 21 reports of 21 studies: see <a href="./references#CD009510-sec-0112" title="">Characteristics of excluded studies</a>. We identified one new ongoing study (<a href="./references#CD009510-bbs2-0037" title="NCT03108352. Conbercept ophthalmic injection for patients with macular edema caused by branch retinal vein occlusion. clinicaltrials.gov/ct2/show/NCT03108352 (first received 11 April 2017). ">NCT03108352</a>); and have followed up on the five ongoing studies that were cited in the previous version of the review. Studies <a href="./references#CD009510-bbs2-0035" title="NCT01189526. Comparison of intravitreal ranibizumab and macular laser photocoagulation for ME following branch retinal vein occlusion (BRVO). clinicaltrials.gov/ct2/show/NCT01189526 (first received 26 August 2010). ">NCT01189526</a> and <a href="https://archie.cochrane.org/sections/documents/view?version=z1211261603450976286212009980708&amp;format=REVMAN#STD-NCT01635803" target="_blank">NCT01635803</a> are ongoing; the three other studies have been completed and incorporated into the following new studies: <a href="./references#CD009510-bbs2-0001" title="BandelloF , AugustinA , TufailA , LeabackR . A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. European Journal of Ophthalmology2018;28(6):697–705. EU-CTR 2010-023900-29. A 12-month, multicentre, randomised, parallel group study to compare the efficacy and safety of OZURDEX® versus Lucentis® in patients with branch retinal vein occlusion. www.clinicaltrialsregister.eu/ctr-search/trial/2010-023900-29/results (first received 28 August 2011). NCT01427751. Safety and efficacy study of Ozurdex® compared to Lucentis® in patients with branch retinal vein occlusion. clinicaltrials.gov/ct2/show/NCT01427751 (first received 2 September 2011). ">Bandello 2018</a>, <a href="./references#CD009510-bbs2-0004" title="HattenbachLO , FeltgenN , BertelmannT , Schmitz-ValckenbergS , BerkH , EterN , et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmologica2018;96(1):e10-8. ">COMRADE‐B</a> and <a href="./references#CD009510-bbs2-0008" title="CampochiaroPA , ClarkWL , BoyerDS , HeierJS , BrownDM , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology2015;122(3):538-44. ClarkWL , BoyerDS , HeierJS , BrownDM , HallerJA , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology2016;123(2):330-6. ">VIBRANT</a>. </p> <div class="figure" id="CD009510-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009510-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>In the previous version of this review there were two included studies and five excluded studies. For this update we have excluded the two studies which were previously included; see <a href="#CD009510-sec-0109">Differences between protocol and review</a>. Consequently this review now contains eight included studies, 26 excluded studies and three ongoing studies. </p> </section> <section id="CD009510-sec-0048"> <h4 class="title">Included studies</h4> <p><a href="./references#CD009510-bbs2-0001" title="BandelloF , AugustinA , TufailA , LeabackR . A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. European Journal of Ophthalmology2018;28(6):697–705. EU-CTR 2010-023900-29. A 12-month, multicentre, randomised, parallel group study to compare the efficacy and safety of OZURDEX® versus Lucentis® in patients with branch retinal vein occlusion. www.clinicaltrialsregister.eu/ctr-search/trial/2010-023900-29/results (first received 28 August 2011). NCT01427751. Safety and efficacy study of Ozurdex® compared to Lucentis® in patients with branch retinal vein occlusion. clinicaltrials.gov/ct2/show/NCT01427751 (first received 2 September 2011). ">Bandello 2018</a> was a 12‐month multi‐centre randomised controlled trial of 307 eyes in 307 participants with branch retinal vein occlusion. Participants were randomised to dexamethasone implant (n = 154) or ranibizumab injection (n = 153). Eyes in the dexamethasone arm all received treatment at baseline, then again at month 5 and month 10/11 if required. Eyes in the ranibizumab group received injection at baseline then monthly to month 5, with treatment as required thereafter to month 12. </p> <p><a href="./references#CD009510-bbs2-0002" title="NCT01976338. Ranibizumab intravitreal injections versus sham control in patients with branch retinal vein occlusion (BRVO) (Blossom). ClinicalTrials.gov/show/NCT01976338 (first received 5 November 2013). WeiW . To assess the efficacy and safety of individualized intravitreal ranibizumab 0.5 mg in Asian (primarily Chinese) patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). In: Annual Meeting of the Association for Research in Vision and Ophthalmology. 2017. ">BLOSSOM</a> was a 12‐month, phase III, multicentre randomised controlled trial of 283 participants with branch retinal vein occlusion. Participants were randomised to receive ranibizumab (n = 190) or sham (n = 93). The ranibizumab arm received three ranibizumab 0.5 mg injections spaced monthly, followed by injections as required based on pre‐defined re‐treatment criteria. The sham arm consisted of treatment in the form of sham injections until six months, after which participants could receive ranibizumab 0.5 mg as required. Hence we excluded data points from this arm from six months. </p> <p><a href="./references#CD009510-bbs2-0003" title="TadayoniR , WaldsteinSM , BosciaF , GerdingH , GekkievaM , BarnesE , et al. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology2017;124(12):1778-87. TadayoniR , WaldsteinSM , BosciaF , GerdingH , PearceI , PriglingerS , et al. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology2016;123(6):1332-44. ">BRIGHTER</a> was a phase III open label study of 455 participants across 17 countries comparing ranibizumab (n = 183), ranibizumab plus laser (n = 180), and laser alone (n = 92) for the treatment of cystoid macular oedema in BRVO. Participants were assigned with a ratio of 2:2:1 to these groups. Participants received monthly injection or laser every four months until visual acuity was deemed stable, after which treatment was given on an 'as needed' basis. Importantly, participants in the laser arm were also able to receive ranibizumab from month 6. We excluded data points from this arm from six months onwards. </p> <p><a href="./references#CD009510-bbs2-0004" title="HattenbachLO , FeltgenN , BertelmannT , Schmitz-ValckenbergS , BerkH , EterN , et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmologica2018;96(1):e10-8. ">COMRADE‐B</a> was a 6‐month, phase IIIb, multicentre, randomised, double‐masked study that enrolled participants with visual impairment due to macular oedema secondary to BRVO. Two hundred and forty‐four participants were enrolled from 74 sites across Europe. Ranibizumab (n = 126) was given as three loading injections at the start of the study until a stable VA was reached followed by 'as needed' treatment; whilst the dexamethasone arm (n = 118) was given as a single injection at baseline with monthly sham injections until month 3 followed by an 'as needed' regimen. The primary outcome was mean average change in BCVA from baseline to month 1 through month 6. </p> <p><a href="./references#CD009510-bbs2-0005" title="HigashiyamaT , SawadaO , KakinokiM , SawadaT , KawamuraH , OhjiM . Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion. Acta Ophthalmologica2013;91(4):318-24. ">Higashiyama 2013</a> performed a prospective, comparative, randomised, interventional clinical trial. Forty‐three eyes of 43 participants with macular oedema because of BRVO were randomly assigned to 4 mg intravitreal injections of TA (IVTA) (21 participants, IVTA group) or 1.25 mg intravitreal injections of bevacizumab (IVB) (22 participants, IVB group) and followed for 12 months. No additional treatments were administered for three months after the initial injection; additional injections were administered when macular oedema recurred between three and 12 months after the initial injection. The main outcome measures were changes in the logarithm of the minimal angle of resolution BCVA and CRT from baseline to 12 months. </p> <p>The <a href="./references#CD009510-bbs2-0006" title="PielenA , MirshahiA , FeltgenN , LorenzK , KorbC , JunkerB , et al. Ranibizumab for branch retinal vein occlusion associated macular edema study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmologica2015;93(1):e29-37. ">RABAMES</a> trial was a prospective, randomised, controlled, multicentre investigator‐initiated clinical trial over six months on 30 participants with BRVO and macular oedema. The three arms of the study were: intravitreal ranibizumab (n = 10) versus grid‐pattern laser photocoagulation (n = 10) versus a combination of both (n = 10) in participants with chronic macular oedema secondary to BRVO. During the 3‐month treatment period, participants received either three monthly intravitreal ranibizumab injections, or up to two treatment sessions of macular laser photocoagulation or intravitreal ranibizumab combined with laser photocoagulation. The primary outcomes were mean gain in ETDRS letters, proportion of participants gaining 15 or more letters and improvement in central retinal thickness. </p> <p><a href="./references#CD009510-bbs2-0007" title="RamezaniA , EsfandiariH , EntezariM , MoradianS , SoheilianM , DehsarviB , et al. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology2012;250(8):1149-60. ">Ramezani 2012</a> performed a controlled, randomised single‐masked clinical trial on treatment‐naive BRVO with duration of less than 12 weeks. Eligible eyes were randomly assigned to intravitreal bevacizumab (IVB) (n = 43) and intravitreal triamcinolone (IVT) (n = 43) groups. In the IVB group, the eyes received three prescheduled monthly intravitreal injections of 1.25 mg/0.5 ml bevacizumab. The eyes in the IVT group had two prescheduled intravitreal injections of 2 mg/0.5 ml triamcinolone acetonide, performed two months apart. The primary outcome was the change in BCVA at six months. Secondary outcome measures consisted of CMT changes, determined by OCT, and intraocular pressure (IOP) changes. </p> <p>The <a href="./references#CD009510-bbs2-0008" title="CampochiaroPA , ClarkWL , BoyerDS , HeierJS , BrownDM , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology2015;122(3):538-44. ClarkWL , BoyerDS , HeierJS , BrownDM , HallerJA , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology2016;123(2):330-6. ">VIBRANT</a> study was a phase III, multicentre, randomised, double‐masked, active‐controlled, 52‐week trial comparing the efficacy and safety of intravitreal aflibercept injection (IAI) with macular grid laser photocoagulation for treatment of macular oedema after BRVO. Participants 18 years old with BRVO or hemi‐retinal vein occlusion (HRVO) causing oedema involving the centre of the macula were eligible for enrolment if the occlusion occurred within 12 months, and BCVA was between 73 and 24 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (20/40 to 20/320 Snellen equivalent). Eyes in the IAI group (n = 91) received 2 mg IAI every four weeks from baseline to week 20. A sham laser treatment was also performed at baseline. After this, eyes received 2 mg IAI every eight weeks with rescue laser at week 36 if needed. Eyes in the laser group (n = 92) received macular laser photocoagulation at baseline and sham injections every four weeks from baseline to week 20. After this, eyes received three 2 mg IAI every four weeks; then 8‐weekly with rescue laser at week 36 if needed. Eyes in both treatment groups were evaluated for rescue treatment from week 12 onward. The primary efficacy outcome measure was the proportion of eyes that gained 15 ETDRS letters in BCVA from baseline at week 24. The secondary efficacy outcome measures were a change from baseline in BCVA, CRT, and the National Eye Institute 25‐item Visual Function Questionnaire (NEI VFQ‐25) total scores. Additional prespecified endpoints were the time to first sustained gain of 15 letters, change from baseline in NEI VFQ‐25 subscales (near activities, distance activities, and visual dependency), and proportion of participants with a change in retinal perfusion. Safety assessments included ocular and non‐ocular adverse events (AEs) and serious AEs (SAEs).This cross‐over design means results at six months are a true reflection of treatment efficacy. After this, eyes in the laser group were eligible to receive IAI, of which 80.7% did. In comparison, 10.6% of the IAI group received rescue laser at week 36. Standard deviations for this study were obtained by email correspondence with the authors. </p> <p>Included studies typically reported proportion of participants gaining 15 letters or more (<a href="./references#CD009510-bbs2-0006" title="PielenA , MirshahiA , FeltgenN , LorenzK , KorbC , JunkerB , et al. Ranibizumab for branch retinal vein occlusion associated macular edema study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmologica2015;93(1):e29-37. ">RABAMES</a>); or the mean change in visual acuity (<a href="./references#CD009510-bbs2-0003" title="TadayoniR , WaldsteinSM , BosciaF , GerdingH , GekkievaM , BarnesE , et al. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology2017;124(12):1778-87. TadayoniR , WaldsteinSM , BosciaF , GerdingH , PearceI , PriglingerS , et al. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology2016;123(6):1332-44. ">BRIGHTER</a>; <a href="./references#CD009510-bbs2-0005" title="HigashiyamaT , SawadaO , KakinokiM , SawadaT , KawamuraH , OhjiM . Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion. Acta Ophthalmologica2013;91(4):318-24. ">Higashiyama 2013</a>). Some reported both (<a href="./references#CD009510-bbs2-0001" title="BandelloF , AugustinA , TufailA , LeabackR . A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. European Journal of Ophthalmology2018;28(6):697–705. EU-CTR 2010-023900-29. A 12-month, multicentre, randomised, parallel group study to compare the efficacy and safety of OZURDEX® versus Lucentis® in patients with branch retinal vein occlusion. www.clinicaltrialsregister.eu/ctr-search/trial/2010-023900-29/results (first received 28 August 2011). NCT01427751. Safety and efficacy study of Ozurdex® compared to Lucentis® in patients with branch retinal vein occlusion. clinicaltrials.gov/ct2/show/NCT01427751 (first received 2 September 2011). ">Bandello 2018</a>; <a href="./references#CD009510-bbs2-0002" title="NCT01976338. Ranibizumab intravitreal injections versus sham control in patients with branch retinal vein occlusion (BRVO) (Blossom). ClinicalTrials.gov/show/NCT01976338 (first received 5 November 2013). WeiW . To assess the efficacy and safety of individualized intravitreal ranibizumab 0.5 mg in Asian (primarily Chinese) patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). In: Annual Meeting of the Association for Research in Vision and Ophthalmology. 2017. ">BLOSSOM</a>; <a href="./references#CD009510-bbs2-0004" title="HattenbachLO , FeltgenN , BertelmannT , Schmitz-ValckenbergS , BerkH , EterN , et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmologica2018;96(1):e10-8. ">COMRADE‐B</a>; <a href="./references#CD009510-bbs2-0027" title="RamezaniA , EsfandiariH , EntezariM , MoradianS , SoheilianM , DehsarviB , et al. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent onset central retinal vein occlusion. Acta Ophthalmologica2014;92(7):e530-9. ">Ramezani 2014</a>; <a href="./references#CD009510-bbs2-0008" title="CampochiaroPA , ClarkWL , BoyerDS , HeierJS , BrownDM , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology2015;122(3):538-44. ClarkWL , BoyerDS , HeierJS , BrownDM , HallerJA , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology2016;123(2):330-6. ">VIBRANT</a>). </p> <p>See the '<a href="./references#CD009510-sec-0111" title="">Characteristics of included studies</a>' table for additional details. </p> </section> <section id="CD009510-sec-0049"> <h4 class="title">Excluded studies</h4> <p>We excluded 26 studies. We excluded <a href="./references#CD009510-bbs2-0009" title="BrownDM , CampochiaroPA , BhisitkulRB , HoAC , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology2011;118(8):1594-602. CampochiaroPA , HeierJS , FeinerL , GrayS , SarojN , RundleAC , et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology2010;117(6):1102-12. ">BRAVO 2010</a> due to the use of rescue laser treatment in both the sham and anti‐VEGF arms; and <a href="./references#CD009510-bbs2-0029" title="RussoV , BaroneA , ConteE , PrascinaF , StellaA , NociND . Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina2009;29(4):511-5. ">Russo 2009</a> due to its quasi‐RCT design. Three trials were dose‐finding studies (<a href="./references#CD009510-bbs2-0010" title="CampochiaroPA , HafizG , ShahSM , NguyenQD , YingH , DoDV , et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Molecular Therapy2008;16(4):791-9. ">Campochiaro 2008</a>; <a href="./references#CD009510-bbs2-0011" title="CampochiaroPA , HafizG , ChannaR , ShahSM , NguyenQD , YingH , et al. Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes. Ophthalmology2010;117(12):2387-94. ">Campochiaro 2010a</a>; <a href="./references#CD009510-bbs2-0033" title="WroblewskiJJ , Wells JA 3rd, GonzalesCR . Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion. American Journal of Ophthalmology2010;149(1):147-54. ">Wroblewski 2010</a>); and one study had a follow‐up period of less than six months (<a href="./references#CD009510-bbs2-0026" title="MoradianS , FaghihiH , SadeghiB , PiriN , AhmadiehH , SoheilianM , et al. Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1). Graefe's Archive for Clinical and Experimental Ophthalmology2011;249(2):193-200. ">Moradian 2011</a>). We excluded an additional seven studies as they examined combination therapy (<a href="./references#CD009510-bbs2-0013" title="ChiquetC , BronAM , StraubM , DupuyC , IsaicoR , AptelF , et al. Retinal vein occlusions: therapeutic switch in macular oedema treatment with a 12-month follow-up. Ophthalmic Research2016;55(3):152-8. ">Chiquet 2016</a>; <a href="./references#CD009510-bbs2-0016" title="DonatiS , BarosiP , BianchiM , Al OumM , AzzoliniC . Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion. European Journal of Ophthalmology2012;22(4):607-14. ">Donati 2012</a>; <a href="./references#CD009510-bbs2-0019" title="HanhartJ , RozenmanY . Comparison of intravitreal ranibizumab, aflibercept, and dexamethasone implant after bevacizumab failure in macular edema secondary to retinal vascular occlusions. Ophthalmologica2017;238(1-2):110-8. ">Hanhart 2017</a>; <a href="./references#CD009510-bbs2-0020" title="KartasasmitaAS , TakaraiS , SwitaniaA , EnusS . Efficacy of single bevacizumab injection as adjuvant therapy to laser photocoagulation in macular edema secondary to branch retinal vein occlusion. Clinical Ophthalmology2016;10:2135-40. ">Kartasasmita 2016</a>; <a href="./references#CD009510-bbs2-0025" title="MoonJ , KimM , SagongM . Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion. Eye2016;30(8):1084-90. ">Moon 2016</a>; <a href="./references#CD009510-bbs2-0032" title="TomomatsuY , TomomatsuT , TakamuraY , GozawaM , ArimuraS , TakiharaY , et al. Comparative study of combined bevacizumab/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions. Acta Ophthalmologica2016;94(3):e225-30. ">Tomomatsu 2016</a>; <a href="./references#CD009510-bbs2-0034" title="ZhangXY , LiYB , ZhouLW , WangXB , LuoXD . Observation on intravitreal injection of ranibizumab combined with laser photocoagulation for the treatment of macular edema in BRVO. International Eye Science2014;14:747-9. ">Zhang 2014</a>). We excluded four studies as they compared anti‐VEGF treatment to other anti‐VEGF therapy (<a href="./references#CD009510-bbs2-0015" title="RajagopalR , ShahGK , BlinderKJ , AltaweelM , EliottD , WeeR , et al. Bevacizumab versus ranibizumab in the treatment of macular edema due to retinal vein occlusion: 6-month results of the CRAVE study. Ophthalmic Surgery, Lasers &amp; Imaging Retina2015;46(8):844-50. ">CRAVE 2015</a>; <a href="./references#CD009510-bbs2-0021" title="KlimesJ , RegnierSA , MahonR , BudekT , DostalF , SkalickyD , DeptaJ . Cost effectiveness analysis of ranibizumab compared to aflibercept and laser intervention In treatment of diabetic macular edema (DME) In the Czech Republic. Value in Health2015;18:A 419. ">Klimes 2015</a>; <a href="./references#CD009510-bbs2-0024" title="NarayananR , PanchalB , DasT , ChhablaniJ , JalaliS , AliMH , et al. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1. British Journal of Ophthalmology2015;99(7):954–9. ">MARVEL</a>; <a href="./references#CD009510-bbs2-0030" title="CampochiaroPA , WykoffCC , SingerM , JohnsonR , MarcusD , YauL , et al. Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study. Ophthalmology2014;121(12):2432-42. ">SHORE 2014</a>). Four studies had a retrospective, non‐randomised design (<a href="./references#CD009510-bbs2-0012" title="ChiquetC , DupuyC , BronAM , AptelF , StraubM , IsaicoR , et al. Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naive patients with retinal vein occlusion and macular edema: a 12-month follow-up study. Graefe's Archive for Clinical and Experimental Ophthalmology2015;253(12):2095-102. ">Chiquet 2015</a>; <a href="./references#CD009510-bbs2-0017" title="GuX , YuX , SongS , DaiH . Intravitreal dexamethasone implant versus intravitreal ranibizumab for the treatment of macular edema secondary to retinal vein occlusion in a Chinese population. Ophthalmic Research2017;58(1):8-14. ">Gu 2017</a>; <a href="./references#CD009510-bbs2-0018" title="GuignierB , Subilia-GuignierA , FournierI , BallonzoliL , Speeg-SchatzC , GaucherD . Prospective pilot study: efficacy of intravitreal dexamethasone and bevacizumab injections in the treatment of macular oedema associated with branch retinal vein occlusion. Ophthalmologica2013;230(1):43-9. ">Guignier 2013</a>; <a href="./references#CD009510-bbs2-0022" title="LeitritzMA , GeliskenF , ZiemssenF , SzurmanP , Bartz-SchmidtKU , JaissleGB . Grid laser photocoagulation for macular oedema due to branch retinal vein occlusion in the age of bevacizumab? Results of a prospective study with crossover design. British Journal of Ophthalmology2013;97(2):215-9. ">Leitritz 2013</a>). <a href="./references#CD009510-bbs2-0028" title="RegnierSA , LarsenM , BezlyakV , AllenF . Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis. BMJ Open2015;5(6):e007527. ">Regnier 2015</a> is a review article. See the '<a href="./references#CD009510-sec-0112" title="">Characteristics of excluded studies</a>' table and <a href="#CD009510-tbl-0005">Table 2</a> for further details. From the search, we identified numerous interventional case series where anti‐VEGF agents for MO secondary to BRVO were used. These did not meet the inclusion criteria for the systematic review, and primary outcomes for these are summarised in <a href="#CD009510-tbl-0004">Table 1</a>. </p> <div class="table" id="CD009510-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Excluded studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conclusion</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0011" title="CampochiaroPA , HafizG , ChannaR , ShahSM , NguyenQD , YingH , et al. Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes. Ophthalmology2010;117(12):2387-94. ">Campochiaro 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose‐finding study: patients with CRVO (n = 14) and BRVO (n = 17) were randomised to receive either 0.3 mg ranibizumab or 0.5 mg ranibizumab and followed for 2 years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 0.3 mg and 0.5 mg doses had similar results and when combined showed that 20 patients with BRVO had mean and median improvements in BCVA of 16.1 and 15 letters. After 2 years of follow‐up, only 5 of 17 patients with BRVO and 3 of 14 patients with CRVO were oedema‐free with no injections for at least 1 year. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0010" title="CampochiaroPA , HafizG , ShahSM , NguyenQD , YingH , DoDV , et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Molecular Therapy2008;16(4):791-9. ">Campochiaro 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose‐finding study: patients with CRVO (n = 20) and BRVO (n = 20) were randomised to receive 3 monthly injections either 0.3 mg ranibizumab or 0.5 mg ranibizumab. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary end point at 3 months: improvement of 10 and 18 letters in the BRVO group for the lower and higher doses respectively. </p> <p>OCT showed that compared to lower dose injections, 0.5 mg of ranibizumab tended to cause more rapid reductions of central retinal thickening that lasted longer between injections. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0012" title="ChiquetC , DupuyC , BronAM , AptelF , StraubM , IsaicoR , et al. Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naive patients with retinal vein occlusion and macular edema: a 12-month follow-up study. Graefe's Archive for Clinical and Experimental Ophthalmology2015;253(12):2095-102. ">Chiquet 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective study in eyes with CRVO and BRVO, 102 patients (64 in the anti‐VEGF (bevacizumab or ranibizumab) group, 38 in the DEX group) without previous treatment were included in this multi‐centre retrospective study and evaluated at baseline and 1, 3, 6, and 12 months after the onset of treatment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both the DEX and anti‐VEGF groups showed similar improvements in visual acuity and central retinal thickness. However, at 3 months, 5 patients (13%) in the DEX group and 20 (31%) in the anti‐VEGF group (P &lt; 0.001) changed treatment due to poor response. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0013" title="ChiquetC , BronAM , StraubM , DupuyC , IsaicoR , AptelF , et al. Retinal vein occlusions: therapeutic switch in macular oedema treatment with a 12-month follow-up. Ophthalmic Research2016;55(3):152-8. ">Chiquet 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination therapy retrospective study in CRVO and BRVO. 48 patients – 40 in the anti‐VEGF DEX sequence (AD group), 8 in the DEX anti‐VEGF sequence (DA group) – were included in this multicentre retrospective study and evaluated at baseline, 1, 3, 6 and 12 months after the switch. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VA significantly improved at 1 month in the AD group (P = 0.03) but not in the DA group (P = 0.40). CMT decreased significantly in the AD group at 1, 6 and 12 months (P = 0.002, P = 0.005 and P = 0.002, respectively). In the DA group, VA did not change from baseline at any time point, and CMT decreased at 1 month (P = 0.02) but not later on. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0015" title="RajagopalR , ShahGK , BlinderKJ , AltaweelM , EliottD , WeeR , et al. Bevacizumab versus ranibizumab in the treatment of macular edema due to retinal vein occlusion: 6-month results of the CRAVE study. Ophthalmic Surgery, Lasers &amp; Imaging Retina2015;46(8):844-50. ">CRAVE 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants were randomised 1:1 to receive monthly treatment with bevacizumab or ranibizumab. The primary outcome was change in central foveal thickness at 6 months compared to baseline. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial randomised 98 patients to treatment with bevacizumab or ranibizumab. At 6 months, there were no differences in change in central foveal thickness between groups (bevacizumab: mean reduction of 212.6 microns, 95% CI (confidence interval) −288.3 to −137.0; ranibizumab: mean reduction of 243.8 microns, 95% CI, −309.6 to −178.0; P = 0.72, analysis of variance (ANOVA)). Both groups showed similar functional outcomes (bevacizumab: 0.33 logMAR gain, 95% CI, −0.47 to −0.18; ranibizumab: 0.34 log‐ MAR gain, 95% CI, −0.45 to −0.23; P = 0.38, ANOVA). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0014" title="FeltgenN , HattenbachLO , BertelmannT , CallizoJ , RehakM , WolfA , et al. Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study. Acta Ophthalmologica2018;96(8):e933-e941. ">COMRADE Extension 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The COMRADE‐B study was a 6‐month RCT comparing ranibizumab with dexamethasone implant. The extension study followed up a subset of the original study group for a further 6 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients enrolled in the extension study were limited only to German centres, and in general had better visual acuity outcomes at 6 months than those not enrolled. In the extension 6 months, eyes in the ranibizumab arm could receive ranibizumab as required. Eyes in the dexamethasone arm could receive 1 further dexamethasone implant in the extension 6 month period. 'Mean average change in best‐corrected visual acuity (BCVA) was significantly better for ranibizumab than dexamethasone (P = 0.0249).' Also, "elevated intraocular pressure (IOP) was more frequent with dexamethasone than ranibizumab treatment." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0016" title="DonatiS , BarosiP , BianchiM , Al OumM , AzzoliniC . Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion. European Journal of Ophthalmology2012;22(4):607-14. ">Donati 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 eyes with MO secondary to BRVO (of at least 3 months duration) were randomised to receive either IVB (n = 9) at baseline, month 1 and month 2 or (n = 9) IVB at baseline, month 1 and month 2 with grid laser photocoagulation after the second injection. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups demonstrated a mean improvement in BCVA and CMT at 12 months, however the combination groups required fewer IVB injections; (median of 4 ± 1.1 for IVB alone versus 3 ± 0.4 in the combination group) (P = 0.03). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0017" title="GuX , YuX , SongS , DaiH . Intravitreal dexamethasone implant versus intravitreal ranibizumab for the treatment of macular edema secondary to retinal vein occlusion in a Chinese population. Ophthalmic Research2017;58(1):8-14. ">Gu 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐randomised case series in CRVO and BRVO. 32 ME cases treated with Ozurdex and 32 ME cases treated with ranibizumab were enrolled, with 26 central (C)RVO and 6 branch (B)RVO participants in each group. The authors compared the results of best‐corrected visual acuity (BCVA), central retinal thickness, number of injections, and intraocular pressure (IOP) at 1, 2, 3, and 6 months after injection. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BCVA in both groups at each follow‐up were significantly increased compared to baseline with no statistical difference between the groups. Ozurdex and ranibizumab successfully reduced CMT at each follow‐up. Both CRVO and BRVO patients had significant between‐group differences in the mean number of injections. Among the CRVO patients, IOP in the Ozurdex group was significantly increased compared to baseline and the ranibizumab group at 1, 2, and 3 months postinjection. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0018" title="GuignierB , Subilia-GuignierA , FournierI , BallonzoliL , Speeg-SchatzC , GaucherD . Prospective pilot study: efficacy of intravitreal dexamethasone and bevacizumab injections in the treatment of macular oedema associated with branch retinal vein occlusion. Ophthalmologica2013;230(1):43-9. ">Guignier 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐randomised case series in BRVO. A total of 19 patients (19 eyes) were included in this prospective pilot study. Initially, 8 eyes received three IV bevacizumab (group 1) and 11 received one IV Ozurdex (group 2). All the patients underwent a 1‐, 3‐, 4‐ and 6‐month follow‐up visit. A repeated IV bevacizumab (group 1) or IV Ozurdex (group 2) was proposed at 4 months when necessary. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean visual acuity was significantly better 1 month after treatment in group 2, while the mean central macular thickness was also significantly lower in group 2. However, there was no longer any difference between the 2 groups at 3, 4 and 6 months, neither in terms of visual<br/>acuity nor in terms of retinal thickness. More than three IVBs were needed in 3 of 10 patients in group 1 while 2 IVDs were required in 10 of 11 patients in group 2. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0019" title="HanhartJ , RozenmanY . Comparison of intravitreal ranibizumab, aflibercept, and dexamethasone implant after bevacizumab failure in macular edema secondary to retinal vascular occlusions. Ophthalmologica2017;238(1-2):110-8. ">Hanhart 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐randomised combination comparative study in CRVO and BRVO. Fifteen eyes were switched to ranibizumab, 12 to aflibercept, and 10 to dexamethasone. At 3, 6, 9, and 12 months, the outcome measures were visual acuity (VA) and central macular thickness (CMT). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 year after the switch, CMT decreased from 430.11 ± 91.21 to 291.86 ± 43.87 μm ( P &lt; 0.001). VA increased in 59.5% of the eyes. No difference between the groups was found in those outcomes at 1 year, but the number of injections varied: 3.30 ± 0.95 for dexamethasone, 6.50 ± 2.11 for aflibercept, and 8.27 ± 2.37 for ranibizumab ( P &lt; 0.001). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0020" title="KartasasmitaAS , TakaraiS , SwitaniaA , EnusS . Efficacy of single bevacizumab injection as adjuvant therapy to laser photocoagulation in macular edema secondary to branch retinal vein occlusion. Clinical Ophthalmology2016;10:2135-40. ">Kartasasmita 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐randomised comparative study in BRVO of laser alone or laser with bevacizumab. 19 patients with macular oedema secondary to BRVO were assigned to either the group of 9 patients in combination therapy of laser photocoagulation with intravitreal bevacizumab or the group of 10 patients in the laser photocoagulation therapy. Complete ophthalmologic examinations were performed just before the therapy and at 1 month following the therapy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination therapy of laser photocoagulation and single intravitreal bevacizumab injection resulted in a significantly better visual acuity compared to laser photocoagulation therapy (0.35 versus 0.13 logMAR; P = 0.041) and reduced macular thickness by 120.33 µm versus 71.50 µm (P = 0.277), although this difference was not significant. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0022" title="LeitritzMA , GeliskenF , ZiemssenF , SzurmanP , Bartz-SchmidtKU , JaissleGB . Grid laser photocoagulation for macular oedema due to branch retinal vein occlusion in the age of bevacizumab? Results of a prospective study with crossover design. British Journal of Ophthalmology2013;97(2):215-9. ">Leitritz 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In this prospective interventional consecutive case series, previously untreated eyes with perfused MO were enclosed over a period of 16 months for bevacizumab (BEV) and for 29 months for grid laser photocoagulation (GLP). The follow‐up period was 1 year. Patients with persistent MO after 12 months of BEV were offered GLP and vice versa, and were followed up for another 12 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both BEV (23 eyes) and GLP (21 eyes) caused a significant ( P &lt; 0.05) reduction in central retinal thickness (CRT) at 12 months although this was delayed with GLP. However, BEV revealed a significantly better 'best‐corrected visual acuity' (BCVA) compared with GLP (0.2 vs 0.5 logMAR; P &lt; 0.04). Switching therapy for non‐responders revealed a reduced CRT at another 12 months, although this was not significant. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0023" title="LiuB , YangY , LiuX , LiW , MoZ . Clinical therapeutic effects of intravitreal Ranibizumab injection combined laser photocoagulation for macular edema in BRVO. Guoji Yanke Zazhi2014;14(11):2006-8. ">Liu 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 confirmed cases (42 eyes) with macular oedema secondary to BRVO were randomised into 3 groups, each group contained 14 eyes. The ranibizumab group received intravitreal injection of ranibizumab (0.05 mL), the laser group received grid laser photocoagulation, and the combined group received a second therapy of grid laser photocoagulation after 1 wk of the intravitreal injection of ranibizumab. Best‐corrected visual acuity (BCVA) and the central macular thickness (CMT) preoperative and at 1, 3, 6 months after therapy was recorded. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The BCVA and the CMT had no differences among 3 groups pretherapy (P &gt; 0.05). While BCVA was much better and CMT was reduced significantly post‐therapy than pre‐therapy in all 3 groups (P &lt; 0.05). The BCVA and CMT in the ranibizumab group were significantly different in every time point (1, 3, 6 months) (P &lt; 0.05). The BCVA declined and the CMT was thicker as time went on. In the laser group and the combined group, BCVA and CMT had little differences at different time points (P &gt; 0.05); while the BCVA was better and the CMT was thinner in the combined group than ranibizumab group and laser group at every time point (P &lt; 0.05). At 3 and 6 months, the BCVA was better and the CMT was thinner in laser group than ranibizumab group (P &lt; 0.05). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0021" title="KlimesJ , RegnierSA , MahonR , BudekT , DostalF , SkalickyD , DeptaJ . Cost effectiveness analysis of ranibizumab compared to aflibercept and laser intervention In treatment of diabetic macular edema (DME) In the Czech Republic. Value in Health2015;18:A 419. ">Klimes 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A 25‐health‐state Markov model considering ranges of visual acuity in both eyes was developed. Patients had a confirmed diagnosis of macular oedema secondary to BRVO and had best‐corrected visual acuity (BCVA) at baseline between 25 and 73 letters. The evaluation compared IVT‐AFL 2 mg with ranibizumab 0.5 mg: the frequency of injections and monitoring were identical for both treatments, taken from randomised trials and a physician survey. A systematic review and indirect comparison were conducted to determine the probabilities of gaining at least 15 BCVA letters from baseline to 6 months; BCVA was then extrapolated over time to determine costs and outcomes. Utilities were taken from published literature and costs were estimated from a UK payer perspective. Published drug prices were discounted to reflect patient access schemes. Costs and benefits were discounted at 3.5%. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The indirect comparison found that IVT‐AFL was associated with a small numerical advantage in the likelihood of gaining 15 BCVA letters, compared with ranibizumab (median odds ratio = 1.08, 95% Cl 0.43 to 2.56). IVT‐AFL was associated with a higher number of QALYs (0.045) per patient than ranibizumab. Both treatments are available to the National Health Service under confidential patient access schemes. Cost effectiveness was estimated for a range of possible discounts for each treatment. At price parity, IVT‐AFL reduces cost by GBP 4 per patient and was a dominant therapy. Results were sensitive to the unit cost of the drugs used, to comparative efficacy and number of injections for both treatments. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0024" title="NarayananR , PanchalB , DasT , ChhablaniJ , JalaliS , AliMH , et al. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1. British Journal of Ophthalmology2015;99(7):954–9. ">MARVEL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In this prospective, randomised, non‐inferiority trial, 75 participants with macular oedema due to BRVO received intravitreal injections of ranibizumab (IVR) or bevacizumab (IVB) after 1:1 block randomisation. The primary outcome measure was the difference in mean changes in best‐corrected visual acuity (BCVA) at 6 months. Secondary outcome measures included mean change in central retinal thickness (CRT), the proportion of patients improving by &gt; 15 letters and the proportion of patients developing neovascularisation. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants received either IVR (n = 37) or IVB (n = 38). The mean BCVA at baseline was 52.8 ± 14.4 letters (20/80) and 56.1 ± 10.0 letters (20/80) (P = 0.24) in the ranibizumab and bevacizumab groups, respectively. At 6 months, the mean gains in BCVA were +18.1 letters (95% CI +12.8 to +22.6; P &lt; 0.0001) in the ranibizumab group and +15.6 letters (95% CI +12.0 to +20.5; P &lt; 0.0001) in the bevacizumab group. The difference between the mean visual gains of the treated groups (bevacizumab–ranibizumab) was −2.5 letters (95% CI −8.0 to +5.0; P = 0.74). Mean reductions in CRT at 6 months were 177.1 ± 122.3 mm in the ranibizumab group (P &lt; 0.0001) and 201.7 ± 166.2 mm in the bevacizumab group ( P &lt; 0.0001), with no significant difference between the 2 groups (P = 0.48). The mean numbers of ranibizumab and bevacizumab injections were 3.2 ± 1.5 and 3.0 ± 1.4, respectively (P = 0.55). 2 serious adverse events occurred in the ranibizumab group and 1 in the bevacizumab group but both were unrelated to intravitreal injections. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0025" title="MoonJ , KimM , SagongM . Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion. Eye2016;30(8):1084-90. ">Moon 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This was a prospective, randomised, interventional comparative study conducted in 45 eyes with ME secondary to BRVO who were treated primarily with IVB 1.25 mg (23 eyes, IVB group) or combination therapy of IVB 1.25 mg with a single simultaneous STA 40 mg (18 eyes, IVB/STA group). Re‐injections were performed with IVB if optical coherence tomography (OCT) showed recurrent ME associated with decreased visual acuity. The main outcome measurement was the number of additional IVB injections, and changes of best‐corrected visual acuity (BCVA) and central macular thickness (CMT) during a 6‐month follow‐up period were compared. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BCVA showed significant improvement in 2 groups at 6 months. In addition, CMT showed significant decrease in 2 groups at 6 months. No significant differences in the change of BCVA and CMT at 6 months after injection (P = 0.973, P = 0.639) were observed between the 2 groups. A statistically significant difference was found regarding the number of additional IVB injections (IVB group 0.96 ± 0.83; IVB/STA group 0.44 ± 0.70, P = 0.034). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0026" title="MoradianS , FaghihiH , SadeghiB , PiriN , AhmadiehH , SoheilianM , et al. Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1). Graefe's Archive for Clinical and Experimental Ophthalmology2011;249(2):193-200. ">Moradian 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 eyes with acute (&lt; 3 months) BRVO were randomly assigned to receive either 2 injections of 1.25 mg bevacizumab 6 weeks apart or sham injections. Follow‐up results were reported at 6 weeks and 12 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After week 6, visual improvements in the bevacizumab treated group were significantly better than the sham group. At 12 weeks there was no significant difference. There was a significant reduction in CMT both at 6 and at 12 weeks. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0027" title="RamezaniA , EsfandiariH , EntezariM , MoradianS , SoheilianM , DehsarviB , et al. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent onset central retinal vein occlusion. Acta Ophthalmologica2014;92(7):e530-9. ">Ramezani 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In this randomised clinical trial, 86 eyes with recent onset (&lt; 12 weeks) CRVO were assigned to 2 groups: bevacizumab (IVB) group (43 eyes) that received 3 monthly injections of 1.25 mg of IVB, and triamcinolone (IVT) group (43 eyes) that received 2 injections of 2 mg IVT 2 months apart. Outcomes were best‐corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) changes. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BCVA improved significantly at 6 months in both groups; from 0.87 ± 0.49 to 0.41 ± 0.35 logMAR in IVB group, and from 0.81 ± 0.45 to 0.62 ± 0.48 logMAR in IVT group (P &lt; 0.001). However, between‐group differences reach a significant level at months 4 (P = 0.003) and 6 (P &lt; 0.001) in favour of the IVB group. In terms of CMT reduction, the difference between the groups was statistically significant (P = 0.002) at month 6. Significant differences were noted more in the ischaemic cases in favour of the IVB group. Mean IOP rise was significantly higher in the IVT group at all visits. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0028" title="RegnierSA , LarsenM , BezlyakV , AllenF . Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis. BMJ Open2015;5(6):e007527. ">Regnier 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A Bayesian network meta‐analysis of RCTs of treatments for macular oedema secondary to BRVO. Interventions: ranibizumab 0.5 mg when necessary, aflibercept 2 mg monthly, dexamethasone 0.7 mg implant, laser photocoagulation, ranibizumab + laser, or sham intervention. Bevacizumab and triamcinolone were excluded. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 RCTs were identified for inclusion with 1743 adult patients. The probability of being the most efficacious treatment at month 6 or 12 based on letters gained was 54% for ranibizumab monotherapy, 30% for aflibercept, 16% for ranibizumab plus laser (adjunctive or prompt), and 0% for dexamethasone implant, laser or sham. The probability of being the most efficacious treatment for patients gaining ≥15 letters was 39% for aflibercept, 35% for ranibizumab monotherapy, 24% for ranibizumab plus laser, 2% for dexamethasone implant, and less than 1% for laser or sham. There was no statistical difference between ranibizumab monotherapy and aflibercept for letters gained (+1.4 letters for ranibizumab vs aflibercept with 95% credible interval (CrI) of −5.2 to +8.5 letters) or the OR for gaining ≥15 letters: 1.06 (95% CrI 0.16 to 8.94)). Dexamethasone implant was associated with significantly higher IOP/OH than antivascular endothelial growth factor agents (OR 13.1 (95% CrI 1.7 to 116.9)). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0029" title="RussoV , BaroneA , ConteE , PrascinaF , StellaA , NociND . Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina2009;29(4):511-5. ">Russo 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A quasi‐RCT of 30 eyes in 30 patients in a single centre in Italy. 15 eyes received bevacizumab whilst 15 eyes received laser treatment. Follow‐up was for 12 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The laser arm showed improvement in VA of 0.21 and 0.20 logMAR at 6 and 12 months, respectively. The bevacizumab arm showed mean VA improvement at 6 and 12 months of 0.30 and 0.31, respectively (P &lt; 0.05). CRT decreased by 42% in the laser arm and 60.3% in the bevacizumab arm at 12 months (P &lt; 0.05). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0030" title="CampochiaroPA , WykoffCC , SingerM , JohnsonR , MarcusD , YauL , et al. Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study. Ophthalmology2014;121(12):2432-42. ">SHORE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants received monthly injections of 0.5 mg ranibizumab for 7 months and those meeting<br/>stability criteria between months 7 and 14 were randomised (1:1) to 'as needed' injections versus continued monthly injections. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference in the slope of change in BCVA between months 7 and 15 in patients treated 'as needed' versus those treated with monthly injections (P = 0.509). Mean (standard deviation) change from baseline BCVA in Early Treatment Diabetic Retinopathy Study letter score at month 15 was 21.0 ± 14.1 in the PRN group (n = 82) versus 18.7 ± 14.1 in the monthly group (n = 80) and 14.5 ± 14.7 in NR participants (n = 13). The percentage of participants who achieved BCVA 20/40 at month 15 was 76.8% in the PRN group, 71.3% in the monthly group, and 46.2% in NR participants. The mean (standard deviation) change from baseline central subfield thickness was 247.8 ± 207.5 mm in the PRN group, 289.9 ± 177.2 mm in the monthly group, and 93.2 ± 225.2 mm in NR participants. There were no significant differences in mean BCVA gains or central subfield thickness reductions at month 15 between the PRN and monthly injection groups (all &gt; 0.05). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0032" title="TomomatsuY , TomomatsuT , TakamuraY , GozawaM , ArimuraS , TakiharaY , et al. Comparative study of combined bevacizumab/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions. Acta Ophthalmologica2016;94(3):e225-30. ">Tomomatsu 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A study to investigate whether targeted retinal photocoagulation (TRP) of peripheral non‐perfused areas (NPAs) could prevent the recurrence of macular oedema (ME) due to branch retinal vein occlusion (BRVO) after intravitreal bevacizumab injection (IVB). Eyes received 1.25 mg IVB only (IVB group) or combined with TRP (IVB + TRP group) of NPAs, more than 5 disc areas identified by fluorescein angiography in the patients with ME secondary to BRVO. Best‐corrected visual acuity (BCVA) and central retinal thickness (CRT) determined by optical coherence tomography were measured every month for 6 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 patients were enrolled and randomised to IVB group (n = 19) and IVB + TRP group (n = 19). Both groups showed similar thinning in CRT at 1 week after IVB. The IVB + TRP group maintained thinner CRT at 2 (P = 0.0072) and 3 (P = 0.0086) months compared with IVB group. However, the difference in CRT became insignificant at 4, 5 and 6 months. The number of reinjections (± standard deviation) in IVB group (1.58 ±0.69) was significantly greater (P = 0.0025) than that in IVB + TRP group (0.83±0.62). BCVA significantly improved at 6 month in IVB + TRP group (P = 0.015), but not in IVB group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0033" title="WroblewskiJJ , Wells JA 3rd, GonzalesCR . Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion. American Journal of Ophthalmology2010;149(1):147-54. ">Wroblewski 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 eyes were randomised 3:1 to intravitreous injections of pegaptanib 0.3 or 1 mg at baseline and at weeks 6 and 12 with subsequent injections at 6‐week intervals at investigator discretion until week 48. Principal efficacy outcomes were change from baseline to week 54. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results were similar in both dosage groups. Mean BCVA improved 14 letters and mean CMT decreased by 205 microns<b>.</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0034" title="ZhangXY , LiYB , ZhouLW , WangXB , LuoXD . Observation on intravitreal injection of ranibizumab combined with laser photocoagulation for the treatment of macular edema in BRVO. International Eye Science2014;14:747-9. ">Zhang 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 eyes of 30 patients with BRVO were randomised into 3 groups: group 1 (10 eyes) received grid laser treatment alone, group 2 received a single dose of intravitreal injection of ranibizumab (0.05 mL/0.5 mg) followed by grid laser treatment 7 days following injection. Group 3 (10 eyes) received 3 loading doses of intravitreal ranibizumab with grid laser treatment 7 days after the first injection. After 6 months follow‐up, the best‐corrected visual acuity and optical coherence tomography (OCT) and central macular thickness were observed. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After 6 months, the visual acuity of patients was improved significantly. There was an average increase of 11 letters, 17 letters and 18 letters in group 1, 2, and 3 respectively, with the average decrease in OCT being 208.7 mum, 312.9 mum and 326.8 mum, respectively, in these groups. Gain in visual acuity more than 3 lines was 1 case (10%) in group 1. There were 3 cases (30%) in group 2 and 4 cases (40%) in group 3. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BCVA: best‐corrected visual acuity; BRVO: branch retinal vein occlusion; CMT: central macular thickness; CRVO: central retinal vein occlusion; IVB: intravitreal bevacizumab; MO: macular oedema; OCT: optical coherence tomography </p> </div> </div> </section> </section> <section id="CD009510-sec-0050"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD009510-fig-0002">Figure 2</a> highlights the 'Risk of bias' assessment for included studies in each domain. </p> <div class="figure" id="CD009510-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009510-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>The included studies varied slightly in their eligibility criteria. Some only included treatment‐naive participants, whilst others allowed previous treatment as long as it was given some time previously. Although no study gave a specific age range for inclusion, the mean participant age did vary between trials. Some studies were double‐masked, whilst others had poorer levels of masking. </p> <p>Nevertheless, we judge the differences between studies to be small compared to the treatment effect and the results of this review can be interpreted with a high degree of certainty. </p> <section id="CD009510-sec-0051"> <h4 class="title">Allocation</h4> <p><a href="./references#CD009510-bbs2-0001" title="BandelloF , AugustinA , TufailA , LeabackR . A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. European Journal of Ophthalmology2018;28(6):697–705. EU-CTR 2010-023900-29. A 12-month, multicentre, randomised, parallel group study to compare the efficacy and safety of OZURDEX® versus Lucentis® in patients with branch retinal vein occlusion. www.clinicaltrialsregister.eu/ctr-search/trial/2010-023900-29/results (first received 28 August 2011). NCT01427751. Safety and efficacy study of Ozurdex® compared to Lucentis® in patients with branch retinal vein occlusion. clinicaltrials.gov/ct2/show/NCT01427751 (first received 2 September 2011). ">Bandello 2018</a> showed unclear levels of selection bias with no information given about random sequence generation or allocation concealment. </p> <p><a href="./references#CD009510-bbs2-0002" title="NCT01976338. Ranibizumab intravitreal injections versus sham control in patients with branch retinal vein occlusion (BRVO) (Blossom). ClinicalTrials.gov/show/NCT01976338 (first received 5 November 2013). WeiW . To assess the efficacy and safety of individualized intravitreal ranibizumab 0.5 mg in Asian (primarily Chinese) patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). In: Annual Meeting of the Association for Research in Vision and Ophthalmology. 2017. ">BLOSSOM</a> remains unpublished so the risk of allocation bias is unclear. </p> <p><a href="./references#CD009510-bbs2-0003" title="TadayoniR , WaldsteinSM , BosciaF , GerdingH , GekkievaM , BarnesE , et al. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology2017;124(12):1778-87. TadayoniR , WaldsteinSM , BosciaF , GerdingH , PearceI , PriglingerS , et al. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology2016;123(6):1332-44. ">BRIGHTER</a> had low risk of selection bias. The randomisation list was generated using a validated system that automates the random assignment of treatment arms to randomisation numbers in the specified ratio. Concealment of allocations was performed prior to assignment. </p> <p><a href="./references#CD009510-bbs2-0004" title="HattenbachLO , FeltgenN , BertelmannT , Schmitz-ValckenbergS , BerkH , EterN , et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmologica2018;96(1):e10-8. ">COMRADE‐B</a> also showed low risk of allocation bias and appropriate randomisation. At enrolment, participants were randomised 1:1 to receive either ranibizumab or dexamethasone intravitreal implant treatment. A randomisation list was produced using a validated system that randomly assigned the treatment arms to randomisation numbers in the specified ratio. </p> <p>The study by Higashiyama and colleagues had unclear levels of selection bias. The doctor who designed and conducted this study (OS) was responsible for randomisation and random allocation performed by the others on the day that the participants received an intravitreal injection. The 'envelope' method was used for randomisation (<a href="./references#CD009510-bbs2-0005" title="HigashiyamaT , SawadaO , KakinokiM , SawadaT , KawamuraH , OhjiM . Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion. Acta Ophthalmologica2013;91(4):318-24. ">Higashiyama 2013</a>). </p> <p>We judge <a href="./references#CD009510-bbs2-0006" title="PielenA , MirshahiA , FeltgenN , LorenzK , KorbC , JunkerB , et al. Ranibizumab for branch retinal vein occlusion associated macular edema study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmologica2015;93(1):e29-37. ">RABAMES</a> to be at low risk for selection bias. The randomisation list implemented blocked randomisation with one block of size 30 (10 eyes and participants per study arm) without any stratification. Randomization was performed by the coordinating study centre.<br/><br/>The study by Ramezani and colleagues is low risk for selection bias. Randomization was performed using a random block permutation method according to a computer‐generated randomisation list. The block length varied randomly (4, 8). Random allocation sequence was performed by a biostatistician. He put the randomisation sequence in numbered, labelled, concealed envelopes. Whenever a new participant passed inclusion criteria a new envelope was opened and the group was revealed (<a href="./references#CD009510-bbs2-0007" title="RamezaniA , EsfandiariH , EntezariM , MoradianS , SoheilianM , DehsarviB , et al. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology2012;250(8):1149-60. ">Ramezani 2012</a>). </p> <p><a href="./references#CD009510-bbs2-0008" title="CampochiaroPA , ClarkWL , BoyerDS , HeierJS , BrownDM , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology2015;122(3):538-44. ClarkWL , BoyerDS , HeierJS , BrownDM , HallerJA , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology2016;123(2):330-6. ">VIBRANT</a> was a large trial with low risk for selection bias. Eyes were randomised 1:1 into the IAI and laser groups according to a predetermined central randomisation scheme. Randomisation was provided by an interactive voice/web response system to the designated unmasked personnel. </p> </section> <section id="CD009510-sec-0052"> <h4 class="title">Blinding</h4> <p>We deemed <a href="./references#CD009510-bbs2-0001" title="BandelloF , AugustinA , TufailA , LeabackR . A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. European Journal of Ophthalmology2018;28(6):697–705. EU-CTR 2010-023900-29. A 12-month, multicentre, randomised, parallel group study to compare the efficacy and safety of OZURDEX® versus Lucentis® in patients with branch retinal vein occlusion. www.clinicaltrialsregister.eu/ctr-search/trial/2010-023900-29/results (first received 28 August 2011). NCT01427751. Safety and efficacy study of Ozurdex® compared to Lucentis® in patients with branch retinal vein occlusion. clinicaltrials.gov/ct2/show/NCT01427751 (first received 2 September 2011). ">Bandello 2018</a> to be high risk for performance bias due to failure to mask investigators and participants. </p> <p><a href="./references#CD009510-bbs2-0002" title="NCT01976338. Ranibizumab intravitreal injections versus sham control in patients with branch retinal vein occlusion (BRVO) (Blossom). ClinicalTrials.gov/show/NCT01976338 (first received 5 November 2013). WeiW . To assess the efficacy and safety of individualized intravitreal ranibizumab 0.5 mg in Asian (primarily Chinese) patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). In: Annual Meeting of the Association for Research in Vision and Ophthalmology. 2017. ">BLOSSOM</a> remains unpublished so the risk of performance and detection bias is unclear. </p> <p><a href="./references#CD009510-bbs2-0003" title="TadayoniR , WaldsteinSM , BosciaF , GerdingH , GekkievaM , BarnesE , et al. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology2017;124(12):1778-87. TadayoniR , WaldsteinSM , BosciaF , GerdingH , PearceI , PriglingerS , et al. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology2016;123(6):1332-44. ">BRIGHTER</a> had a high risk of performance and detection bias. There was no masking of investigators or participants (save for a visual acuity assessment investigator). Failing to mask the participant makes unmasking a high risk. </p> <p><a href="./references#CD009510-bbs2-0004" title="HattenbachLO , FeltgenN , BertelmannT , Schmitz-ValckenbergS , BerkH , EterN , et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmologica2018;96(1):e10-8. ">COMRADE‐B</a> was judged low risk for performance bias. A minimum of two investigators were involved, per study site, to fulfil the masking requirements. The injecting physician was unmasked and performed the study drug administrations as per the protocol; the physician was not involved in any other aspects of the study, however, and was not allowed to communicate the details of the treatment to anyone. Participants were masked and sham injections were given to the dexamethasone group after the baseline injection. The evaluating physician was masked to the treatment assigned so detection bias was minimal. </p> <p>The risk of performance and detection bias was high in <a href="./references#CD009510-bbs2-0005" title="HigashiyamaT , SawadaO , KakinokiM , SawadaT , KawamuraH , OhjiM . Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion. Acta Ophthalmologica2013;91(4):318-24. ">Higashiyama 2013</a>. Treating doctors were not masked. Participants were masked although the nature of triamcinolone and bevacizumab injections are different symptomatically so this masking is likely compromised. Furthermore, outcome assessors were not masked. </p> <p><a href="./references#CD009510-bbs2-0006" title="PielenA , MirshahiA , FeltgenN , LorenzK , KorbC , JunkerB , et al. Ranibizumab for branch retinal vein occlusion associated macular edema study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmologica2015;93(1):e29-37. ">RABAMES</a> showed high risk of performance bias as there was no masking of investigators or participants save for OCT assessment. Nevertheless, OCT scans were evaluated by an independent retina specialist masked to the individual treatment. </p> <p><a href="./references#CD009510-bbs2-0007" title="RamezaniA , EsfandiariH , EntezariM , MoradianS , SoheilianM , DehsarviB , et al. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology2012;250(8):1149-60. ">Ramezani 2012</a> showed unclear risk of performance bias. The study group masked participants to their treatment; however, since triamcinolone might cause floaters they do not consider this study as a double‐masked one. Detection bias was minimised at baseline and at each study visit thereafter: refraction and BCVA were determined, and OCT was performed by certified examiners masked both to the randomisation and to the findings of previous measurements. </p> <p><a href="./references#CD009510-bbs2-0008" title="CampochiaroPA , ClarkWL , BoyerDS , HeierJS , BrownDM , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology2015;122(3):538-44. ClarkWL , BoyerDS , HeierJS , BrownDM , HallerJA , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology2016;123(2):330-6. ">VIBRANT</a> had low risk of bias due to poor masking. A sham laser treatment was also performed at baseline. Eyes in the laser group received macular laser photocoagulation at baseline and sham injections every four weeks from baseline to week 20. Optical coherence tomography images were evaluated by an independent central reading centre. </p> </section> <section id="CD009510-sec-0053"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD009510-bbs2-0001" title="BandelloF , AugustinA , TufailA , LeabackR . A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. European Journal of Ophthalmology2018;28(6):697–705. EU-CTR 2010-023900-29. A 12-month, multicentre, randomised, parallel group study to compare the efficacy and safety of OZURDEX® versus Lucentis® in patients with branch retinal vein occlusion. www.clinicaltrialsregister.eu/ctr-search/trial/2010-023900-29/results (first received 28 August 2011). NCT01427751. Safety and efficacy study of Ozurdex® compared to Lucentis® in patients with branch retinal vein occlusion. clinicaltrials.gov/ct2/show/NCT01427751 (first received 2 September 2011). ">Bandello 2018</a> was judged as high risk for attrition bias. Forty‐two participants did not complete the study in the Ozurdex arm compared to only 14 in the ranibizumab arm. The most common reason for Ozurdex failure of completion was adverse event (raised IOP). </p> <p>In <a href="./references#CD009510-bbs2-0002" title="NCT01976338. Ranibizumab intravitreal injections versus sham control in patients with branch retinal vein occlusion (BRVO) (Blossom). ClinicalTrials.gov/show/NCT01976338 (first received 5 November 2013). WeiW . To assess the efficacy and safety of individualized intravitreal ranibizumab 0.5 mg in Asian (primarily Chinese) patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). In: Annual Meeting of the Association for Research in Vision and Ophthalmology. 2017. ">BLOSSOM</a>, 94.0% of participants completed 12 months' follow‐up (93.2% in the ranibizumab arm and 95.7% in the sham arm). The intent‐to‐treat approach was used for efficacy analyses and included all participants as randomised. </p> <p>There was a high risk of attrition bias in <a href="./references#CD009510-bbs2-0003" title="TadayoniR , WaldsteinSM , BosciaF , GerdingH , GekkievaM , BarnesE , et al. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology2017;124(12):1778-87. TadayoniR , WaldsteinSM , BosciaF , GerdingH , PearceI , PriglingerS , et al. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology2016;123(6):1332-44. ">BRIGHTER</a>: 13% loss of participants from 'laser only' group at six months (half of these due to physicians' decision). The risk was also high in <a href="./references#CD009510-bbs2-0004" title="HattenbachLO , FeltgenN , BertelmannT , Schmitz-ValckenbergS , BerkH , EterN , et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmologica2018;96(1):e10-8. ">COMRADE‐B</a>, where the ranibizumab arm showed 91.3% follow‐up at six months, higher than the 84.7% in the dexamethasone arm. The dexamethasone arm had six participant withdrawals due to inadequate response to treatment and six withdrawals due to adverse events (the nature of these is not clear). </p> <p>In the <a href="./references#CD009510-bbs2-0005" title="HigashiyamaT , SawadaO , KakinokiM , SawadaT , KawamuraH , OhjiM . Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion. Acta Ophthalmologica2013;91(4):318-24. ">Higashiyama 2013</a> study, three triamcinolone and four bevacizumab participants were lost to follow‐up. These were not analysed in the 12‐month results. </p> <p><a href="./references#CD009510-bbs2-0006" title="PielenA , MirshahiA , FeltgenN , LorenzK , KorbC , JunkerB , et al. Ranibizumab for branch retinal vein occlusion associated macular edema study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmologica2015;93(1):e29-37. ">RABAMES</a> was low risk for attrition bias as only one participant withdrew from the study. This was due to stroke and occurred in the combined ranibizumab and laser group. This was also the case for the study by <a href="./references#CD009510-bbs2-0007" title="RamezaniA , EsfandiariH , EntezariM , MoradianS , SoheilianM , DehsarviB , et al. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology2012;250(8):1149-60. ">Ramezani 2012</a>, where only one participant was lost to follow‐up at six months. This occurred in the bevacizumab group. </p> <p><a href="./references#CD009510-bbs2-0008" title="CampochiaroPA , ClarkWL , BoyerDS , HeierJS , BrownDM , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology2015;122(3):538-44. ClarkWL , BoyerDS , HeierJS , BrownDM , HallerJA , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology2016;123(2):330-6. ">VIBRANT</a> was low risk for attrition bias. All randomised eyes in both treatment groups were included in the full analysis set, except for two eyes in the laser group that did not have a post‐baseline BCVA assessment. </p> </section> <section id="CD009510-sec-0054"> <h4 class="title">Selective reporting</h4> <p>The following trials reported all pre‐specified primary and secondary outcomes listed in their study protocol on ClinicalTrials.gov and we considered them at low risk for selective reporting: <a href="./references#CD009510-bbs2-0002" title="NCT01976338. Ranibizumab intravitreal injections versus sham control in patients with branch retinal vein occlusion (BRVO) (Blossom). ClinicalTrials.gov/show/NCT01976338 (first received 5 November 2013). WeiW . To assess the efficacy and safety of individualized intravitreal ranibizumab 0.5 mg in Asian (primarily Chinese) patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). In: Annual Meeting of the Association for Research in Vision and Ophthalmology. 2017. ">BLOSSOM</a>, <a href="./references#CD009510-bbs2-0003" title="TadayoniR , WaldsteinSM , BosciaF , GerdingH , GekkievaM , BarnesE , et al. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology2017;124(12):1778-87. TadayoniR , WaldsteinSM , BosciaF , GerdingH , PearceI , PriglingerS , et al. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology2016;123(6):1332-44. ">BRIGHTER</a> (<a href="https://clinicaltrials.gov/ct2/show/NCT01599650" target="_blank">NCT01599650</a>), <a href="./references#CD009510-bbs2-0004" title="HattenbachLO , FeltgenN , BertelmannT , Schmitz-ValckenbergS , BerkH , EterN , et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmologica2018;96(1):e10-8. ">COMRADE‐B</a> (<a href="https://clinicaltrials.gov/ct2/show/NCT01396057" target="_blank">NCT01396057</a>), <a href="./references#CD009510-bbs2-0001" title="BandelloF , AugustinA , TufailA , LeabackR . A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. European Journal of Ophthalmology2018;28(6):697–705. EU-CTR 2010-023900-29. A 12-month, multicentre, randomised, parallel group study to compare the efficacy and safety of OZURDEX® versus Lucentis® in patients with branch retinal vein occlusion. www.clinicaltrialsregister.eu/ctr-search/trial/2010-023900-29/results (first received 28 August 2011). NCT01427751. Safety and efficacy study of Ozurdex® compared to Lucentis® in patients with branch retinal vein occlusion. clinicaltrials.gov/ct2/show/NCT01427751 (first received 2 September 2011). ">Bandello 2018</a> (<a href="https://clinicaltrials.gov/ct2/show/NCT01427751" target="_blank">NCT01427751</a>), <a href="./references#CD009510-bbs2-0006" title="PielenA , MirshahiA , FeltgenN , LorenzK , KorbC , JunkerB , et al. Ranibizumab for branch retinal vein occlusion associated macular edema study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmologica2015;93(1):e29-37. ">RABAMES</a> (<a href="https://clinicaltrials.gov/ct2/show/NCT00562406" target="_blank">NCT00562406</a>), <a href="./references#CD009510-bbs2-0007" title="RamezaniA , EsfandiariH , EntezariM , MoradianS , SoheilianM , DehsarviB , et al. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology2012;250(8):1149-60. ">Ramezani 2012</a> (<a href="https://clinicaltrials.gov/ct2/show/NCT00370266" target="_blank">NCT00370266</a>) and <a href="./references#CD009510-bbs2-0008" title="CampochiaroPA , ClarkWL , BoyerDS , HeierJS , BrownDM , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology2015;122(3):538-44. ClarkWL , BoyerDS , HeierJS , BrownDM , HallerJA , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology2016;123(2):330-6. ">VIBRANT</a> (<a href="https://clinicaltrials.gov/ct2/show/NCT01521559" target="_blank">NCT01521559</a>). </p> <p>The protocol for <a href="./references#CD009510-bbs2-0005" title="HigashiyamaT , SawadaO , KakinokiM , SawadaT , KawamuraH , OhjiM . Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion. Acta Ophthalmologica2013;91(4):318-24. ">Higashiyama 2013</a> was not available and we are unable to exclude the possibility of selective reporting: we consider the study ‘unclear’ in this domain. </p> </section> <section id="CD009510-sec-0055"> <h4 class="title">Other potential sources of bias</h4> <p>Some trials received pharmaceutical company funding.</p> <p>Of the eight trials included, five received pharmaceutical company funding: <a href="./references#CD009510-bbs2-0003" title="TadayoniR , WaldsteinSM , BosciaF , GerdingH , GekkievaM , BarnesE , et al. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology2017;124(12):1778-87. TadayoniR , WaldsteinSM , BosciaF , GerdingH , PearceI , PriglingerS , et al. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology2016;123(6):1332-44. ">BRIGHTER</a>, <a href="./references#CD009510-bbs2-0004" title="HattenbachLO , FeltgenN , BertelmannT , Schmitz-ValckenbergS , BerkH , EterN , et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmologica2018;96(1):e10-8. ">COMRADE‐B</a>, <a href="./references#CD009510-bbs2-0001" title="BandelloF , AugustinA , TufailA , LeabackR . A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. European Journal of Ophthalmology2018;28(6):697–705. EU-CTR 2010-023900-29. A 12-month, multicentre, randomised, parallel group study to compare the efficacy and safety of OZURDEX® versus Lucentis® in patients with branch retinal vein occlusion. www.clinicaltrialsregister.eu/ctr-search/trial/2010-023900-29/results (first received 28 August 2011). NCT01427751. Safety and efficacy study of Ozurdex® compared to Lucentis® in patients with branch retinal vein occlusion. clinicaltrials.gov/ct2/show/NCT01427751 (first received 2 September 2011). ">Bandello 2018</a>, <a href="./references#CD009510-bbs2-0006" title="PielenA , MirshahiA , FeltgenN , LorenzK , KorbC , JunkerB , et al. Ranibizumab for branch retinal vein occlusion associated macular edema study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmologica2015;93(1):e29-37. ">RABAMES</a> and <a href="./references#CD009510-bbs2-0008" title="CampochiaroPA , ClarkWL , BoyerDS , HeierJS , BrownDM , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology2015;122(3):538-44. ClarkWL , BoyerDS , HeierJS , BrownDM , HallerJA , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology2016;123(2):330-6. ">VIBRANT</a>. This support included study design, conducting the study, data collection, management and data interpretation to various degrees. There was also support for medical writing and editorial assistance. </p> </section> </section> <section id="CD009510-sec-0056"> <h3 class="title" id="CD009510-sec-0056">Effects of interventions</h3> <p>See: <a href="./full#CD009510-tbl-0001"><b>Summary of findings 1</b> Anti‐VEGF compared to sham for macular oedema secondary to branch retinal vein occlusion</a>; <a href="./full#CD009510-tbl-0002"><b>Summary of findings 2</b> Anti‐VEGF compared to laser for branch retinal vein occlusion (BRVO)</a>; <a href="./full#CD009510-tbl-0003"><b>Summary of findings 3</b> Anti‐VEGF compared to steroid for branch retinal vein occlusion (BRVO)</a> </p> <section id="CD009510-sec-0057"> <h4 class="title">Anti‐VEGF treatment versus sham</h4> <section id="CD009510-sec-0058"> <h5 class="title">Improvement of 15 or more letters (primary outcome)</h5> <p>People receiving anti‐VEGF showed better outcome than those treated with sham injections at six months (RR 1.72, 95% CI 1.19 to 2.49; 1 study, 283 participants; moderate‐certainty evidence; <a href="./references#CD009510-fig-0007" title="">Analysis 1.1</a>). Unfortunately, this outcome was limited to only one trial and for only six months, as rescue treatment was available after this time (<a href="./references#CD009510-bbs2-0002" title="NCT01976338. Ranibizumab intravitreal injections versus sham control in patients with branch retinal vein occlusion (BRVO) (Blossom). ClinicalTrials.gov/show/NCT01976338 (first received 5 November 2013). WeiW . To assess the efficacy and safety of individualized intravitreal ranibizumab 0.5 mg in Asian (primarily Chinese) patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). In: Annual Meeting of the Association for Research in Vision and Ophthalmology. 2017. ">BLOSSOM</a>). </p> </section> <section id="CD009510-sec-0059"> <h5 class="title">Mean change in best‐corrected visual acuity (BCVA)</h5> <p>People receiving anti‐VEGF showed better improvement in mean visual acuity than those receiving sham at six months (MD 7.50 letters, 95% CI 5.29 to 9.71; 1 study, 282 participants; moderate‐certainty evidence; <a href="./references#CD009510-fig-0008" title="">Analysis 1.2</a>). </p> </section> <section id="CD009510-sec-0060"> <h5 class="title">Loss of 15 or more letters</h5> <p>People receiving anti‐VEGF showed better outcome than those treated with sham injections at six months (RR 0.24). However, the 95% CI (0.05 to 1.31) included 1.00 (<a href="./references#CD009510-fig-0009" title="">Analysis 1.3</a>). </p> </section> <section id="CD009510-sec-0061"> <h5 class="title">Central retinal thickness (CRT)</h5> <p>No data was available for 12 months but results at six months showed participants receiving anti‐VEGF had a greater reduction in central retinal thickness than those receiving sham (MD −57.50 microns, 95% CI −108.63 to −6.37; 1 study, 281 participants; moderate‐certainty evidence; <a href="./references#CD009510-fig-0010" title="">Analysis 1.4</a>). </p> </section> <section id="CD009510-sec-0062"> <h5 class="title">Adverse events (AEs)</h5> <p>The anti‐VEGF and sham cohorts reported similar levels of ocular and systemic adverse events. Antiplatelet Trialists’ Collaboration (APTC) arterial thromboembolic events were equally common in both groups. Endophthalmitis was rare. </p> </section> <section id="CD009510-sec-0063"> <h5 class="title">Quality of life</h5> <p>The mean improvement in quality of life (QoL) at 12 months on the National Eye Institute Visual Functioning Questionnaire‐25 (VFQ‐25) (scored 0 to 100; higher score is better quality of life) was 7.60 higher (4.30 to 10.90) (1 study, 281 participants; moderate‐certainty evidence; <a href="./references#CD009510-fig-0014" title="">Analysis 1.8</a>). </p> </section> </section> <section id="CD009510-sec-0064"> <h4 class="title">Anti‐VEGF treatment versus laser photocoagulation</h4> <section id="CD009510-sec-0065"> <h5 class="title">Improvement of 15 or more letters (primary outcome)</h5> <p>Eyes receiving anti‐VEGF showed better outcome than the laser arm at six months (RR 2.09, 95% CI 1.44 to 3.05; 2 studies, 201 participants; I² = 0%; moderate‐certainty evidence; <a href="./references#CD009510-fig-0015" title="">Analysis 2.1</a>). There were no results available for 12 months. </p> </section> <section id="CD009510-sec-0066"> <h5 class="title">Mean change in best‐corrected visual acuity (BCVA)</h5> <p>People receiving anti‐VEGF showed greater gains than those receiving laser at six months (MD 9.63 letters, 95% CI 7.23 to 12.03; 3 studies, 473 participants; I² = 0%; moderate‐certainty evidence; <a href="./references#CD009510-fig-0016" title="">Analysis 2.2</a>; <a href="#CD009510-fig-0003">Figure 3</a>). There were no results available for 12 months. </p> <div class="figure" id="CD009510-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Anti‐VEGF v laser, outcome: 2.2 Mean VA change at 6 months [letters]." data-id="CD009510-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Anti‐VEGF v laser, outcome: 2.2 Mean VA change at 6 months [letters]. </p> </div> </div> </div> </section> <section id="CD009510-sec-0067"> <h5 class="title">Central retinal thickness (CRT)</h5> <p>Mean change in CRT was greater in the anti‐VEGF than the laser group at six months (MD −147.47 microns, 95% CI −200.19 to −94.75; 2 studies, 201 participants; I² = 0%; moderate‐certainty evidence; <a href="./references#CD009510-fig-0017" title="">Analysis 2.3</a>) although no data was available for 12 months of treatment. </p> </section> <section id="CD009510-sec-0068"> <h5 class="title">Adverse events</h5> <p>Systemic adverse events were well‐matched between the anti‐VEGF and laser cohorts. There was no sign that thromboembolic events were more common in either group (<a href="#CD009510-fig-0004">Figure 4</a>). There were no episodes of endophthalmitis after any intravitreal anti‐VEGF injection. </p> <div class="figure" id="CD009510-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Anti‐VEGF v laser, outcome: 2.5 APTC events." data-id="CD009510-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Anti‐VEGF v laser, outcome: 2.5 APTC events.</p> </div> </div> </div> </section> <section id="CD009510-sec-0069"> <h5 class="title">Quality of life</h5> <p>This data was not reported.</p> </section> </section> <section id="CD009510-sec-0070"> <h4 class="title">Anti‐VEGF treatment versus steroid</h4> <section id="CD009510-sec-0071"> <h5 class="title">Improvement of 15 or more letters (primary outcome)</h5> <p>Participants receiving anti‐VEGF showed better outcomes than steroid at six months (RR 1.67, 95% CI 1.33 to 2.10; 2 studies, 330 participants; I² = 0%; high‐certainty evidence; <a href="./references#CD009510-fig-0020" title="">Analysis 3.1</a>; <a href="#CD009510-fig-0005">Figure 5</a>); and 12 months (RR 1.76, 95% CI 1.36 to 2.28; 1 study, 307 participants; high‐certainty evidence; <a href="./references#CD009510-fig-0021" title="">Analysis 3.2</a>). </p> <div class="figure" id="CD009510-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Anti‐VEGF v steroid, outcome: 3.1 Gain of 15 letters or more at 6 months." data-id="CD009510-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Anti‐VEGF v steroid, outcome: 3.1 Gain of 15 letters or more at 6 months. </p> </div> </div> </div> </section> <section id="CD009510-sec-0072"> <h5 class="title">Mean change in best‐corrected visual acuity (BCVA)</h5> <p>Eyes receiving anti‐VEGF showed a great improvement in visual acuity than those in the steroid arm both at six months (MD 8.22 letters, 95% CI 5.69 to 10.76; 2 studies, 330 participants; I² = 0%; high‐certainty evidence; <a href="./references#CD009510-fig-0022" title="">Analysis 3.3</a>); and 12 months (MD 9.15 letters, 95% CI 6.32 to 11.97; 2 studies, 343 participants; I² = 0%; high‐certainty evidence; <a href="./references#CD009510-fig-0023" title="">Analysis 3.4</a>). </p> </section> <section id="CD009510-sec-0073"> <h5 class="title">Central retinal thickness (CRT)</h5> <p>Central macular thickness showed a greater reduction at 12 months in eyes receiving anti‐VEGF than those receiving steroid (MD −26.92 microns, 95% CI −65.88 to 12.04; 3 studies, 343 participants; I² = 0%; moderate‐certainty grade; <a href="./references#CD009510-fig-0025" title="">Analysis 3.6</a>). </p> </section> <section id="CD009510-sec-0074"> <h5 class="title">Adverse events</h5> <p>Systemic adverse events were similar in the anti‐VEGF and steroid cohorts. However, ocular adverse events were more common in the steroid cohort, who had greater rates of cataract formation (moderate‐certainty evidence) and raised intraocular pressure (moderate‐certainty evidence; <a href="#CD009510-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD009510-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Anti‐VEGF v steroid, outcome: 3.9 Raised IOP." data-id="CD009510-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Anti‐VEGF v steroid, outcome: 3.9 Raised IOP.</p> </div> </div> </div> </section> <section id="CD009510-sec-0075"> <h5 class="title">Quality of life</h5> <p>Participants receiving anti‐VEGF showed a greater improvement in quality of life at 12 months compared to those receiving steroid (MD 3.10, 95% CI 0.22 to 5.98; 1 study, 307 participants; moderate‐certainty evidence). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009510-sec-0076" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009510-sec-0076"></div> <section id="CD009510-sec-0077"> <h3 class="title" id="CD009510-sec-0077">Summary of main results</h3> <p>This systematic review and meta‐analysis has revealed that in the treatment of macular oedema secondary to branch retinal vein occlusion, intravitreal anti‐VEGF agents give the best outcomes and are as safe, or safer, than sham, laser photocoagulation or intravitreal steroid. </p> <p><a href="./references#CD009510-bbs2-0002" title="NCT01976338. Ranibizumab intravitreal injections versus sham control in patients with branch retinal vein occlusion (BRVO) (Blossom). ClinicalTrials.gov/show/NCT01976338 (first received 5 November 2013). WeiW . To assess the efficacy and safety of individualized intravitreal ranibizumab 0.5 mg in Asian (primarily Chinese) patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). In: Annual Meeting of the Association for Research in Vision and Ophthalmology. 2017. ">BLOSSOM</a> study showed that anti‐VEGF is more effective than sham in promoting visual gain and reducing visual loss over a 6‐month follow‐up. Anti‐VEGF was also more effective at reducing central macular thickness. </p> <p>Several studies compared anti‐VEGF with laser, with follow‐up of six months (<a href="./references#CD009510-bbs2-0006" title="PielenA , MirshahiA , FeltgenN , LorenzK , KorbC , JunkerB , et al. Ranibizumab for branch retinal vein occlusion associated macular edema study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmologica2015;93(1):e29-37. ">RABAMES</a>, <a href="./references#CD009510-bbs2-0003" title="TadayoniR , WaldsteinSM , BosciaF , GerdingH , GekkievaM , BarnesE , et al. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology2017;124(12):1778-87. TadayoniR , WaldsteinSM , BosciaF , GerdingH , PearceI , PriglingerS , et al. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology2016;123(6):1332-44. ">BRIGHTER</a> and <a href="./references#CD009510-bbs2-0008" title="CampochiaroPA , ClarkWL , BoyerDS , HeierJS , BrownDM , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology2015;122(3):538-44. ClarkWL , BoyerDS , HeierJS , BrownDM , HallerJA , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology2016;123(2):330-6. ">VIBRANT</a>). Together, these studies showed anti‐VEGF is more effective than laser at improving visual outcome, reducing visual loss and promoting resolution of macular oedema. </p> <p>Anti‐VEGF is also more effective in achieving functional and anatomical outcomes than intravitreal steroid, both triamcinolone and dexamethasone implant (<a href="./references#CD009510-bbs2-0004" title="HattenbachLO , FeltgenN , BertelmannT , Schmitz-ValckenbergS , BerkH , EterN , et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmologica2018;96(1):e10-8. ">COMRADE‐B</a>, <a href="./references#CD009510-bbs2-0007" title="RamezaniA , EsfandiariH , EntezariM , MoradianS , SoheilianM , DehsarviB , et al. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology2012;250(8):1149-60. ">Ramezani 2012</a>, <a href="./references#CD009510-bbs2-0001" title="BandelloF , AugustinA , TufailA , LeabackR . A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. European Journal of Ophthalmology2018;28(6):697–705. EU-CTR 2010-023900-29. A 12-month, multicentre, randomised, parallel group study to compare the efficacy and safety of OZURDEX® versus Lucentis® in patients with branch retinal vein occlusion. www.clinicaltrialsregister.eu/ctr-search/trial/2010-023900-29/results (first received 28 August 2011). NCT01427751. Safety and efficacy study of Ozurdex® compared to Lucentis® in patients with branch retinal vein occlusion. clinicaltrials.gov/ct2/show/NCT01427751 (first received 2 September 2011). ">Bandello 2018</a>, and <a href="./references#CD009510-bbs2-0005" title="HigashiyamaT , SawadaO , KakinokiM , SawadaT , KawamuraH , OhjiM . Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion. Acta Ophthalmologica2013;91(4):318-24. ">Higashiyama 2013</a>). Anti‐VEGF has a better adverse event profile, and improves quality of life more than steroid. </p> </section> <section id="CD009510-sec-0078"> <h3 class="title" id="CD009510-sec-0078">Overall completeness and applicability of evidence</h3> <section id="CD009510-sec-0079"> <h4 class="title">Intravitreal anti‐VEGF treatment and sham</h4> <p>This comparison included only one study, and this was limited to six months as rescue treatment with anti‐VEGF was possible after this for the sham arm (<a href="./references#CD009510-bbs2-0002" title="NCT01976338. Ranibizumab intravitreal injections versus sham control in patients with branch retinal vein occlusion (BRVO) (Blossom). ClinicalTrials.gov/show/NCT01976338 (first received 5 November 2013). WeiW . To assess the efficacy and safety of individualized intravitreal ranibizumab 0.5 mg in Asian (primarily Chinese) patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). In: Annual Meeting of the Association for Research in Vision and Ophthalmology. 2017. ">BLOSSOM</a>). The <a href="./references#CD009510-bbs2-0009" title="BrownDM , CampochiaroPA , BhisitkulRB , HoAC , GrayS , SarojN , et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology2011;118(8):1594-602. CampochiaroPA , HeierJS , FeinerL , GrayS , SarojN , RundleAC , et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology2010;117(6):1102-12. ">BRAVO 2010</a> study had to be excluded as rescue laser was available to both the sham and anti‐VEGF arms of the study. Although <a href="./references#CD009510-bbs2-0002" title="NCT01976338. Ranibizumab intravitreal injections versus sham control in patients with branch retinal vein occlusion (BRVO) (Blossom). ClinicalTrials.gov/show/NCT01976338 (first received 5 November 2013). WeiW . To assess the efficacy and safety of individualized intravitreal ranibizumab 0.5 mg in Asian (primarily Chinese) patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). In: Annual Meeting of the Association for Research in Vision and Ophthalmology. 2017. ">BLOSSOM</a> remains unpublished, the data provided by this trial give good high‐certainty evidence for the benefit of anti‐VEGF over sham. </p> </section> <section id="CD009510-sec-0080"> <h4 class="title">Intravitreal anti‐VEGF treatment and grid laser photocoagulation (GLP)</h4> <p>Overall, this involved a total of 473 participants and two anti‐VEGF agents were represented: ranibizumab (<a href="./references#CD009510-bbs2-0006" title="PielenA , MirshahiA , FeltgenN , LorenzK , KorbC , JunkerB , et al. Ranibizumab for branch retinal vein occlusion associated macular edema study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmologica2015;93(1):e29-37. ">RABAMES</a> and <a href="./references#CD009510-bbs2-0003" title="TadayoniR , WaldsteinSM , BosciaF , GerdingH , GekkievaM , BarnesE , et al. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology2017;124(12):1778-87. TadayoniR , WaldsteinSM , BosciaF , GerdingH , PearceI , PriglingerS , et al. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology2016;123(6):1332-44. ">BRIGHTER</a>), and aflibercept (<a href="./references#CD009510-bbs2-0008" title="CampochiaroPA , ClarkWL , BoyerDS , HeierJS , BrownDM , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology2015;122(3):538-44. ClarkWL , BoyerDS , HeierJS , BrownDM , HallerJA , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology2016;123(2):330-6. ">VIBRANT</a>). </p> <p>The studies generally included participants with a wide range of baseline visual acuity, typically 20/40 and 20/400. <a href="./references#CD009510-bbs2-0006" title="PielenA , MirshahiA , FeltgenN , LorenzK , KorbC , JunkerB , et al. Ranibizumab for branch retinal vein occlusion associated macular edema study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmologica2015;93(1):e29-37. ">RABAMES</a> included only perfused (non‐ischaemic) BRVO whereas this was not a specified criterion in <a href="./references#CD009510-bbs2-0003" title="TadayoniR , WaldsteinSM , BosciaF , GerdingH , GekkievaM , BarnesE , et al. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology2017;124(12):1778-87. TadayoniR , WaldsteinSM , BosciaF , GerdingH , PearceI , PriglingerS , et al. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology2016;123(6):1332-44. ">BRIGHTER</a> or <a href="./references#CD009510-bbs2-0008" title="CampochiaroPA , ClarkWL , BoyerDS , HeierJS , BrownDM , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology2015;122(3):538-44. ClarkWL , BoyerDS , HeierJS , BrownDM , HallerJA , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology2016;123(2):330-6. ">VIBRANT</a>. Eyes with ischaemic BRVO tend to have poorer baseline acuity, and there is thus insufficient study data to predict the efficacy of anti‐VEGF or laser treatment in these eyes. </p> <p>Furthermore, <a href="./references#CD009510-bbs2-0008" title="CampochiaroPA , ClarkWL , BoyerDS , HeierJS , BrownDM , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology2015;122(3):538-44. ClarkWL , BoyerDS , HeierJS , BrownDM , HallerJA , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology2016;123(2):330-6. ">VIBRANT</a> included hemi‐retinal vein occlusion (HRVO) as a form of BRVO whereas it is not clear whether the other studies did this also. As HRVO is considered by some authorities as a subtype of CRVO rather than BRVO, it is unclear whether the inclusion of these eyes makes a meaningful difference to the results and conclusions. </p> <p><a href="./references#CD009510-bbs2-0006" title="PielenA , MirshahiA , FeltgenN , LorenzK , KorbC , JunkerB , et al. Ranibizumab for branch retinal vein occlusion associated macular edema study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmologica2015;93(1):e29-37. ">RABAMES</a> included treatment‐naive participants only although the other studies permitted inclusion of participants who had previously been treated. Participants seen in clinic outside a clinical trial setting are more likely to have had previous treatment, as well as ocular comorbidities such as diabetic retinopathy. As more such participants were excluded from the clinical trials, the effect of ocular comorbidity cannot be determined with any certainty. </p> </section> <section id="CD009510-sec-0081"> <h4 class="title">Intravitreal anti‐VEGF treatment and intravitreal steroid</h4> <p>Four RCTs contributed data to this comparison, two comparing anti‐VEGF with intravitreal triamcinolone (<a href="./references#CD009510-bbs2-0005" title="HigashiyamaT , SawadaO , KakinokiM , SawadaT , KawamuraH , OhjiM . Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion. Acta Ophthalmologica2013;91(4):318-24. ">Higashiyama 2013</a> and <a href="./references#CD009510-bbs2-0007" title="RamezaniA , EsfandiariH , EntezariM , MoradianS , SoheilianM , DehsarviB , et al. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology2012;250(8):1149-60. ">Ramezani 2012</a>) and two comparing anti‐VEGF with intravitreal dexamethasone implant (<a href="./references#CD009510-bbs2-0004" title="HattenbachLO , FeltgenN , BertelmannT , Schmitz-ValckenbergS , BerkH , EterN , et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmologica2018;96(1):e10-8. ">COMRADE‐B</a> and <a href="./references#CD009510-bbs2-0001" title="BandelloF , AugustinA , TufailA , LeabackR . A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. European Journal of Ophthalmology2018;28(6):697–705. EU-CTR 2010-023900-29. A 12-month, multicentre, randomised, parallel group study to compare the efficacy and safety of OZURDEX® versus Lucentis® in patients with branch retinal vein occlusion. www.clinicaltrialsregister.eu/ctr-search/trial/2010-023900-29/results (first received 28 August 2011). NCT01427751. Safety and efficacy study of Ozurdex® compared to Lucentis® in patients with branch retinal vein occlusion. clinicaltrials.gov/ct2/show/NCT01427751 (first received 2 September 2011). ">Bandello 2018</a>). Both bevacizumab (<a href="./references#CD009510-bbs2-0005" title="HigashiyamaT , SawadaO , KakinokiM , SawadaT , KawamuraH , OhjiM . Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion. Acta Ophthalmologica2013;91(4):318-24. ">Higashiyama 2013</a> and <a href="./references#CD009510-bbs2-0007" title="RamezaniA , EsfandiariH , EntezariM , MoradianS , SoheilianM , DehsarviB , et al. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology2012;250(8):1149-60. ">Ramezani 2012</a>) and ranibizumab (<a href="./references#CD009510-bbs2-0004" title="HattenbachLO , FeltgenN , BertelmannT , Schmitz-ValckenbergS , BerkH , EterN , et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmologica2018;96(1):e10-8. ">COMRADE‐B</a> and <a href="./references#CD009510-bbs2-0001" title="BandelloF , AugustinA , TufailA , LeabackR . A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. European Journal of Ophthalmology2018;28(6):697–705. EU-CTR 2010-023900-29. A 12-month, multicentre, randomised, parallel group study to compare the efficacy and safety of OZURDEX® versus Lucentis® in patients with branch retinal vein occlusion. www.clinicaltrialsregister.eu/ctr-search/trial/2010-023900-29/results (first received 28 August 2011). NCT01427751. Safety and efficacy study of Ozurdex® compared to Lucentis® in patients with branch retinal vein occlusion. clinicaltrials.gov/ct2/show/NCT01427751 (first received 2 September 2011). ">Bandello 2018</a>) were included. </p> <p><a href="./references#CD009510-bbs2-0005" title="HigashiyamaT , SawadaO , KakinokiM , SawadaT , KawamuraH , OhjiM . Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion. Acta Ophthalmologica2013;91(4):318-24. ">Higashiyama 2013</a> included treatment‐naive eyes of less than 12‐months disease duration, although there is no mention of ischaemic status. <a href="./references#CD009510-bbs2-0007" title="RamezaniA , EsfandiariH , EntezariM , MoradianS , SoheilianM , DehsarviB , et al. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology2012;250(8):1149-60. ">Ramezani 2012</a> also included treatment‐naive eyes only, but limited this to disease duration of 12 weeks or less at baseline. <a href="./references#CD009510-bbs2-0004" title="HattenbachLO , FeltgenN , BertelmannT , Schmitz-ValckenbergS , BerkH , EterN , et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmologica2018;96(1):e10-8. ">COMRADE‐B</a> permitted previously treated eyes but stipulated a treatment‐free period of three months for anti‐VEGF and six months for prior intravitreal steroids. <a href="./references#CD009510-bbs2-0001" title="BandelloF , AugustinA , TufailA , LeabackR . A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. European Journal of Ophthalmology2018;28(6):697–705. EU-CTR 2010-023900-29. A 12-month, multicentre, randomised, parallel group study to compare the efficacy and safety of OZURDEX® versus Lucentis® in patients with branch retinal vein occlusion. www.clinicaltrialsregister.eu/ctr-search/trial/2010-023900-29/results (first received 28 August 2011). NCT01427751. Safety and efficacy study of Ozurdex® compared to Lucentis® in patients with branch retinal vein occlusion. clinicaltrials.gov/ct2/show/NCT01427751 (first received 2 September 2011). ">Bandello 2018</a> included treatment‐naive eyes only with symptom duration of three months or less. The study also excluded eyes with 'severe macular ischaemia'. </p> </section> </section> <section id="CD009510-sec-0082"> <h3 class="title" id="CD009510-sec-0082">Quality of the evidence</h3> <section id="CD009510-sec-0083"> <h4 class="title">Intravitreal anti‐VEGF treatment and sham</h4> <p>We found one RCT with good methodological quality for this comparison (<a href="./references#CD009510-bbs2-0002" title="NCT01976338. Ranibizumab intravitreal injections versus sham control in patients with branch retinal vein occlusion (BRVO) (Blossom). ClinicalTrials.gov/show/NCT01976338 (first received 5 November 2013). WeiW . To assess the efficacy and safety of individualized intravitreal ranibizumab 0.5 mg in Asian (primarily Chinese) patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). In: Annual Meeting of the Association for Research in Vision and Ophthalmology. 2017. ">BLOSSOM</a>). This, however, remains unpublished so we obtained data from ClinicalTrials.gov. </p> </section> <section id="CD009510-sec-0084"> <h4 class="title">Intravitreal anti‐VEGF treatment and grid laser photocoagulation (GLP)</h4> <p>A total of three studies contributed data to this comparison (<a href="./references#CD009510-bbs2-0006" title="PielenA , MirshahiA , FeltgenN , LorenzK , KorbC , JunkerB , et al. Ranibizumab for branch retinal vein occlusion associated macular edema study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmologica2015;93(1):e29-37. ">RABAMES</a>, <a href="./references#CD009510-bbs2-0003" title="TadayoniR , WaldsteinSM , BosciaF , GerdingH , GekkievaM , BarnesE , et al. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology2017;124(12):1778-87. TadayoniR , WaldsteinSM , BosciaF , GerdingH , PearceI , PriglingerS , et al. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology2016;123(6):1332-44. ">BRIGHTER</a> and <a href="./references#CD009510-bbs2-0008" title="CampochiaroPA , ClarkWL , BoyerDS , HeierJS , BrownDM , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology2015;122(3):538-44. ClarkWL , BoyerDS , HeierJS , BrownDM , HallerJA , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology2016;123(2):330-6. ">VIBRANT</a>). <a href="./references#CD009510-bbs2-0008" title="CampochiaroPA , ClarkWL , BoyerDS , HeierJS , BrownDM , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology2015;122(3):538-44. ClarkWL , BoyerDS , HeierJS , BrownDM , HallerJA , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology2016;123(2):330-6. ">VIBRANT</a> and <a href="./references#CD009510-bbs2-0003" title="TadayoniR , WaldsteinSM , BosciaF , GerdingH , GekkievaM , BarnesE , et al. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology2017;124(12):1778-87. TadayoniR , WaldsteinSM , BosciaF , GerdingH , PearceI , PriglingerS , et al. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology2016;123(6):1332-44. ">BRIGHTER</a> were particularly large studies with good study design. </p> <p><a href="./references#CD009510-bbs2-0006" title="PielenA , MirshahiA , FeltgenN , LorenzK , KorbC , JunkerB , et al. Ranibizumab for branch retinal vein occlusion associated macular edema study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmologica2015;93(1):e29-37. ">RABAMES</a> has low risk of selection bias but high risk of performance and detection bias due to a lack of masking of participants or assessors. Nevertheless, the two largest RCTs (<a href="./references#CD009510-bbs2-0003" title="TadayoniR , WaldsteinSM , BosciaF , GerdingH , GekkievaM , BarnesE , et al. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology2017;124(12):1778-87. TadayoniR , WaldsteinSM , BosciaF , GerdingH , PearceI , PriglingerS , et al. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology2016;123(6):1332-44. ">BRIGHTER</a> and <a href="./references#CD009510-bbs2-0008" title="CampochiaroPA , ClarkWL , BoyerDS , HeierJS , BrownDM , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology2015;122(3):538-44. ClarkWL , BoyerDS , HeierJS , BrownDM , HallerJA , VittiR , et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology2016;123(2):330-6. ">VIBRANT</a>) showed good study design with a low risk of bias. </p> </section> <section id="CD009510-sec-0085"> <h4 class="title">Intravitreal anti‐VEGF treatment and intravitreal steroid</h4> <p>Four RCTs were included in this analysis. These studies showed a high risk of bias. <a href="./references#CD009510-bbs2-0005" title="HigashiyamaT , SawadaO , KakinokiM , SawadaT , KawamuraH , OhjiM . Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion. Acta Ophthalmologica2013;91(4):318-24. ">Higashiyama 2013</a> failed to mask participants and outcome assessors, meaning a high risk of performance and detection bias. <a href="./references#CD009510-bbs2-0007" title="RamezaniA , EsfandiariH , EntezariM , MoradianS , SoheilianM , DehsarviB , et al. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology2012;250(8):1149-60. ">Ramezani 2012</a> did mask outcome assessors, but there was insufficient information in the article to determine whether allocation concealment was performed to a high enough level to avoid selection bias. Although <a href="./references#CD009510-bbs2-0004" title="HattenbachLO , FeltgenN , BertelmannT , Schmitz-ValckenbergS , BerkH , EterN , et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmologica2018;96(1):e10-8. ">COMRADE‐B</a> was well designed to avoid bias, limiting dexamethasone use to baseline only with outcomes reported at six months meant a waning of the treatment effect of this drug. <a href="./references#CD009510-bbs2-0001" title="BandelloF , AugustinA , TufailA , LeabackR . A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. European Journal of Ophthalmology2018;28(6):697–705. EU-CTR 2010-023900-29. A 12-month, multicentre, randomised, parallel group study to compare the efficacy and safety of OZURDEX® versus Lucentis® in patients with branch retinal vein occlusion. www.clinicaltrialsregister.eu/ctr-search/trial/2010-023900-29/results (first received 28 August 2011). NCT01427751. Safety and efficacy study of Ozurdex® compared to Lucentis® in patients with branch retinal vein occlusion. clinicaltrials.gov/ct2/show/NCT01427751 (first received 2 September 2011). ">Bandello 2018</a> failed to mask investigators and participants, so has high risk of performance and detection bias. </p> </section> <section id="CD009510-sec-0086"> <h4 class="title">Heterogeneity</h4> <p>Subgroup analysis comparing the effect of the three anti‐VEGF agents (bevacizumab, ranibizumab and aflibercept) showed no difference in efficacy. </p> <p>Overall, heterogeneity was low across studies, with low Chi², high P values and low I² values. There was, however, one exception to this. </p> <p>In <a href="./references#CD009510-fig-0024" title="">Analysis 3.5</a>, heterogeneity was observed between <a href="./references#CD009510-bbs2-0004" title="HattenbachLO , FeltgenN , BertelmannT , Schmitz-ValckenbergS , BerkH , EterN , et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmologica2018;96(1):e10-8. ">COMRADE‐B</a> and <a href="./references#CD009510-bbs2-0007" title="RamezaniA , EsfandiariH , EntezariM , MoradianS , SoheilianM , DehsarviB , et al. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology2012;250(8):1149-60. ">Ramezani 2012</a> for mean CRT at six months. Participants in the steroid arm of <a href="./references#CD009510-bbs2-0004" title="HattenbachLO , FeltgenN , BertelmannT , Schmitz-ValckenbergS , BerkH , EterN , et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmologica2018;96(1):e10-8. ">COMRADE‐B</a> did poorly compared to those in the steroid arm of <a href="./references#CD009510-bbs2-0007" title="RamezaniA , EsfandiariH , EntezariM , MoradianS , SoheilianM , DehsarviB , et al. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology2012;250(8):1149-60. ">Ramezani 2012</a>. In <a href="./references#CD009510-bbs2-0007" title="RamezaniA , EsfandiariH , EntezariM , MoradianS , SoheilianM , DehsarviB , et al. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology2012;250(8):1149-60. ">Ramezani 2012</a>, eyes in the steroid arm received two injections of intravitreal steroid spaced two months apart, meaning the treatment effect was more sustained, whilst those in <a href="./references#CD009510-bbs2-0004" title="HattenbachLO , FeltgenN , BertelmannT , Schmitz-ValckenbergS , BerkH , EterN , et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmologica2018;96(1):e10-8. ">COMRADE‐B</a> only received a single dose of steroid at baseline. This might explain the observed heterogeneity. </p> </section> </section> <section id="CD009510-sec-0087"> <h3 class="title" id="CD009510-sec-0087">Potential biases in the review process</h3> <p>The studies included in this review typically only provided data for six months of treatment, save <a href="./references#CD009510-bbs2-0005" title="HigashiyamaT , SawadaO , KakinokiM , SawadaT , KawamuraH , OhjiM . Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion. Acta Ophthalmologica2013;91(4):318-24. ">Higashiyama 2013</a> and <a href="./references#CD009510-bbs2-0001" title="BandelloF , AugustinA , TufailA , LeabackR . A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. European Journal of Ophthalmology2018;28(6):697–705. EU-CTR 2010-023900-29. A 12-month, multicentre, randomised, parallel group study to compare the efficacy and safety of OZURDEX® versus Lucentis® in patients with branch retinal vein occlusion. www.clinicaltrialsregister.eu/ctr-search/trial/2010-023900-29/results (first received 28 August 2011). NCT01427751. Safety and efficacy study of Ozurdex® compared to Lucentis® in patients with branch retinal vein occlusion. clinicaltrials.gov/ct2/show/NCT01427751 (first received 2 September 2011). ">Bandello 2018</a>, which had 12 months of follow‐up. Typically, the study designs permitted rescue treatment after six months, hence necessitating exclusion after this. Short follow‐up of six months can introduce bias, particularly in investigation of adverse events, such as cataract formation in the use of intravitreal steroids. </p> <p>Included studies showed some clinical heterogeneity as they were conducted in diverse ethnicities and also showed differences in inclusion criteria, such as the inclusion or exclusion of ischaemic BRVO. We judged the effect of this to be small compared to the treatment effects observed. </p> <p>Further heterogeneity arose from the anti‐VEGF used within the studies, as bevacizumab, ranibizumab and aflibercept were all used. We judged the effect of this also to be small due to the similar efficacy of all three agents demonstrated in the results. </p> <p>Statistical heterogeneity between studies was low.</p> <p>We found intra‐study selective outcome reporting to be minimal for all but two of the included studies. This was demonstrated by comparing the published results with the study protocol. The protocol for <a href="./references#CD009510-bbs2-0005" title="HigashiyamaT , SawadaO , KakinokiM , SawadaT , KawamuraH , OhjiM . Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion. Acta Ophthalmologica2013;91(4):318-24. ">Higashiyama 2013</a> was not available on ClinicalTrials.gov and we are unable to exclude the possibility of selective reporting. </p> <p>Publication bias was avoided by using trial registries to look for studies to include. One study was not published but we obtained data from the trial registry (<a href="./references#CD009510-bbs2-0002" title="NCT01976338. Ranibizumab intravitreal injections versus sham control in patients with branch retinal vein occlusion (BRVO) (Blossom). ClinicalTrials.gov/show/NCT01976338 (first received 5 November 2013). WeiW . To assess the efficacy and safety of individualized intravitreal ranibizumab 0.5 mg in Asian (primarily Chinese) patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). In: Annual Meeting of the Association for Research in Vision and Ophthalmology. 2017. ">BLOSSOM</a>). We also contacted the authors of this study to obtain further study information, such as that needed to assess risk of bias. </p> <p>Studies comparing anti‐VEGF with steroid showed poor masking of study participants and outcome assessors. This is most likely due to the nature of the respective injection, which is colourless liquid for anti‐VEGF and crystals/implant for steroid. This exposes this group of studies to performance and detection bias. </p> </section> <section id="CD009510-sec-0088"> <h3 class="title" id="CD009510-sec-0088">Agreements and disagreements with other studies or reviews</h3> <p>We found three systematic reviews using our search strategy. The first preceded the widespread use of intravitreal anti‐VEGF for BRVO and does not report recent studies examining the efficacy of this treatment (<a href="./references#CD009510-bbs2-0083" title="McIntoshRL , MohamedQ , SawSM , WongTY . Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology2007;114(5):835-54.">McIntosh 2007</a>). The second, <a href="./references#CD009510-bbs2-0028" title="RegnierSA , LarsenM , BezlyakV , AllenF . Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis. BMJ Open2015;5(6):e007527. ">Regnier 2015</a>, evaluated treatments for BRVO to 2015, finding eight RCTs with a total of 1743 adult participants. As with our systematic review, anti‐VEGF agents were found to be more effective than steroids or laser in improving visual acuity at six and 12 months. Anti‐VEGF agents were also safer than intravitreal steroids, that were associated with intraocular pressure rise. <a href="./references#CD009510-bbs2-0094" title="QianT , ZhaoM , XuX . Comparison between anti-VEGF therapy and corticosteroid or laser therapy for macular oedema secondary to retinal vein occlusion: a meta-analysis. Journal of Clinical Pharmacy and Therapeutics2017;42(5):519-29.">Qian 2017</a>, the third systematic review that we found, also performed a systematic review but included CRVO as well as BRVO studies to 2017. In BRVO, this review found anti‐VEGF agents to be more effective than steroids or laser in improving visual acuity at three, six and 12 months, with lower IOP compared to steroids. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009510-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009510-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/full#CD009510-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009510-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/full#CD009510-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Anti‐VEGF v laser, outcome: 2.2 Mean VA change at 6 months [letters]." data-id="CD009510-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Anti‐VEGF v laser, outcome: 2.2 Mean VA change at 6 months [letters]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/full#CD009510-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Anti‐VEGF v laser, outcome: 2.5 APTC events." data-id="CD009510-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Anti‐VEGF v laser, outcome: 2.5 APTC events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/full#CD009510-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Anti‐VEGF v steroid, outcome: 3.1 Gain of 15 letters or more at 6 months." data-id="CD009510-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Anti‐VEGF v steroid, outcome: 3.1 Gain of 15 letters or more at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/full#CD009510-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Anti‐VEGF v steroid, outcome: 3.9 Raised IOP." data-id="CD009510-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Anti‐VEGF v steroid, outcome: 3.9 Raised IOP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/full#CD009510-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐VEGF v sham, Outcome 1: Gain of 15 letters or more at 6 months" data-id="CD009510-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Anti‐VEGF v sham, Outcome 1: Gain of 15 letters or more at 6 months</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐VEGF v sham, Outcome 2: Mean VA change at 6 months" data-id="CD009510-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Anti‐VEGF v sham, Outcome 2: Mean VA change at 6 months</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐VEGF v sham, Outcome 3: Loss of 15 letters or more at 6 months" data-id="CD009510-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Anti‐VEGF v sham, Outcome 3: Loss of 15 letters or more at 6 months</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐VEGF v sham, Outcome 4: Mean CRT change at 6 months" data-id="CD009510-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Anti‐VEGF v sham, Outcome 4: Mean CRT change at 6 months</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐VEGF v sham, Outcome 5: Cataract" data-id="CD009510-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Anti‐VEGF v sham, Outcome 5: Cataract</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐VEGF v sham, Outcome 6: Raised IOP" data-id="CD009510-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Anti‐VEGF v sham, Outcome 6: Raised IOP</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐VEGF v sham, Outcome 7: APTC events" data-id="CD009510-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Anti‐VEGF v sham, Outcome 7: APTC events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anti‐VEGF v sham, Outcome 8: Quality of life change" data-id="CD009510-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Anti‐VEGF v sham, Outcome 8: Quality of life change</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anti‐VEGF v laser, Outcome 1: Gain of 15 letters or more at 6 months" data-id="CD009510-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Anti‐VEGF v laser, Outcome 1: Gain of 15 letters or more at 6 months</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anti‐VEGF v laser, Outcome 2: Mean VA change at 6 months" data-id="CD009510-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Anti‐VEGF v laser, Outcome 2: Mean VA change at 6 months</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anti‐VEGF v laser, Outcome 3: Mean CRT change at 6 months" data-id="CD009510-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Anti‐VEGF v laser, Outcome 3: Mean CRT change at 6 months</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anti‐VEGF v laser, Outcome 4: Cataract" data-id="CD009510-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Anti‐VEGF v laser, Outcome 4: Cataract</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anti‐VEGF v laser, Outcome 5: APTC events" data-id="CD009510-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Anti‐VEGF v laser, Outcome 5: APTC events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anti‐VEGF v steroid, Outcome 1: Gain of 15 letters or more at 6 months" data-id="CD009510-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Anti‐VEGF v steroid, Outcome 1: Gain of 15 letters or more at 6 months</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anti‐VEGF v steroid, Outcome 2: Gain of 15 letters or more at 12 months" data-id="CD009510-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Anti‐VEGF v steroid, Outcome 2: Gain of 15 letters or more at 12 months</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anti‐VEGF v steroid, Outcome 3: Mean VA change at 6 months" data-id="CD009510-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Anti‐VEGF v steroid, Outcome 3: Mean VA change at 6 months</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anti‐VEGF v steroid, Outcome 4: Mean VA change at 12 months" data-id="CD009510-fig-0023" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Anti‐VEGF v steroid, Outcome 4: Mean VA change at 12 months</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anti‐VEGF v steroid, Outcome 5: Mean CRT change at 6 months" data-id="CD009510-fig-0024" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Anti‐VEGF v steroid, Outcome 5: Mean CRT change at 6 months</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anti‐VEGF v steroid, Outcome 6: Mean CRT change at 12 months" data-id="CD009510-fig-0025" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Anti‐VEGF v steroid, Outcome 6: Mean CRT change at 12 months</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anti‐VEGF v steroid, Outcome 7: Quality of life change at 12 months" data-id="CD009510-fig-0026" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Anti‐VEGF v steroid, Outcome 7: Quality of life change at 12 months</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anti‐VEGF v steroid, Outcome 8: Cataract" data-id="CD009510-fig-0027" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Anti‐VEGF v steroid, Outcome 8: Cataract</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anti‐VEGF v steroid, Outcome 9: Raised IOP" data-id="CD009510-fig-0028" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Anti‐VEGF v steroid, Outcome 9: Raised IOP</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anti‐VEGF v steroid, Outcome 10: APTC events" data-id="CD009510-fig-0029" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Anti‐VEGF v steroid, Outcome 10: APTC events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009510-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/urn:x-wiley:14651858:media:CD009510:CD009510-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anti‐VEGF v steroid, Outcome 11: Endophthalmitis" data-id="CD009510-fig-0030" src="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_t/tCD009510-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: Anti‐VEGF v steroid, Outcome 11: Endophthalmitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/media/CDSR/CD009510/image_n/nCD009510-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009510-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Anti‐VEGF compared to sham for macular oedema secondary to branch retinal vein occlusion</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Anti‐VEGF v sham for macular oedema secondary to branch retinal vein occlusion</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> macular oedema secondary to branch retinal vein occlusion<br/><b>Setting:</b> eye hospital<br/><b>Intervention:</b> anti‐VEGF<br/><b>Comparison:</b> sham injection </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with sham</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with anti‐VEGF</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Gain of 15 letters or more of visual acuity at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>269 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>462 per 1000<br/>(320 to 669) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.72<br/>(1.19 to 2.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>283<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Data not available because participants in sham group received anti‐VEGF after 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean change in visual acuity letters at 6 months measured with a logMAR chart (higher letter score is better visual acuity) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean VA change with sham was 5 letters</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of letters read with anti‐VEGF was 7.50 letters more (5.29 more to 9.71 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>282<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Data not available because participants in sham group received anti‐VEGF after 6 months</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Mean central retinal thickness (CRT) change at 6 months in microns (lower value is better) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean CRT change with sham was −207 microns</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean CRT with anti‐VEGF was 57.5 microns less<br/>(108.63 less to 6.37 less) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Adverse outcomes at any time point</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cataract</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11 per 1000 (1 to 106)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.98 (0.09 to 10.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>283 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕<br/>VERY LOW<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>12 month results. Patients in the sham arm were able to receive rescue anti‐VEGF after 6 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raised IOP*</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>6 per 1000</p> <p>(0 to 101)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 5.41 (0.30 to 96.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>283 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕<br/>VERY LOW<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>APTC events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>22 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>32 per 1000 (6 to 142)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.47 (0.30 to 7.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>283 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕<br/>VERY LOW<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endophthalmitis</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>No endophthalmitis was reported in either anti‐VEGF (n = 190) or sham (n = 91) arms</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Mean change in quality of life (QoL) at 12 months on the National Eye Institute Visual Functioning Questionnaire‐25 (VFQ‐25) (scored 0 to 100) (higher score is better quality of life) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean QoL change with sham was 0</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean QoL score with anti‐VEGF was 7.60 higher (4.30 to 10.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>281 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕<br/>MODERATE<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data collected at 6 months because participants in sham group received anti‐VEGF after 6 months </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). Where no events observed in control group, we have used an estimate of 1 per 1000 for illustrative purposes.<br/><br/><b>ATPC:</b> Antiplatelet Trialists’ Collaboration; <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup>Downgraded 1 level for risk of bias </p> <p><sup>2</sup>Downgraded 2 levels for imprecision and 1 level for risk of bias </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Anti‐VEGF compared to sham for macular oedema secondary to branch retinal vein occlusion</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/full#CD009510-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009510-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Anti‐VEGF compared to laser for branch retinal vein occlusion (BRVO)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Anti‐VEGF compared to laser for branch retinal vein occlusion (BRVO)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with BRVO<br/><b>Setting:</b> eye hospital<br/><b>Intervention:</b> anti‐VEGF<br/><b>Comparison:</b> laser </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with laser</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with anti‐VEGF</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Gain of 15 letters or more of visual acuity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>260 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>543 per 1000<br/>(374 to 793) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.09<br/>(1.44 to 3.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Data not available because participants in sham group received anti‐VEGF after 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean change in visual acuity letters measured with a logMAR chart (higher letter score is better visual acuity) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean visual acuity change with laser ranged from 2 to 7 letters</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of letters read with anti‐VEGF was 9.63 letters more<br/>(7.23 more to 12.03 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>473<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Data not available because participants in sham group received anti‐VEGF after 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Mean central retinal thickness (CRT) change at 6 months in microns (lower value is better) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean CRT change with laser was −128 microns</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean CRT change with anti‐VEGF was 147.47 microns less<br/>(200.19 less to 94.75 less) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Adverse outcomes at any time point</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cataract*</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3 per 1000 (0 to 75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.97 (0.12 to 71.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>456 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕<br/>VERY LOW<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raised IOP*</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No raised IOP was reported in either anti‐VEGF (n = 182) or laser (n = 93) groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕<br/>VERY LOW<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>APTC events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>4 per 1000 (1 to 37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.99 (0.15 to 6.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>476 (3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕<br/>VERY LOW<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endophthalmitis</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No endophthalmitis was reported in either anti‐VEGF (n = 284) or laser (n = 192) arms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕<br/>VERY LOW<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Mean change in quality of life at 12 months on the National Eye Institute Visual Functioning Questionnaire‐25 (VFQ‐25) (scored 0 to 100) (higher score is better quality of life) </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). Where no events observed in control group, we have used an estimate of 1 per 1000 for illustrative purposes.<br/><br/><b>ATPC:</b> Antiplatelet Trialists’ Collaboration; <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup>Downgraded 1 level for risk of bias </p> <p><sup>2</sup>Downgraded 1 level for risk of bias and 2 levels for imprecision </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Anti‐VEGF compared to laser for branch retinal vein occlusion (BRVO)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/full#CD009510-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009510-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Anti‐VEGF compared to steroid for branch retinal vein occlusion (BRVO)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Anti‐VEGF compared to steroid for BRVO</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with BRVO<br/><b>Setting:</b> eye hospital<br/><b>Intervention:</b> anti‐VEGF<br/><b>Comparison:</b> steroid </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with steroid</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with anti‐VEGF</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Gain of 15 letters or more of visual acuity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>379 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>633 per 1000<br/>(466 to 802) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.67<br/>(1.33 to 2.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>330<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>338 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>595 per 1000</p> <p>(460 to 771)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.76<br/>(1.36 to 2.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>307<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/>HIGH<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean change in visual acuity letters measured with a logMAR chart (higher letter score is better visual acuity) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean visual acuity change with steroid ranged from 9 to 11 letters</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of letters read with anti‐VEGF was 8.22 more<br/>(5.69 more to 10.76 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>330<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean visual acuity change with steroid ranged from 6 to 8 letters</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean number of letters read with anti‐VEGF was on average 9.15 letters more (6.32 more to 11.97 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>343</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/>HIGH<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Mean central retinal thickness (CRT) change at 12 months in microns (lower value is better) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean CRT change with steroid ranged from −249 to −306 microns</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean CRT change with anti‐VEGF was 26.92 microns less<br/>(65.88 less to 12.04 less) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>343<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕<br/>MODERATE<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Adverse outcomes at any time point</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cataract</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>125 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>22 per 1000 (7 to 75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.12 (0.04 to 0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>551 (3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕<br/>MODERATE<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Raised IOP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>240 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>57 per 1000 (34 to 94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.25 (0.16 to 0.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>673 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕<br/>MODERATE<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>APTC events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3 per 1000 (0 to 74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 3.02 (0.12 to 73.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>587 (3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕<br/>VERY LOW<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endophthalmitis</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No endophthalmitis was reported in either anti‐VEGF (n = 187) or steroid (n = 179) arms. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Mean change in quality of life at 12 months on the National Eye Institute Visual Functioning Questionnaire‐25 (VFQ‐25) (scored 0 to 100) (higher score is better quality of life) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life score with steroid was 3.5</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life score with anti‐VEGF was 3.10 higher<br/>(0.22 higher to 5.98 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>307<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕<br/>MODERATE<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ATPC:</b> Antiplatelet Trialists’ Collaboration; <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> One study was judged to be at high risk of attrition bias because participants in the steroid group dropped out of the study due to adverse effects and poor response. We did not downgrade for risk of bias as the direction of the risk of bias is likely to be favouring the steroid group and so the estimate of effect reported here may well be an under‐estimate. </p> <p><sup>2</sup>Downgraded 1 level for risk of bias (studies were at high risk of attrition bias) </p> <p><sup>3</sup>Downgraded 2 levels for imprecision and 1 level for risk of bias </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Anti‐VEGF compared to steroid for branch retinal vein occlusion (BRVO)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/full#CD009510-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009510-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Interventional case studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study name</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of eyes included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective recruitment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug and dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean IVI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean f‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0038" title="AbeggM , TappeinerC , Wolf-SchnurrbuschU , BarthelmesD , WolfS , FleischhauerJ . Treatment of branch retinal vein occlusion induced macular edema with bevacizumab. BMC Ophthalmology2008;8:18. [DOI: 10.1186/1471-2415-8-18]">Abegg 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 m (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BCVA (logMAR) improved from 0.7 to 0.5 and mean CMT improved from 454 µm to 305 µm </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0039" title="AhmadiAA , ChuoJY , BanashkevichA , MaPE , MaberleyDA . The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion. Canadian Journal of Ophthalmology2009;44(2):154-9.">Ahmadi 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 eyes</p> <p>(All non‐ischaemic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in mean Snellen BCVA from 20/280 to 20/170 at final follow‐up. Mean CMT reduction from 451 µm to 400 µm at 6 mths. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0045" title="ByeonSH , KwonYA , OhHS , KimM , KwonOW . Short-term results of intravitreal bevacizumab for macular edema with retinal vein obstruction and diabetic macular edema. Journal of Ocular Pharmacology and Therapeutics2007;23(4):387-94.">Byeon 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 eyes (14 with MO and BRVO)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50% of patients had previous laser treatment. The mean log‐MAR of the BRVO group was 0.71, and this improved 1 month after the second injection to 0.34. The mean CMT was 468.6 µm which decreased to 186.4 µm at final follow‐up. No significant ocular or systemic SE. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0046" title="ByunYJ , RohMI , LeeSC , KohHJ . Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology2010;248(7):963-71.">Byun 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191 eyes</p> <p>Comparative study: IVB (n = 73) versus IVTA (n = 118)</p> <p>(non‐ischaemic = 90%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.1 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BCVA (logMAR) improved from 0.91 to 0.45 in the IVB group and mean CMT decreased from 477 µm to 218 µm. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0048" title="CekicO , CakirM , YaziciAT , AlagozN , BozkurtE , Faruk YilmazO . A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion. Current Eye Research2010;35(10):925-9.">Cekic 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 eyes</p> <p>Comparative study: IVTA (n = 17), IVB (n = 14), combined  (n = 21)</p> <p>(All non‐ischaemic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BCVA (logMAR) improved from 0.92 to 0.45 in the IVB group. No significant ocular or systemic SE. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0049" title="ChenCH , ChenYH , WuPC , ChenYJ , LeeJJ , LiuYC , et al. Treatment of branch retinal vein occlusion induced macular edema in treatment-naive cases with a single intravitreal triamcinolone or bevacizumab injection. Chang Gung Medical Journal2010;33(4):424-35.">Chen 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83 eyes</p> <p>Comparative study: IVTA (n = 25), IVB (n = 24), no treatment (n = 34)</p> <p>(56% ischaemic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 2.5 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.4 wks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BCVA (logMAR) improved from 0.95 to 0.79 at 12 weeks</p> <p>Mean CMT decreased from 457 µm to 323 µm 24 weeks after treatment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0050" title="ChengKC , WuWC , ChenKJ . Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion. Eye2009;23(11):2023-33.">Cheng 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 eyes</p> <p>Comparative study: IVTA (n = 16), IVB (n = 13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.5% of IVB group received previous laser treatment. Improvement in mean BCVA (logMAR) from 0.99 to 0.35 at final follow‐up. Reduction in mean CMT from 538 µm to 222 µm microns. No significant ocular or systemic side effects. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0051" title="ChungEJ , HongYT , LeeSC , KwonOW , KohHJ . Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology2008;246(9):1241-7.">Chung 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.9 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56% gained 5 or more ETDRS letters; 44% had less than 5 ETDRS letter gain or worse final BCVA. No significant ocular or systemic side effects. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0058" title="FigueroaMS , ContrerasI , NovalS , ArruabarrenaC . Results of bevacizumab as the primary treatment for retinal vein occlusions. British Journal of Ophthalmology2010;94(8):1052-6.">Figueroa 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in mean BCVA (logMAR) from 0.8 to 0.44 at final follow‐up. Reduction in mean CMT from 486 µm to 268 µm. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0067" title="GregoriNZ , RattanGH , RosenfeldPJ , PuliafitoCA , FeuerW , Flynn HW Jr, et al. Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion. Retina2009;29(7):913-25.">Gregori 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 eyes</p> <p>(23% ischaemic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 17 eyes (26%) returned for follow‐up. The median Snellen BCVA improved from 20/100 at baseline to 20/50 at 12 months. The mean CMT decreased by 205 µm compared with baseline. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0068" title="GunduzK , BakriSJ . Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. Eye2008;22(9):1168-71.">Gunduz 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 eyes</p> <p>(40% ischaemic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in mean BCVA (logMAR) from 0.91 to 0.48 at final follow‐up. Reduction in mean CMT from 506 µm to 267.5 µm. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0070" title="HaraS , SakurabaT , KataokaH , YanagihashiS , SaitouK , NodaY . Effect of repeated intravitreal bevacizumab injections for secondary macular edema of branch retinal vein occlusion. Nihon Ganka Gakkai Zasshi2010;114(12):1013-8.">Hara 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 3 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean reduction in CMT from 610 µm to 368 µm after 1 injection</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0072" title="HoehAE , AchT , SchaalKB , ScheuerleAF , DithmarS . Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology2009;247(12):1635-41.">Hoeh 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 eyes (34 with BRVO)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 2.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BCVA (logMAR) improved from 0.50 to 0.32. Mean CMT decreased from 602 µm to 386 µm.  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0073" title="HouJ , TaoY , JiangYR , LiXX , GaoL . Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study. Chinese Medical Journal2009;122(22):2695-9.">Hou 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 eyes</p> <p>Comparative study: IVTA (n = 34), IVB (n = 34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.9 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BCVA improved by 0.14 logMAR units. Mean CMT decreased from 506 µm to 228 µm.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0075" title="JaissleGB , LeitritzM , GeliskenF , ZiemssenF , Bartz-SchmidtKU , SzurmanP . One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology2009;247(1):27-33.">Jaissle 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> <p>(All non‐ischaemic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 in first 6 months and 0.8 in second 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The median VA gained 3.0 lines from baseline at 48 weeks and there was a decrease of 39% of the median CMT. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0076" title="JaissleGB , SzurmanP , FeltgenN , SpitzerB , PielenA , RehakM , et al. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology2011;249(2):183-92.">Jaissle 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.8 wks</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The median BCVA (logMAR) was 0.6 at baseline improving to 0.4. Reduction in CMT, from a baseline of 454 µm to 248 µm. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0079" title="KondoM , KondoN , ItoY , KachiS , KikuchiM , YasumaTR , et al. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion:results after 12 months and multiple regression analysis. Retina2009;29(9):1242-8.">Kondo 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean BCVA (logMAR) improved from 0.53 to 0.26. Mean CMT decreased from 523 µm to 305 µm. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0081" title="KreutzerTC , AlgeCS , WolfAH , KookD , BurgerJ , StraussR , et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. British Journal of Ophthalmology2008;92(3):351-5.">Kreutzer 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean BCVA (logMAR) improved from 0.79 to 0.51 at 6 months. Mean CMT decreased from 474 µm to 316 µm. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0082" title="KriechbaumK , MichelsS , PragerF , GeorgopoulosM , FunkM , GeitzenauerW , et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. British Journal of Ophthalmology2008;92(4):518-22.">Kriechbaum 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 eyes (21 with BRVO)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.0 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline mean BCVA was 50 ETDRS letters, by month 6, BCVA improved  to 65 letters. CMT decreased from 558 µm to 382 µm.  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0085" title="MehanySA . Early Avastin management in acute retinal vein occlusion. Saudi Journal of Ophthalmology2010;24(3):87-94.">Mehany 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 eyes with BRVO</p> <p>(All non‐ischaemic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline BCVA was 20/240 (logMAR 1.08) improving to 20/60 (logMAR 0.48) at the end of follow‐up (approx 12 months). The mean CMT decreased to 250 ± 48 µm. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0090" title="PaiSA , ShettyR , VijayanPB , VenkatasubramaniamG , YadavNK , ShettyBK , et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. American Journal of Ophthalmology2007;143(4):601-6.">Pai 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 wks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BCVA (logMAR) was 1.22 improving to 0.61. The mean CMT was 672.8 µm at baseline. There was a 44.6% decrease in CMT from baseline. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0091" title="PeceA , IsolaV , PiermarocchiS , CaloriG . Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up. British Journal of Ophthalmology2011;95(1):56-68.">Pece 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean improvement in BCVA (logMAR) from 0.80 0.41. Mean reduction of 275 µm in CMT from baseline. Contrast sensitivity, time and reading fluency improved significantly in the treated eyes. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0092" title="PragerF , MichelsS , KriechbaumK , GeorgopoulosM , FunkM , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. British Journal of Ophthalmology2009;93(4):452-6.">Prager 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 eyes (BRVO only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 12 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In the BRVO group (n =  18), visual acuity increased from 55 letters (20/80) at baseline to 73 letters (20/32) at month 12. CMT decreased significantly by 241 μm after 12 months of follow‐up. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0095" title="RabenaMD , PieramiciDJ , CastellarinAA , NasirMA , AveryRL . Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina2007;27(4):419-25.">Rabena 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BCVA improved from 20/200 to 20/100 at final follow‐up. Mean CMT decreased from 487 µm to 332 µm at final follow‐up. No adverse side effects were observed following injections. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0097" title="RenschF , JonasJB , SpandauUH . Early intravitreal bevacizumab for non-ischaemic branch retinal vein occlusion. Ophthalmologica2009;223(2):124-7.">Rensch 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.2 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BCVA (logMAR) improved from 0.81 to 0.55 at 6 months. Mean CMT decreased from 492 µm to 316 µm. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0102" title="RouvasA , PetrouP , NtourakiA , DouvaliM , LadasI , VergadosI . Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study. Retina2010;30(6):893-902.">Rouvas 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BCVA (logMAR) improved from 0.74 to 0.49. Mean CMT decreased from 349 µm at baseline to 229 µm. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0103" title="SchaalKB , HohAE , ScheuerleA , SchuttF , DithmarS . Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe2007;104(4):285-9.">Schaal 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 eyes (BRVO only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 2.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 wks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.5% of those with BRVO had a significant improved visual acuity (by at least 3 lines). Mean CMT decreased from 678 µm to 236 µm. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0106" title="StahlA , AgostiniH , HansenLL , FeltgenN . Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefe's Archive for Clinical and Experimental Ophthalmology2007;245(10):1429-36.">Stahl 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 wks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BCVA (logMAR) improved from 0.5 to 0.31 at 9 weeks. Mean CMT reduced from 408 µm to 309 µm. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0074" title="HungKH , LeeSM , LeeSY , LeeFL , YangCS . Intravitreal bevacizumab (avastin) in the treatment of macular edema associated with perfused retinal vein occlusion. Journal of Ocular Pharmacology and Therapeutics2010;26(1):85-90.">Hung 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 eyes (12 with BRVO only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 2.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 6.5 m</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50% (6/12) had received previous treatment. Mean BCVA (logMAR) improved from 0.94 to 0.54 at final follow‐up. Mean CMT reduced from 392 µm to 234 µm. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>m: months; wks: weeks; BCVA: best‐corrected visual acuity; CMT: central macular thickness; IVTA: intravitreal triamcinolone; IVB: intravitreal bevacizumab; IVI: intravitreal injections; f‐up: follow‐up; VA: visual acuity </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Interventional case studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/full#CD009510-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009510-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Excluded studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study details</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conclusion</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0011" title="CampochiaroPA , HafizG , ChannaR , ShahSM , NguyenQD , YingH , et al. Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes. Ophthalmology2010;117(12):2387-94. ">Campochiaro 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose‐finding study: patients with CRVO (n = 14) and BRVO (n = 17) were randomised to receive either 0.3 mg ranibizumab or 0.5 mg ranibizumab and followed for 2 years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 0.3 mg and 0.5 mg doses had similar results and when combined showed that 20 patients with BRVO had mean and median improvements in BCVA of 16.1 and 15 letters. After 2 years of follow‐up, only 5 of 17 patients with BRVO and 3 of 14 patients with CRVO were oedema‐free with no injections for at least 1 year. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009510-bbs2-0010" title="CampochiaroPA , HafizG , ShahSM , NguyenQD , YingH , DoDV , et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Molecular Therapy2008;16(4):791-9. ">Campochiaro 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose‐finding study: patients with CRVO (n = 20) and BRVO (n = 20) were randomised to receive 3 monthly injections either 0.3 mg ranibizumab or 0.5 mg ranibizumab. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary end point at 3 months: improvement of 10 and 18 letters in the BRVO group for the lower and higher doses respectively. </p> <p>OCT showed that compared to lower dose injections, 0.5 mg of ranibizumab tended to cause more rapid reductions of central retinal thickening that lasted longer between injections. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0012" title="ChiquetC , DupuyC , BronAM , AptelF , StraubM , IsaicoR , et al. Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naive patients with retinal vein occlusion and macular edema: a 12-month follow-up study. Graefe's Archive for Clinical and Experimental Ophthalmology2015;253(12):2095-102. ">Chiquet 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective study in eyes with CRVO and BRVO, 102 patients (64 in the anti‐VEGF (bevacizumab or ranibizumab) group, 38 in the DEX group) without previous treatment were included in this multi‐centre retrospective study and evaluated at baseline and 1, 3, 6, and 12 months after the onset of treatment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both the DEX and anti‐VEGF groups showed similar improvements in visual acuity and central retinal thickness. However, at 3 months, 5 patients (13%) in the DEX group and 20 (31%) in the anti‐VEGF group (P &lt; 0.001) changed treatment due to poor response. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0013" title="ChiquetC , BronAM , StraubM , DupuyC , IsaicoR , AptelF , et al. Retinal vein occlusions: therapeutic switch in macular oedema treatment with a 12-month follow-up. Ophthalmic Research2016;55(3):152-8. ">Chiquet 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination therapy retrospective study in CRVO and BRVO. 48 patients – 40 in the anti‐VEGF DEX sequence (AD group), 8 in the DEX anti‐VEGF sequence (DA group) – were included in this multicentre retrospective study and evaluated at baseline, 1, 3, 6 and 12 months after the switch. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VA significantly improved at 1 month in the AD group (P = 0.03) but not in the DA group (P = 0.40). CMT decreased significantly in the AD group at 1, 6 and 12 months (P = 0.002, P = 0.005 and P = 0.002, respectively). In the DA group, VA did not change from baseline at any time point, and CMT decreased at 1 month (P = 0.02) but not later on. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0015" title="RajagopalR , ShahGK , BlinderKJ , AltaweelM , EliottD , WeeR , et al. Bevacizumab versus ranibizumab in the treatment of macular edema due to retinal vein occlusion: 6-month results of the CRAVE study. Ophthalmic Surgery, Lasers &amp; Imaging Retina2015;46(8):844-50. ">CRAVE 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants were randomised 1:1 to receive monthly treatment with bevacizumab or ranibizumab. The primary outcome was change in central foveal thickness at 6 months compared to baseline. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial randomised 98 patients to treatment with bevacizumab or ranibizumab. At 6 months, there were no differences in change in central foveal thickness between groups (bevacizumab: mean reduction of 212.6 microns, 95% CI (confidence interval) −288.3 to −137.0; ranibizumab: mean reduction of 243.8 microns, 95% CI, −309.6 to −178.0; P = 0.72, analysis of variance (ANOVA)). Both groups showed similar functional outcomes (bevacizumab: 0.33 logMAR gain, 95% CI, −0.47 to −0.18; ranibizumab: 0.34 log‐ MAR gain, 95% CI, −0.45 to −0.23; P = 0.38, ANOVA). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0014" title="FeltgenN , HattenbachLO , BertelmannT , CallizoJ , RehakM , WolfA , et al. Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study. Acta Ophthalmologica2018;96(8):e933-e941. ">COMRADE Extension 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The COMRADE‐B study was a 6‐month RCT comparing ranibizumab with dexamethasone implant. The extension study followed up a subset of the original study group for a further 6 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients enrolled in the extension study were limited only to German centres, and in general had better visual acuity outcomes at 6 months than those not enrolled. In the extension 6 months, eyes in the ranibizumab arm could receive ranibizumab as required. Eyes in the dexamethasone arm could receive 1 further dexamethasone implant in the extension 6 month period. 'Mean average change in best‐corrected visual acuity (BCVA) was significantly better for ranibizumab than dexamethasone (P = 0.0249).' Also, "elevated intraocular pressure (IOP) was more frequent with dexamethasone than ranibizumab treatment." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0016" title="DonatiS , BarosiP , BianchiM , Al OumM , AzzoliniC . Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion. European Journal of Ophthalmology2012;22(4):607-14. ">Donati 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 eyes with MO secondary to BRVO (of at least 3 months duration) were randomised to receive either IVB (n = 9) at baseline, month 1 and month 2 or (n = 9) IVB at baseline, month 1 and month 2 with grid laser photocoagulation after the second injection. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both groups demonstrated a mean improvement in BCVA and CMT at 12 months, however the combination groups required fewer IVB injections; (median of 4 ± 1.1 for IVB alone versus 3 ± 0.4 in the combination group) (P = 0.03). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0017" title="GuX , YuX , SongS , DaiH . Intravitreal dexamethasone implant versus intravitreal ranibizumab for the treatment of macular edema secondary to retinal vein occlusion in a Chinese population. Ophthalmic Research2017;58(1):8-14. ">Gu 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐randomised case series in CRVO and BRVO. 32 ME cases treated with Ozurdex and 32 ME cases treated with ranibizumab were enrolled, with 26 central (C)RVO and 6 branch (B)RVO participants in each group. The authors compared the results of best‐corrected visual acuity (BCVA), central retinal thickness, number of injections, and intraocular pressure (IOP) at 1, 2, 3, and 6 months after injection. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BCVA in both groups at each follow‐up were significantly increased compared to baseline with no statistical difference between the groups. Ozurdex and ranibizumab successfully reduced CMT at each follow‐up. Both CRVO and BRVO patients had significant between‐group differences in the mean number of injections. Among the CRVO patients, IOP in the Ozurdex group was significantly increased compared to baseline and the ranibizumab group at 1, 2, and 3 months postinjection. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0018" title="GuignierB , Subilia-GuignierA , FournierI , BallonzoliL , Speeg-SchatzC , GaucherD . Prospective pilot study: efficacy of intravitreal dexamethasone and bevacizumab injections in the treatment of macular oedema associated with branch retinal vein occlusion. Ophthalmologica2013;230(1):43-9. ">Guignier 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐randomised case series in BRVO. A total of 19 patients (19 eyes) were included in this prospective pilot study. Initially, 8 eyes received three IV bevacizumab (group 1) and 11 received one IV Ozurdex (group 2). All the patients underwent a 1‐, 3‐, 4‐ and 6‐month follow‐up visit. A repeated IV bevacizumab (group 1) or IV Ozurdex (group 2) was proposed at 4 months when necessary. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean visual acuity was significantly better 1 month after treatment in group 2, while the mean central macular thickness was also significantly lower in group 2. However, there was no longer any difference between the 2 groups at 3, 4 and 6 months, neither in terms of visual<br/>acuity nor in terms of retinal thickness. More than three IVBs were needed in 3 of 10 patients in group 1 while 2 IVDs were required in 10 of 11 patients in group 2. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0019" title="HanhartJ , RozenmanY . Comparison of intravitreal ranibizumab, aflibercept, and dexamethasone implant after bevacizumab failure in macular edema secondary to retinal vascular occlusions. Ophthalmologica2017;238(1-2):110-8. ">Hanhart 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐randomised combination comparative study in CRVO and BRVO. Fifteen eyes were switched to ranibizumab, 12 to aflibercept, and 10 to dexamethasone. At 3, 6, 9, and 12 months, the outcome measures were visual acuity (VA) and central macular thickness (CMT). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 year after the switch, CMT decreased from 430.11 ± 91.21 to 291.86 ± 43.87 μm ( P &lt; 0.001). VA increased in 59.5% of the eyes. No difference between the groups was found in those outcomes at 1 year, but the number of injections varied: 3.30 ± 0.95 for dexamethasone, 6.50 ± 2.11 for aflibercept, and 8.27 ± 2.37 for ranibizumab ( P &lt; 0.001). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0020" title="KartasasmitaAS , TakaraiS , SwitaniaA , EnusS . Efficacy of single bevacizumab injection as adjuvant therapy to laser photocoagulation in macular edema secondary to branch retinal vein occlusion. Clinical Ophthalmology2016;10:2135-40. ">Kartasasmita 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐randomised comparative study in BRVO of laser alone or laser with bevacizumab. 19 patients with macular oedema secondary to BRVO were assigned to either the group of 9 patients in combination therapy of laser photocoagulation with intravitreal bevacizumab or the group of 10 patients in the laser photocoagulation therapy. Complete ophthalmologic examinations were performed just before the therapy and at 1 month following the therapy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination therapy of laser photocoagulation and single intravitreal bevacizumab injection resulted in a significantly better visual acuity compared to laser photocoagulation therapy (0.35 versus 0.13 logMAR; P = 0.041) and reduced macular thickness by 120.33 µm versus 71.50 µm (P = 0.277), although this difference was not significant. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0022" title="LeitritzMA , GeliskenF , ZiemssenF , SzurmanP , Bartz-SchmidtKU , JaissleGB . Grid laser photocoagulation for macular oedema due to branch retinal vein occlusion in the age of bevacizumab? Results of a prospective study with crossover design. British Journal of Ophthalmology2013;97(2):215-9. ">Leitritz 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In this prospective interventional consecutive case series, previously untreated eyes with perfused MO were enclosed over a period of 16 months for bevacizumab (BEV) and for 29 months for grid laser photocoagulation (GLP). The follow‐up period was 1 year. Patients with persistent MO after 12 months of BEV were offered GLP and vice versa, and were followed up for another 12 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both BEV (23 eyes) and GLP (21 eyes) caused a significant ( P &lt; 0.05) reduction in central retinal thickness (CRT) at 12 months although this was delayed with GLP. However, BEV revealed a significantly better 'best‐corrected visual acuity' (BCVA) compared with GLP (0.2 vs 0.5 logMAR; P &lt; 0.04). Switching therapy for non‐responders revealed a reduced CRT at another 12 months, although this was not significant. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0023" title="LiuB , YangY , LiuX , LiW , MoZ . Clinical therapeutic effects of intravitreal Ranibizumab injection combined laser photocoagulation for macular edema in BRVO. Guoji Yanke Zazhi2014;14(11):2006-8. ">Liu 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 confirmed cases (42 eyes) with macular oedema secondary to BRVO were randomised into 3 groups, each group contained 14 eyes. The ranibizumab group received intravitreal injection of ranibizumab (0.05 mL), the laser group received grid laser photocoagulation, and the combined group received a second therapy of grid laser photocoagulation after 1 wk of the intravitreal injection of ranibizumab. Best‐corrected visual acuity (BCVA) and the central macular thickness (CMT) preoperative and at 1, 3, 6 months after therapy was recorded. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The BCVA and the CMT had no differences among 3 groups pretherapy (P &gt; 0.05). While BCVA was much better and CMT was reduced significantly post‐therapy than pre‐therapy in all 3 groups (P &lt; 0.05). The BCVA and CMT in the ranibizumab group were significantly different in every time point (1, 3, 6 months) (P &lt; 0.05). The BCVA declined and the CMT was thicker as time went on. In the laser group and the combined group, BCVA and CMT had little differences at different time points (P &gt; 0.05); while the BCVA was better and the CMT was thinner in the combined group than ranibizumab group and laser group at every time point (P &lt; 0.05). At 3 and 6 months, the BCVA was better and the CMT was thinner in laser group than ranibizumab group (P &lt; 0.05). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0021" title="KlimesJ , RegnierSA , MahonR , BudekT , DostalF , SkalickyD , DeptaJ . Cost effectiveness analysis of ranibizumab compared to aflibercept and laser intervention In treatment of diabetic macular edema (DME) In the Czech Republic. Value in Health2015;18:A 419. ">Klimes 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A 25‐health‐state Markov model considering ranges of visual acuity in both eyes was developed. Patients had a confirmed diagnosis of macular oedema secondary to BRVO and had best‐corrected visual acuity (BCVA) at baseline between 25 and 73 letters. The evaluation compared IVT‐AFL 2 mg with ranibizumab 0.5 mg: the frequency of injections and monitoring were identical for both treatments, taken from randomised trials and a physician survey. A systematic review and indirect comparison were conducted to determine the probabilities of gaining at least 15 BCVA letters from baseline to 6 months; BCVA was then extrapolated over time to determine costs and outcomes. Utilities were taken from published literature and costs were estimated from a UK payer perspective. Published drug prices were discounted to reflect patient access schemes. Costs and benefits were discounted at 3.5%. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The indirect comparison found that IVT‐AFL was associated with a small numerical advantage in the likelihood of gaining 15 BCVA letters, compared with ranibizumab (median odds ratio = 1.08, 95% Cl 0.43 to 2.56). IVT‐AFL was associated with a higher number of QALYs (0.045) per patient than ranibizumab. Both treatments are available to the National Health Service under confidential patient access schemes. Cost effectiveness was estimated for a range of possible discounts for each treatment. At price parity, IVT‐AFL reduces cost by GBP 4 per patient and was a dominant therapy. Results were sensitive to the unit cost of the drugs used, to comparative efficacy and number of injections for both treatments. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0024" title="NarayananR , PanchalB , DasT , ChhablaniJ , JalaliS , AliMH , et al. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1. British Journal of Ophthalmology2015;99(7):954–9. ">MARVEL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In this prospective, randomised, non‐inferiority trial, 75 participants with macular oedema due to BRVO received intravitreal injections of ranibizumab (IVR) or bevacizumab (IVB) after 1:1 block randomisation. The primary outcome measure was the difference in mean changes in best‐corrected visual acuity (BCVA) at 6 months. Secondary outcome measures included mean change in central retinal thickness (CRT), the proportion of patients improving by &gt; 15 letters and the proportion of patients developing neovascularisation. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants received either IVR (n = 37) or IVB (n = 38). The mean BCVA at baseline was 52.8 ± 14.4 letters (20/80) and 56.1 ± 10.0 letters (20/80) (P = 0.24) in the ranibizumab and bevacizumab groups, respectively. At 6 months, the mean gains in BCVA were +18.1 letters (95% CI +12.8 to +22.6; P &lt; 0.0001) in the ranibizumab group and +15.6 letters (95% CI +12.0 to +20.5; P &lt; 0.0001) in the bevacizumab group. The difference between the mean visual gains of the treated groups (bevacizumab–ranibizumab) was −2.5 letters (95% CI −8.0 to +5.0; P = 0.74). Mean reductions in CRT at 6 months were 177.1 ± 122.3 mm in the ranibizumab group (P &lt; 0.0001) and 201.7 ± 166.2 mm in the bevacizumab group ( P &lt; 0.0001), with no significant difference between the 2 groups (P = 0.48). The mean numbers of ranibizumab and bevacizumab injections were 3.2 ± 1.5 and 3.0 ± 1.4, respectively (P = 0.55). 2 serious adverse events occurred in the ranibizumab group and 1 in the bevacizumab group but both were unrelated to intravitreal injections. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0025" title="MoonJ , KimM , SagongM . Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion. Eye2016;30(8):1084-90. ">Moon 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This was a prospective, randomised, interventional comparative study conducted in 45 eyes with ME secondary to BRVO who were treated primarily with IVB 1.25 mg (23 eyes, IVB group) or combination therapy of IVB 1.25 mg with a single simultaneous STA 40 mg (18 eyes, IVB/STA group). Re‐injections were performed with IVB if optical coherence tomography (OCT) showed recurrent ME associated with decreased visual acuity. The main outcome measurement was the number of additional IVB injections, and changes of best‐corrected visual acuity (BCVA) and central macular thickness (CMT) during a 6‐month follow‐up period were compared. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BCVA showed significant improvement in 2 groups at 6 months. In addition, CMT showed significant decrease in 2 groups at 6 months. No significant differences in the change of BCVA and CMT at 6 months after injection (P = 0.973, P = 0.639) were observed between the 2 groups. A statistically significant difference was found regarding the number of additional IVB injections (IVB group 0.96 ± 0.83; IVB/STA group 0.44 ± 0.70, P = 0.034). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0026" title="MoradianS , FaghihiH , SadeghiB , PiriN , AhmadiehH , SoheilianM , et al. Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1). Graefe's Archive for Clinical and Experimental Ophthalmology2011;249(2):193-200. ">Moradian 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 eyes with acute (&lt; 3 months) BRVO were randomly assigned to receive either 2 injections of 1.25 mg bevacizumab 6 weeks apart or sham injections. Follow‐up results were reported at 6 weeks and 12 weeks. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After week 6, visual improvements in the bevacizumab treated group were significantly better than the sham group. At 12 weeks there was no significant difference. There was a significant reduction in CMT both at 6 and at 12 weeks. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0027" title="RamezaniA , EsfandiariH , EntezariM , MoradianS , SoheilianM , DehsarviB , et al. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent onset central retinal vein occlusion. Acta Ophthalmologica2014;92(7):e530-9. ">Ramezani 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In this randomised clinical trial, 86 eyes with recent onset (&lt; 12 weeks) CRVO were assigned to 2 groups: bevacizumab (IVB) group (43 eyes) that received 3 monthly injections of 1.25 mg of IVB, and triamcinolone (IVT) group (43 eyes) that received 2 injections of 2 mg IVT 2 months apart. Outcomes were best‐corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) changes. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean BCVA improved significantly at 6 months in both groups; from 0.87 ± 0.49 to 0.41 ± 0.35 logMAR in IVB group, and from 0.81 ± 0.45 to 0.62 ± 0.48 logMAR in IVT group (P &lt; 0.001). However, between‐group differences reach a significant level at months 4 (P = 0.003) and 6 (P &lt; 0.001) in favour of the IVB group. In terms of CMT reduction, the difference between the groups was statistically significant (P = 0.002) at month 6. Significant differences were noted more in the ischaemic cases in favour of the IVB group. Mean IOP rise was significantly higher in the IVT group at all visits. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0028" title="RegnierSA , LarsenM , BezlyakV , AllenF . Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis. BMJ Open2015;5(6):e007527. ">Regnier 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A Bayesian network meta‐analysis of RCTs of treatments for macular oedema secondary to BRVO. Interventions: ranibizumab 0.5 mg when necessary, aflibercept 2 mg monthly, dexamethasone 0.7 mg implant, laser photocoagulation, ranibizumab + laser, or sham intervention. Bevacizumab and triamcinolone were excluded. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 RCTs were identified for inclusion with 1743 adult patients. The probability of being the most efficacious treatment at month 6 or 12 based on letters gained was 54% for ranibizumab monotherapy, 30% for aflibercept, 16% for ranibizumab plus laser (adjunctive or prompt), and 0% for dexamethasone implant, laser or sham. The probability of being the most efficacious treatment for patients gaining ≥15 letters was 39% for aflibercept, 35% for ranibizumab monotherapy, 24% for ranibizumab plus laser, 2% for dexamethasone implant, and less than 1% for laser or sham. There was no statistical difference between ranibizumab monotherapy and aflibercept for letters gained (+1.4 letters for ranibizumab vs aflibercept with 95% credible interval (CrI) of −5.2 to +8.5 letters) or the OR for gaining ≥15 letters: 1.06 (95% CrI 0.16 to 8.94)). Dexamethasone implant was associated with significantly higher IOP/OH than antivascular endothelial growth factor agents (OR 13.1 (95% CrI 1.7 to 116.9)). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0029" title="RussoV , BaroneA , ConteE , PrascinaF , StellaA , NociND . Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina2009;29(4):511-5. ">Russo 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A quasi‐RCT of 30 eyes in 30 patients in a single centre in Italy. 15 eyes received bevacizumab whilst 15 eyes received laser treatment. Follow‐up was for 12 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The laser arm showed improvement in VA of 0.21 and 0.20 logMAR at 6 and 12 months, respectively. The bevacizumab arm showed mean VA improvement at 6 and 12 months of 0.30 and 0.31, respectively (P &lt; 0.05). CRT decreased by 42% in the laser arm and 60.3% in the bevacizumab arm at 12 months (P &lt; 0.05). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0030" title="CampochiaroPA , WykoffCC , SingerM , JohnsonR , MarcusD , YauL , et al. Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study. Ophthalmology2014;121(12):2432-42. ">SHORE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants received monthly injections of 0.5 mg ranibizumab for 7 months and those meeting<br/>stability criteria between months 7 and 14 were randomised (1:1) to 'as needed' injections versus continued monthly injections. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference in the slope of change in BCVA between months 7 and 15 in patients treated 'as needed' versus those treated with monthly injections (P = 0.509). Mean (standard deviation) change from baseline BCVA in Early Treatment Diabetic Retinopathy Study letter score at month 15 was 21.0 ± 14.1 in the PRN group (n = 82) versus 18.7 ± 14.1 in the monthly group (n = 80) and 14.5 ± 14.7 in NR participants (n = 13). The percentage of participants who achieved BCVA 20/40 at month 15 was 76.8% in the PRN group, 71.3% in the monthly group, and 46.2% in NR participants. The mean (standard deviation) change from baseline central subfield thickness was 247.8 ± 207.5 mm in the PRN group, 289.9 ± 177.2 mm in the monthly group, and 93.2 ± 225.2 mm in NR participants. There were no significant differences in mean BCVA gains or central subfield thickness reductions at month 15 between the PRN and monthly injection groups (all &gt; 0.05). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0032" title="TomomatsuY , TomomatsuT , TakamuraY , GozawaM , ArimuraS , TakiharaY , et al. Comparative study of combined bevacizumab/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions. Acta Ophthalmologica2016;94(3):e225-30. ">Tomomatsu 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A study to investigate whether targeted retinal photocoagulation (TRP) of peripheral non‐perfused areas (NPAs) could prevent the recurrence of macular oedema (ME) due to branch retinal vein occlusion (BRVO) after intravitreal bevacizumab injection (IVB). Eyes received 1.25 mg IVB only (IVB group) or combined with TRP (IVB + TRP group) of NPAs, more than 5 disc areas identified by fluorescein angiography in the patients with ME secondary to BRVO. Best‐corrected visual acuity (BCVA) and central retinal thickness (CRT) determined by optical coherence tomography were measured every month for 6 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 patients were enrolled and randomised to IVB group (n = 19) and IVB + TRP group (n = 19). Both groups showed similar thinning in CRT at 1 week after IVB. The IVB + TRP group maintained thinner CRT at 2 (P = 0.0072) and 3 (P = 0.0086) months compared with IVB group. However, the difference in CRT became insignificant at 4, 5 and 6 months. The number of reinjections (± standard deviation) in IVB group (1.58 ±0.69) was significantly greater (P = 0.0025) than that in IVB + TRP group (0.83±0.62). BCVA significantly improved at 6 month in IVB + TRP group (P = 0.015), but not in IVB group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0033" title="WroblewskiJJ , Wells JA 3rd, GonzalesCR . Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion. American Journal of Ophthalmology2010;149(1):147-54. ">Wroblewski 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 eyes were randomised 3:1 to intravitreous injections of pegaptanib 0.3 or 1 mg at baseline and at weeks 6 and 12 with subsequent injections at 6‐week intervals at investigator discretion until week 48. Principal efficacy outcomes were change from baseline to week 54. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results were similar in both dosage groups. Mean BCVA improved 14 letters and mean CMT decreased by 205 microns<b>.</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009510-bbs2-0034" title="ZhangXY , LiYB , ZhouLW , WangXB , LuoXD . Observation on intravitreal injection of ranibizumab combined with laser photocoagulation for the treatment of macular edema in BRVO. International Eye Science2014;14:747-9. ">Zhang 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 eyes of 30 patients with BRVO were randomised into 3 groups: group 1 (10 eyes) received grid laser treatment alone, group 2 received a single dose of intravitreal injection of ranibizumab (0.05 mL/0.5 mg) followed by grid laser treatment 7 days following injection. Group 3 (10 eyes) received 3 loading doses of intravitreal ranibizumab with grid laser treatment 7 days after the first injection. After 6 months follow‐up, the best‐corrected visual acuity and optical coherence tomography (OCT) and central macular thickness were observed. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After 6 months, the visual acuity of patients was improved significantly. There was an average increase of 11 letters, 17 letters and 18 letters in group 1, 2, and 3 respectively, with the average decrease in OCT being 208.7 mum, 312.9 mum and 326.8 mum, respectively, in these groups. Gain in visual acuity more than 3 lines was 1 case (10%) in group 1. There were 3 cases (30%) in group 2 and 4 cases (40%) in group 3. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>BCVA: best‐corrected visual acuity; BRVO: branch retinal vein occlusion; CMT: central macular thickness; CRVO: central retinal vein occlusion; IVB: intravitreal bevacizumab; MO: macular oedema; OCT: optical coherence tomography </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Excluded studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/full#CD009510-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009510-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anti‐VEGF v sham</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Gain of 15 letters or more at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Mean VA change at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Loss of 15 letters or more at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Mean CRT change at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Cataract <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Raised IOP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 APTC events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Quality of life change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anti‐VEGF v sham</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009510-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Anti‐VEGF v laser</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Gain of 15 letters or more at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [1.44, 3.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Mean VA change at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.63 [7.23, 12.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Mean CRT change at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐147.47 [‐200.19, ‐94.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Cataract <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 APTC events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.15, 6.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Anti‐VEGF v laser</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009510-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Anti‐VEGF v steroid</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Gain of 15 letters or more at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.33, 2.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Gain of 15 letters or more at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Mean VA change at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.22 [5.69, 10.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Mean VA change at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.15 [6.32, 11.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Mean CRT change at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐66.79 [‐94.69, ‐38.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Mean CRT change at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐26.92 [‐65.88, 12.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Quality of life change at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Cataract <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>637</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.04, 0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Raised IOP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>673</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.16, 0.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 APTC events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>587</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.02 [0.12, 73.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 Endophthalmitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Anti‐VEGF v steroid</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009510.pub3/references#CD009510-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009510.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009510-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009510-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009510-note-0011">Français</a> </li> <li class="section-language"> <a class="" href="ko#CD009510-note-0010">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD009510-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009510-note-0008">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009510\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009510\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009510\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009510\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009510\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009510\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009510\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009510\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009510\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009510\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009510\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009510\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009510\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009510\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009510\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009510\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009510\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009510\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=loVWuZlx&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009510.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009510.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009510.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009510.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009510.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719919295"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009510.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719919299"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009510.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918df481bc79937f',t:'MTc0MDcxOTkxOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 